An investigation into the relationship between a putative tumour suppressor and a cell shape regulator in the fruit fly. by Hiley, C.J.
IREFERENCE ONLY  
UNIVERSITY OF LONDON THESIS
Degree l^Vw£> Year T o o ^  Name of Author B  <■ c " ^
COPYRIGHT
This is a thesis accepted for a Higher Degree of the University of London. It is an 
unpublished typescript and the copyright is held by the author. All persons consulting 
the thesis must read and abide by the Copyright Declaration below.
COPYRIGHT DECLARATION
I recognise that the copyright of the above-described thesis rests with the author and 
that no quotation from it or information derived from it may be published without the 
prior written consent of the author.
LOANS
Theses may not be lent to individuals, but the Senate House Library may lend a copy 
to approved libraries within the United Kingdom, for consultation solely on the 
premises of those libraries. Application should be made to: Inter-Library Loans, 
Senate House Library, Senate House, Malet Street, London WC1E 7HU.
REPRODUCTION
University of London theses may not be reproduced without explicit written 
permission from the Senate House Library. Enquiries should be addressed to the 
Theses Section of the Library. Regulations concerning reproduction vary according 
to the date of acceptance of the thesis and are listed below as guidelines.
A. Before 1962. Permission granted only upon the prior written consent of the 
author. (The Senate House Library will provide addresses where possible).
B. 1962 - 1974. In many cases the author has agreed to permit copying upon 
completion of a Copyright Declaration.
C. 1975 - 1988. Most theses may be copied upon completion of a Copyright 
Declaration.
D. 1989 onwards. Most theses may be copied.
This thesis comes within category D.
P T  . UI I This copy has been deposited in the Library of ----------------------------------------
□ This copy has been deposited in the Senate House Library, Senate House,Malet Street, London WC1E 7HU. By
kbindc 
o 3965

AN INVESTIGATION INTO THE 
RELATIONSHIP BETWEEN A PUTATIVE 
TUMOUR SUPPRESSOR AND A CELL 
SHAPE REGULATOR IN THE FRUIT FLY
CHARLOTTE JANE HILEY
UNIVERSITY COLLEGE LONDON
PhD
i
UMI Number: U592878
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a complete manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
Dissertation Publishing
UMI U592878
Published by ProQuest LLC 2013. Copyright in the Dissertation held by the Author.
Microform Edition © ProQuest LLC.
All rights reserved. This work is protected against 
unauthorized copying under Title 17, United States Code.
ProQuest LLC 
789 East Eisenhower Parkway 
P.O. Box 1346 
Ann Arbor, Ml 48106-1346
Acknowledgements
I would like to thank my father, Robin Hiley, my mother, Carolyn Hiley, my 
sister, Emma Hiley, my granny, Margaret Whitcher, my boyfriend, Tim 
Landy, and all my friends for their help and support during my PhD. I 
would like to thank my supervisor, Kathy Barrett, for her guidance, and 
everyone past and present in Kathy’s lab and in the Ludwig Institute for 
Cancer Research, UCL, who have helped me along the way.
In memory of my Mum.
2
Abstract
The process of morphogenesis during development involves complex, co­
ordinated changes in cell shape and cell movement. The molecular 
mechanisms underlying this fundamental aspect of development remain 
to be fully elucidated, although some key aspects have been 
characterised.
Drosophila Rho Guanine nucleotide Exchange Factor 2 (DRhoGEF2) is 
required during morphogenesis for control of cell shape. A novel 
interaction has recently been discovered between the DRhoGEF2 PDZ 
domain and the Drosophila orthologue of Mutated in Colorectal Cancer 
(MCC), a putative tumour suppressor gene. The interaction between 
MCC and a RhoGEF has not been previously documented in any 
organism. MCC may act as a block on the cell cycle, and this interaction 
could, therefore, represent a link between morphogenesis and cell 
division. This thesis explores the functional significance of MCC and in 
particular its putative contribution to morphogenesis through its 
interaction with DRhoGEF2.
The observation of MCC expression in the Drosophila embryonic central 
nervous system suggests a functional role in nervous system 
development. Ectopic over-expression of MCC does not produce any 
obvious phenotype over controls. Furthermore, RNAi and P-element 
mutagenesis to knock out MCC expression do not yield a phenotype, and 
therefore do not indicate any clear function for MCC. The potential 
influence of MCC on the signals mediated by DRhoGEF2 therefore 
remains obscure and requires further investigation.
Three potential targets for the DRhoGEF2 PDZ domain identified through 
a yeast 2-hybrid approach, including MCC, carry a proline-X-threonine- 
X-leucine motif at their C-terminus. Initial studies indicate that mutation of 
the proline, threonine and leucine residues at the C-terminus of MCC
3
disrupts its binding to DRhoGEF2 PDZ domain. This work suggests 
further study to explore whether this C-terminal motif defines a group of 
DRhoGEF2-specific interacting proteins.
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1. Introduction
During the development of an organism, signals transmitted from one 
molecule to another regulate important processes such as cell division 
and migration, apoptosis (programmed cell death), and morphogenesis 
(the generation of shape and structure). The signalling pathways that 
directly regulate these and other cellular processes are themselves highly 
regulated, providing reproducible programs of development. It is 
becoming increasingly clear that signalling pathways that were once 
thought of as linear leading to a given outcome (such as entry into the cell 
cycle) are intimately linked to signalling pathways regulating other 
processes. For example, in early fruit fly development the protein 
Tribbles places a temporary block on signals promoting cell division to 
provide time for morphogenetic events to occur before the next round of 
cell division begins (Grosshans and Wieschaus 2000). In this way the 
signalling pathways regulating cell division and morphogenesis are 
regulated in a co-ordinated manner and may be thought of not as linear 
pathways, but as part of a complex network of signals within the cell.
The molecular components of cellular signalling pathways are primarily 
proteins. One group of proteins involved in cellular signalling is the Rho 
GTPases.
1.1. The Rho GTPase family
Rho GTPases are found in all eukaryotic cells from yeast to humans. 
They form a subgroup of the Ras superfamily of small GTPases, which 
number over 60 in mammalian cells. There are 20 Rho GTPase family 
members in humans, three of which are well-characterised in tissue 
culture systems; these are RhoA, Rac1 and Cdc42 (Etienne-Maneville 
and Hall, 2002). The phylogenetic tree of human Rho GTPase family 
members (fig. 1.1) illustrates that the naming of members does not 
necessarily indicate their degree of sequence similarity. For example, 
RhoG is more closely related to Rac1 than to RhoA. The Rho
19
GTPase family in Drosophila is much smaller than in mammals, with only 
seven identified thus far.
RhoA Rho-liko
RhoC
RhoB
Rnd1 Rnd
Rnd2
RhoD
Rif
Cdc42
TC10
I CL
Wrchl
Rac1
Rac3
Rac2
RhoG
RhoH/TTF
r ~  RhoBTBI
-RhoBTB2 RhoBTB
Figure 1.1. The human Rho GTPase family. -  a phylogenetic 
tree. Taken from (Burridge and Wennerberg 2004).
Human Rho GTPases are liable to regulation by more than 70 activators 
and 80 inactivators. This large number of upstream regulators combined 
with the expanding number of Rho GTPase downstream targets that are 
continuously being identified (over 60 so far), indicates the complexity of 
Rho GTPase-mediated signalling (fig. 1.2).
Different Rho GTPases may have exclusive or over-lapping functions. 
However, the function of a particular Rho GTPase seems to be at least 
partially conserved through evolution since the best-characterised 
proteins (Rac, Rho and Cdc42) have similar functions in fruit flies and 
humans (see sections 1.6 -  1.7).
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Figure 1.2. Rho GTPase activators and effectors. Rho signalling is very 
complex due to the large number of upstream activators and downstream 
effectors. There is also substantial cross-talk between the different Rho 
GTPase signalling pathways. Taken from (Karnoub, Symons et al. 2004)
1.2. The molecular switch
Most Rho GTPases act as molecular switches in cell signalling pathways. 
They are small G-proteins that cycle between an active, guanosine 
triphosphate (GTP)-bound, and an inactive, guanosine diphosphate 
(GDP)-bound, state (fig. 1.3) (Etienne-Manneville and Hall, 2002). The 
innate ability of the GTPase to hydrolyse GTP to GDP allows it to “switch 
itself off’, and this switching is subject to regulation by external proteins. 
The guanine nucleotide exchange factors (GEFs) promote the release of 
GDP and replacement with GTP, thereby activating the Rho GTPase.
The guanine nucleotide activating proteins (GAPs) catalyse hydrolysis of 
GTP by the Rho GTPase, thereby inactivating it. Rho GTPases are 
prenylated at their C-terminus, facilitating the association with a cellular 
membrane, that is required for function. The guanine nucleotide 
dissociation inhibitors (GDIs) inhibit the activation of Rho GTPases by 
stabilising the GDP-bound form and extracting it from the membrane.
Plasma membrane
Rho-GDP Rho-GTP
GTP GDP
Rho-GDP GAP Effectors
Figure 1.3. Rho GTPases are molecular switches. Rho GTPases are 
negatively regulated by GAPs and GDIs, and positively regulated by GEFs. Rho- 
GTP is the form that activates downstream effectors. Taken from (Etienne- 
Manneville and Hall 2002).
1.3. Rho GTPases have numerous effectors
Rho GTPases are involved in a diverse variety of cellular functions both 
in vitro and in vivo. This diversity of function is partially derived from the 
numerous downstream targets activated by Rho GTPases (fig. 1.2) 
(Bishop and Hall 2000). Since Rho GTPase effectors do not all contain a 
recognisable conserved motif they may have to be identified 
experimentally. A large number of identified effectors are kinases, 
including serine/threonine kinases (e.g. p21-activated kinase (PAK), 
mitogen-activated protein kinase (MAPK)/EGF receptor kinase kinase 
(ERKK)) and lipid kinases (e.g. phosphoinositide-3 kinase (PI3K)). The 
molecular mechanism by which Rho GTPases activate effectors is not 
entirely understood but is known to involve residues within a region 
termed the switch 1 domain as well as other regions of the Rho GTPase 
protein (Karnoub, Symons et al. 2004). Rho GTPase single amino acid 
mutations have begun to tease out differential effector functions. For 
example, the identification of Rac1 mutants that retain the ability to 
induce lamellipodia but have lost transforming activity implicate different 
effectors for these functions (Westwick, Lambert et al. 1997).
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It is not clear why a Rho GTPase can activate one of its effectors and not 
another whilst it is itself in an active state. In vivo studies indicate that the 
Rho GEF activating the Rho GTPase may dictate the downstream 
effector, although the mechanism behind this is not understood (see 
section 1.5).
1.4. Rho GEFs are major regulators of Rho GTPase activity
Although Rho GTPase activation can be achieved by either GEF 
activation or inhibition of GAP or GDI activity, studies of oncogenic GEFs 
suggest that it is the exchange of guanine nucleotide that is the rate- 
limiting step. Therefore, localised control of GEF activity is extremely 
important in the regulation of Rho GTPases.
There are over 70 known Rho GEFs. Until recently, all Rho GEFs were 
found to contain Dbl (Diffuse B-cell lymphoma)-homology and pleckstrin 
homology domains which conferred their Rho GEF activity. The Dbl 
homology domain takes its name from a region of Dbl Rho GEF, the first 
Rho GEF to be identified. This region confers the ability to exchange 
GTP for GDP on Rho GTPases. The pleckstrin homology domain takes 
its name from a region of the pleckstrin protein that mediates localisation 
to the plasma membrane via interaction with phospholipids (Fuentes, 
Karnoub et al. 2003). Both domains are necessary for Rho GEF activity 
in vivo. However, members of the CDM (Ced-5, DOCK180, Myoblast 
city) family activate Rac, and zizimin activates Cdc42 despite a lack of 
Dbl homology domains (Braga 2002). In these cases the CZH2 (CDM 
zizimin homology 2) domain, which also mediates dimerisation, is 
required for activation of the GTPase (Meller, Irani-Tehrani et al. 2004).
The Dbl family GEFs, which form the vast majority of Rho GEFs, have 
three conserved helices that reorient the switch region of the GTPase to 
promote ejection of GDP. GTP can then take its place, and since GTP is 
more abundant in the cell than GDP this is the likely outcome, leading to 
activation of the Rho GTPase (Snyder, Worthylake et al. 2002).
It is only recently that the mechanism of specificity of a GEF for one Rho 
GTPase over another has begun to be elucidated. GEF promiscuity is 
variable, with some GEFs able to activate more than one Rho GTPase, 
e.g. Vav and Vav2 can activate RhoA/B/G, Rac1 and Cdc42, and others 
specifically activating only one e.g. Tiam-1 is Rac1-specific (Erickson and 
Cerione 2004). The basis for this specificity of activation is unravelling 
with the determination of crystal structures and mutational analyses. 
Whether a GEF activates Rac or Cdc42 is dependent on its ability to 
interact with the residue at position 56 of the GTPase -  mutation of 
tryptophan in R ad  to phenylalanine, the corresponding residue in Cdc42, 
prevents Tiaml from activating R a d , but enables a Cdc42-specific GEF, 
lntersectin-1, to activate it (Karnoub, Worthylake et al. 2001). The 56 
position may not be important for RhoA activation since RhoA has a 
Trp56 residue, as Rac, but Tiaml does not activate RhoA. The Asp45 
and Glu54 residues may prove to dictate GEF specificity for RhoA based 
on initial studies (Snyder, Worthylake et al. 2002; Oleksy, Barton et al. 
2004). Studies of this type have determined that the (32-p3 region of Rho 
GTPases, a poorly conserved region amongst them, determines which 
GEFs can activate a particular GTPase and which cannot.
The elucidation of structural specificity for one GTPase over another will 
permit the use of GTPase-specific tools in studies of GEF function. For 
example, Dbs Rho GEF is able to activate both RhoA and Cdc42. A 
mutant form of Dbs Rho GEF that can activate RhoA but not Cdc42 leads 
to a transformed phenotype when over-expressed. This result, along with 
further studies, indicates that it is the activation of RhoA, rather than 
Cdc42, that leads to the transformed phenotype (Cheng, Rossman et al. 
2002). Similar studies may also shed light on some of the confusing 
phenotypes observed with the use of Rho GTPase dominant negative 
mutants. A dominant negative Rho GTPase may inhibit GEFs that are 
able to activate itself and other Rho GTPases, and therefore lead to non- 
GTPase specific effects.
1.5. Rho GEFs may dictate the downstream outcome of Rho 
activation
It is clear that the activation of a specific Rho GTPase can produce 
radically different outcomes (see sections 1.6.2-1.6.6). For example, 
RhoA activation can lead to cell migration, cell cycle regulation, or gene 
expression. Some evidence points towards Rho GEFs determining the 
outcome of Rho GTPase activation. Co-expression studies in 
mammalian cells reveal different outcomes of Rac or Cdc42 activation 
when different GEFs are over-expressed (Zhou, Wang et al. 1998). 
Recent work in Drosophila illustrates the reiteration of a specific outcome 
of Rho activation by a single GEF (Nikolaidou and Barrett 2004). In this 
case DRhoGEF2 activates Rho1 leading to epithelial sheet folding at 
multiple stages of development, but DRhoGEF2 is not thought to be 
required for other processes involving Rho1 such as cytokinesis, which 
requires a different Rho GEF, Pebble. Similarly, the Rac GEF Trio is 
required for axonal guidance and growth, but not for myoblast fusion 
which are all Rac-dependent processes (Hakeda-Suzuki, Ng et al. 2002). 
This differential outcome of activation of a given Rho GTPase could be 
the result of differential Rho effector expression patterns at different 
stages of development, differential subcellular localisation or potentially a 
molecular mechanism whereby activation by a specific GEF produces a 
differential molecular conformation of the Rho GTPase that dictates 
effector activation. At present there is no evidence for the latter theory.
1.6. Rho GTPases have numerous functions in tissue culture cells
The vast majority of information about the functions of Rho GTPases 
since they were first identified in 1985 comes from studies of their 
function in mammalian tissue culture cells.
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1.6.1. Rho GTPases primarily mediate their effects via 
regulation of the actin cytoskeleton
Of the 24 Rho GTPase family members in mammalian cells, three are 
well-characterised. Rho A, Cdc42 and Rac1 all function primarily by 
regulating the actin cytoskeleton, although other functions have also been 
assigned. In short, Rho A is required for the assembly of actin-myosin 
filaments (stress fibres), Cdc42 is required for the formation of finger-like 
actin protrusions (filopodia), and Rac is required for the formation of actin- 
rich sheet-like protrusions (lamellipodia) (Ridley and Hall 1992; Ridley, 
Paterson et al. 1992; Kozma, Ahmed et al. 1995; Nobes and Hall 1995). 
The actin cytoskeleton provides the structural framework of the cell (along 
with the microtubules and intermediate filaments). In this respect it 
dictates the shape (i.e. physical structure) of a cell. Since the actin 
cytoskeleton is dynamic, it also plays a vital role in changes in cell 
morphology and cell migration.
1.6.2. Rho GTPases regulate cell migration
Rho GTPases act as regulators for both independent cell movement, and 
the co-ordinated cell movement of an epithelial layer. A single 
mammalian cell in tissue culture requires Rac to form actin-rich 
membrane protrusions at the leading edge and make new adhesions with 
the substratum (Small, Stradal et al. 2002), Cdc42 to control the direction 
of protrusion with regard to extracellular cues (Etienne-Manneville and 
Hall 2003), and Rho to stimulate actin-myosin contraction in the cell body 
and retraction of membrane at the rear of the migrating cell (Worthylake, 
Lemoine et al. 2001).
How does the cell actually process forward? The active GTPases are 
localised to specific areas of the migrating cell which allows the cell to 
regulate the actin cytoskeleton differentially at the front (“leading edge”) 
and rear.
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Figure 1.4. Rho GTPases are required for cell migration.
Rho proteins are required for protrusion at the leading edge, 
contraction in the main body of the cell, and retraction of the tail 
during migration. Based on (Etienne-Manneville and Hall 2002).
Rac function is required in the leading edge to promote the formation of 
lamellipodia which make new adhesions with the underlying substratum 
and allow the cell to move forward (Nobes and Hall 1995). Rho mediates 
its effects on tail retraction via phosphorylation of non-muscle myosin by 
myosin light chain kinase, which is regulated by Rho-dependent kinase 
(ROK). Inhibition of this pathway leads to inhibition of cell constriction 
and tail retraction, but protrusion at the leading edge is not affected 
(Kolega 2003). RhoA and ROK activity are also required to inhibit 
integrin-mediated adhesion to allow tail retraction (Worthylake, Lemoine 
et al. 2001). Although most studies to date have focussed on Rho A in 
mammalian cells, it is likely that Rho B also signals to ROK and thereby 
contributes to cell migration (Conway, James et al. 2004).
For a cell to process forward, protrusions must be co-ordinated to give 
rise to uni-directional migration (fig. 1.4). In a migrating cell Cdc42 
dictates the direction of protrusion by interaction with atypical protein 
kinase C (aPKC). This interaction leads to the phosphorylation of
glycogen synthase kinase 3 (GSK-3) specifically at the leading edge of 
the cell. Gsk-3 phosphorylation promotes interaction of the adenomatous 
polyposis coli (APC) protein with the plus ends of microtubules (Etienne- 
Manneville and Hall 2003). In this way, the microtubule cytoskeleton 
becomes polarised and dictates the direction of protrusion.
Although the vast majority of studies have focussed on the role of Rho 
GTPases in regulation of the actin cytoskeleton, during cell migration the 
microtubule cytoskeleton is highly polarised, and new roles for Rho 
GTPases in the regulation of this part of the cytoskeleton are beginning to 
be unravelled. Rho is necessary for the accumulation of stabilised 
detyrosinated microtubules at the leading edge via integrin-mediated 
activation of focal adhesion kinase (FAK) (Palazzo, Eng et al. 2004). Rac 
inactivates the microtubule destabilising protein, stathmin, and thus 
encourages microtubule growth at the leading edge (Daub, Gevaert et al. 
2001). Cdc42 is required for the orientation of the microtubule organising 
centre (MTOC) which is localised in front of the nucleus with respect to 
cell migration (Etienne-Manneville and Hall 2001).
Cells also move in a co-ordinated manner, for example as epithelial 
sheets. These are highly polarised structures which separate distinct 
extracellular spaces by virtue of junctions between neighbouring cells. 
Cells in a migrating epithelium must, therefore, move whilst attached to 
their neighbours, and Rho GTPases are also required for this process. In 
mammalian cell scratch assays inhibition of Cdc42 leads to random 
protrusive activity and cells do not migrate with normal efficiency 
(Etienne-Manneville and Hall 2001). It is also clear from in vivo studies of 
migrating epithelial sheets that other Rho GTPases are also required (see 
section 1.7.5).
1.6.3. Rho GTPases regulate cell morphology
Rho GTPases are required in the maintenance of integrity of epithelial 
and endothelial layers of cells. Cells within an epithelial layer exhibit a
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cuboidal shape and are intimately connected to their neighbours via 
adherens junctions, which act as a mechanical link, and tight junctions, 
which act as a physical barrier. The development and maintenance of 
this specialised cell morphology is critical to the function of the epithelium. 
RhoA, Rac1 and Cdc42 are activated by, and required for, the formation 
of cadherin-cadherin cell contacts, which precede the formation of 
adherens junctions (Braga 2000). These cadherin-mediated cell contacts 
are initially brought about by filopodia and/or lamellipodia catalysing inter­
cellular membrane contact (Vasioukhin, Bauer et al. 2000). Within an 
endothelium, a specialised form of epithelium that lines blood vessels, 
RhoA and Rac1 regulate permeability via effects on the formation of actin 
stress fibres and intercellular gaps (Wojciak-Stothard, Potempa et al.
2001).
Rho GTPases are also involved in the regulation of morphology of 
isolated cells. The changing shape of neuronal growth cones, which 
enables them to find their targets in vivo, provides a good system for 
study of Rho GTPase involvement in cell morphology. The axonal growth 
cone undergoes morphological changes in response to attractive and 
repulsive cues that direct it towards its target. A recent study showed that 
the plexin receptor, which is involved in repellent axon guidance via its 
interaction with semaphorin ligands, acts as a GAP for the small GTPase, 
Ras, which mediates the repulsive signal. However, this requires the 
interaction of Rnd1, a Rho GTPase, with the plexin receptor (Oinuma, 
Ishikawa et al. 2004). The RhoA GTPase is also required for 
semaphorin-mediated growth cone collapse via its regulation by 
PDZRhoGEF and Leukaemia Associated Rho GEF (LARG) which 
interact with plexin B1 (Aurandt, Vikis et al. 2002; Perrot, Vazquez-Prado 
et al. 2002; Swiercz, Kuner et al. 2002). Rac is required for growth cone 
collapse mediated by the semaphorins acting through plexin, and in this 
case (plexin A1) it appears that Rac is acting upstream of the plexin 
receptor (Turner, Nicholls et al. 2004). These are recent examples of the
29
many studies that highlight the importance of Rho GTPases in the 
process of axonal guidance.
1.6.4. Rho GTPases are required for the establishment of cell 
polarity
Cell polarity is important in unicellular organisms during chemotaxis and 
budding, and for various cell types in multicellular organisms such as 
neurons that receive a signal at one end of the cell and send it onwards 
at the other.
Without Cdc42 function, the yeast Saccharomyces cerevisiae cannot 
establish a defined site for daughter cell growth during the budding phase 
of the cell cycle, and cells therefore grow isotropically (Pruyne and 
Bretscher 2000). In multicellular organisms, Cdc42 plays a role in the 
development of apical/basolateral polarity within an epithelium via its 
interaction at the tight junction with Par proteins and atypical protein 
kinase C (Lin, Edwards et al. 2000). This polarity-determining role 
extends to migrating epithelial cells where Cdc42, once again in 
conjunction with aPKC and Par-6, regulates the positioning of the 
microtubule organising centre (MTOC) and the direction of protrusive 
activity (Etienne-Manneville and Hall 2001). Thus Cdc42 is required for 
the determination of cell polarity from yeast to mammalian cells.
1.6.5. Rho GTPases are required for cell proliferation
Rho proteins are required for cell cycle progression in tissue culture ceils. 
Rho, Rac and Cdc42 all promote entry into G 1, and progression into S- 
phase when expressed in quiescent fibroblasts. Inhibition of any of the 
three using either dominant negatives or toxins blocks G1 progression 
(Olson, Ashworth et al. 1995). The way in which the Rho GTPases exert 
their effects on cell cycle progression appears to be cell-type specific and 
is not fully understood (Coleman, Marshall et al. 2004). Rho GTPases 
are known to affect cyclin-dependent kinase (CDK) inhibitor levels and 
cyclin D levels. RhoA inhibits expression of the CDK inhibitors
p21v'fafi/c'Pi, p27kip1 and p16,nk4 to promote G1-S phase transition. Cyclin 
D levels are regulated by two separate pathways. Upon mitogenic 
stimulation Ras activation promotes an increase in cyclin D levels, and 
Rho GTPases receive inputs from integrins that determine adhesion 
status in order to increase cyclin D levels at the correct time. Rac and 
Cdc42 are likely to be involved in a separate signalling pathway affecting 
cyclin D levels that is Ras-independent.
RhoE is a member of the Rho GTPase family that receives little attention, 
perhaps because it is not able to hydrolyse GTP and is therefore unusual 
among Rho GTPases. However, it does inhibit progression of the cell 
cycle at S-phase entry by preventing accumulation of cyclin D1, and this 
effect is independent of RhoA (Villalonga, Guasch et al. 2004).
Cdc42 regulates the attachment of microtubules to chromosomal 
kinetochores during mitosis (Yasuda, Oceguera-Yanez et al. 2004). This 
is a further example of Rho GTPases regulating the microtubule 
cytoskeleton. RhoA and Cdc42 are also both required for cytokinesis, the 
separation of daughter cells. Inhibition or constitutive activation of RhoA 
or Cdc42 inhibits the formation of a contractile actin-myosin ring required 
for cytokinesis (Glotzer 2001).
Since Rho GTPases regulate the cell cycle it is perhaps not surprising 
that they are implicated in the progression of cells to a cancerous state 
(see section 1.25).
1.6.6. Rho GTPases are required for membrane trafficking
Membrane trafficking involves the transport of membrane, proteins, and 
vesicular contents from one part of the cell to another. In polarised cells 
proteins may be trafficked specifically to only one plasma membrane 
compartment. The process of endocytosis involves the formation of 
vesicles at the plasma membrane which then move along the endocytic 
pathway to their final destination, commonly the lysosome. RhoB and
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RhoD are implicated in the regulation of endosomal trafficking (Qualmann 
and Mellor 2003). RhoD regulates the interactions of early endosomes 
with the actin cytoskeleton. RhoB (and not RhoA) is involved in the 
trafficking of the epidermal growth factor receptor (EGFR) along the 
endocytic pathway to the lysosome.
Phagocytosis may be considered a specialised form of endocytosis 
whereby foreign material is ingested via a membrane-bound vesicle. Two 
phagocytic pathways in mammalian macrophages require the 
involvement of distinct Rho GTPases. Type I phagocytosis, which can 
occur through activation of the immunoglobulin receptor, requires Rac 
and Cdc42, whereas type II activation, which can occur through the 
complement receptor, requires Rho (Caron and Hall 1998). The 
involvement of Rho GTPases in phagocytosis by professional phagocytes 
of the immune system helps explain why they are such common targets 
for bacterial toxins.
Cdc42 has also been shown to regulate protein transport from the Golgi 
apparatus to the endoplasmic reticulum (Luna, Matas et al. 2002).
Exactly how Cdc42 is mediating these effects is unclear, but it does 
appear to require Wiskott-Aldrich syndrome protein (WASP) and the actin 
cytoskeleton.
1.7. Rho and the fruit fly
Tissue culture studies of Rho GTPase function in mammalian cells have 
elucidated many basic cellular functions and biochemical interactors for 
Rho GTPases. More recent work using model organisms such as the 
mouse, fruit fly, Drosophila melanogaster, and nematode worm, 
Caenorhabditis elegans, is now shedding light on the biological functions 
of Rho GTPases in vivo. Rho GTPases play important roles at numerous 
stages of organism development. Here, the known functions of Rho 
GTPases in Drosophila development will be discussed.
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Drosophila is an enormously powerful tool for the study of cell biology as 
it is amenable to genetic manipulation. Drosophila has been studied in 
this way since the early 1900s and a great deal of information and 
reagents are available for use today. The complete sequencing of the 
Drosophila genome further strengthened the use of Drosophila in cell 
biology (Adams, Celniker et al. 2000). For these reasons, and the fact 
that genetics can be used to study interactions between proteins, 
Drosophila has been used in numerous studies of the function of Rho 
GTPases.
Seven Rho GTPases have been identified thus far in Drosophila: Rho1, 
Rac1, Rac2, RhoL (Rac3), Rho BTB, Mtl, and Cdc42 (Rivero, Dislich et 
al. 2001; Settleman 2001). All are expressed during embryogenesis, 
some with restricted expression (Rac1 and Cdc42), others ubiquitously 
(Mtl, Rho1 and Rac2). As with Rho GTPases in mammalian cells, most 
studies have focussed on the roles of Rho1, R a d  and Cdc42, the closest 
orthologues of RhoA, R a d  and Cdc42 respectively. Functions for Rho 
GTPases have been identified at various stages of development from 
oogenesis through to eye development. Many of these functions tie in 
with observations from tissue culture studies.
1.7.1. Oogenesis
During oogenesis the developing oocyte receives cytoplasm from the 
nurse cells to which it is connected via actin-rich ring canals. These germ 
cells are surrounded by a single layer of somatic follicle cells which are 
also connected to the nurse cells via actin-rich adherens junctions. 
Studies of constitutively active and dominant negative forms of RhoL, 
R a d  and Cdc42 have implicated these proteins in the regulation of actin- 
rich connections between these different cell types (Murphy and Montell 
1996). Studies of Rho1 maternal mutants illustrate that it is also required 
for proper ring canal function (Magie, Meyer et al. 1999) and Cdc42 loss 
of function mutants indicate that Cdc42 is required throughout
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development to maintain monolayered epithelia, for example in the 
follicular cell epithelium during oogenesis (Genova, Jong et al. 2000).
As well as their function in regulating actin-rich cell connections, Rho 
GTPases may also be important in cell migratory events during 
oogenesis. A group of follicle cells termed border cells migrate towards 
the oocyte at the anterior tip of the egg chamber. A receptor-tyrosine 
kinase mediated signal is received by these cells to guide them on their 
journey. Rac1 and one of its GEFs, Myoblast city (Mbc), act downstream 
of the receptor and are likely to influence the actin cytoskeleton during the 
process of guided cell migration (Duchek and Rorth 2001).
1.7.2. Pole cell formation
The first cells to form in the Drosophila embryo are the pole cells, which 
constitute the germline. DRhoGEF2, an upstream activator of Rho1, is 
required for normal actin and myosin localisation within the pole cells, and 
in DRhoGEF2 mutants the majority of pole cells fail to pinch off from the 
somatic syncytium and are destroyed (Padash Barmchi, Rogers et al. 
2005). In the formation of the pole cells, DRhoGEF2 appears to be 
functioning in the regulation of actin-mediated cellular contraction, a 
process in which it is repeatedly implicated during embryonic 
development (see below).
1.7.3. Cellularisation
Cellularisation is a specialised form of cytokinesis whereby membrane 
moves inwards between adjacent nuclei in the early embryo forming 
furrow canals. These furrow canals are actin and myosin-rich at their 
leading edge. Dominant negative Rho and constitutively active Cdc42 
disrupt the formation of furrow canals between nuclei during 
cellularisation and phenocopy the effect of cytochalasin (an inhibitor of 
actin polymerisation) implying that it is their role in regulation of the actin 
cytoskeleton that is required (Crawford, Harden et al. 1998). Studies of 
Rho1, its upstream activator, Pebble (Pbl), and its downstream effector,
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Citron kinase, implicate this signalling pathway in cytokinesis in every 
tissue examined (Shandala, Gregory et al. 2004). Thus Rho GTPases 
are required for cellularisation and cytokinesis throughout Drosophila 
development, corroborating their requirement during cytokinesis of tissue 
culture cells.
DRhoGEF2 and Diaphanous (Dia), a downstream effector of Rho1, may 
function in the same pathway during furrow canal formation since both 
are localised to forming furrows and are required for proper furrow 
formation (Grosshans, Wenzl et al. 2005). As for pole cell formation, this 
process involves actomyosin-mediated constriction. Dia is a member of 
the formin family that organises actin polymerisation (Wallar and Alberts
2003). Dia localisation may be dependent on DRhoGEF2, and it is likely 
that Rho1 provides a link between the two proteins since both can 
interact with it (Grosshans, Wenzl et al. 2005). Both DRhoGEF2 and Dia 
have also been reported to interact with EB1, a microtubule associated 
protein (Rogers, Wiedemann et al. 2004; Wen, Eng et al. 2004). EB1 
could, therefore, provide a second link between DRhoGEF2 and Dia.
1.7.4. Gastrulation
Gastrulation is a process common to multicellular organisms whereby 
cells become specified as endodermal, mesodermal or ectodermal. This 
process is accompanied by morphogenetic cell movements which result 
in the physical separation of these cell types. During Drosophila 
gastrulation cells along the ventral midline of the embryo invaginate to 
form the ventral furrow. Dominant negative studies suggest that these 
mesodermal precursor cells constrict their apical membranes in a Rho1- 
dependent manner. DRhoGEF2 orchestrates these cell shape changes 
(fig. 1.5) (Barrett, Leptin et al. 1997; Hacker and Perrimon 1998), 
probably via regulation of myosin II localisation (Nikolaidou and Barrett
2004).
DRhoGEF2 is thought to be functioning in a signalling pathway from the 
cell surface to the actin cytoskeleton. Embryos lacking Folded
gastrulation (Fog) (a putative extracellular ligand) or Concertina (Cta), a 
Ga constituent of a heterotrimeric G protein, also fail to execute the cell 
shape changes necessary for ventral furrow formation (Parks and 
Wieschaus 1991; Costa, Wilson et al. 1994). Thus, a signalling pathway 
is postulated whereby Fog binds to an unknown G-protein coupled 
receptor (GPCR) and activates Cta, which in turn binds to and activates 
DRhoGEF2 leading to Rho1 activation, myosin relocalisation, actin 
cytoskeleton rearrangements and cell shape changes. This pathway 
seems to be conserved from flies to humans (see section 1.11).
Following gastrulation, the newly designated mesodermal cells undergo a 
transition from epithelium to mesenchyme in order to migrate internally 
along the ectoderm. The Fibroblast Growth Factor (FGF) receptor, 
Heartless (Htl), is required for these cell shape changes and for 
attachment of mesodermal cells to the ectoderm. Recent work has also 
indicated a role for the Rho GEF, Pbl, in the regulation of these cell shape 
changes (Schumacher, Gryzik et al. 2004). Unusually, Pbl appears to be 
acting independently of Rho1 since the expression of dominant negative 
Rho1 does not affect mesodermal cell shape changes.
1.7.5. Epithelial regulation
As for tissue culture cells, Rho GTPases are necessary in Drosophila 
development for the formation and maintenance of epithelial layers. As 
mentioned above, Cdc42 is required for the maintenance of a 
monolayered epithelium throughout development (Genova, Jong et al.
2000) and Rac is required for the formation of adherens junctions (Eaton, 
Auvinen et al. 1995). Rho acts antagonistically to moesin, an actin- 
binding protein, in the maintenance of integrity of an epithelium. Moesin 
appears to function by keeping Rho signalling “in check” thus preventing 
epithelial cells from losing their apical actin and migrating away (Speck, 
Hughes et al. 2003). It remains to be seen whether the same is true in 
mammalian cell epithelia.
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wild type DRhoGEF2
Flattening of apical 
membrane
Cells constrict apical 
membranes and begin to 
invaginate
The ventral furrow 
forms
Figure 1.5. DRhoGEF2 is required for cell shape changes during 
gastrulation. Cross-sections of early embryos show that DRhoGEF2 mutants 
{DRhoGEF241) do not undergo the cell shape changes required for 
invagination of the ventral furrow. Occasionally a cell does constrict its apical 
membrane in the DRhoGEF2 mutant (arrowhead) but there is no co-ordinated 
constriction. A, C, E: wild-type, B, D, F: DRhoGEF2 mutant. Taken from 
(Barrett, Leptin et al. 1997).
Epithelia are not static structures; they must maintain integrity during the 
numerous morphogenetic movements they undergo during development. 
Rho GTPases play important roles in this maintenance. DRhoGEF2 is 
required during ventral furrow formation, but it is also required 
reiteratively during embryogenesis when an epithelial sheet is required to 
fold during a morphogenetic process, such as salivary gland formation 
(Nikolaidou and Barrett 2004). During germ band elongation, when 
epithelial cells intercalate to elongate the embryo, myosin II is required for
37
the junctional remodelling that accompanies this process (Bertet, Sulak et 
al. 2004). The injection of a Rho kinase (ROK) inhibitor into a 
cellularising embryo causes defects in junctional remodelling exactly as 
seen in a myosin II mutant, thus Rho is likely to be playing an important 
role in germ band extension.
1.7.6. Dorsal closure
Another process involving the morphogenesis of epithelia is dorsal 
closure. During dorsal closure sheets of epithelial cells migrate over a 
substratum in order to close a hole in the epithelium. Cells within the 
epithelium form an actin-myosin cable that runs around the hole acting as 
a “purse-string” to provide force to close the hole (Hutson, Tokutake et al. 
2003). Rho1 is necessary for the formation of this cable and for 
maintenance of the integrity of the epithelium whilst it moves over the 
substratum (Bloor and Kiehart 2002; Jacinto, Wood et al. 2002). 
Interestingly, Rac1 is required for contraction of amnioserosa cells, over 
which the epithelial sheets move (Harden, Ricos et al. 2002). The 
leading edge cells within the migrating epithelium also send out 
lamellipodia and filopodia which are regulated by Cdc42 and Rac1, and 
enable cells to adhere to their correct partners in the final stages of dorsal 
closure (Jacinto, Wood et al. 2000).
The initiation of dorsal closure is regulated by the JNK (Jun N-terminal 
kinase) signalling cascade. Studies in mammalian systems show this 
cascade to be downstream of Rho GTPase signalling and there is 
evidence to support Rac and Cdc42 involvement in initiation of 
Drosophila dorsal closure, although it is unlikely that Rho1 is involved 
(Settleman 2001).
1.7.7. Nervous system development
As described above, the requirement for Rho GTPases in axonal 
guidance is well-established in tissue culture systems. Studies in
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Drosophila confirm the requirement for Rho GTPases in axon guidance in 
vivo, but some results conflict with tissue culture studies. Contrary to 
studies with mammalian tissue culture neurons, in a Drosophila embryo it 
appears that Rho does not play a role in axon guidance since axons 
project normally in a fly mutant for Rho1 (Lee, Winter et al. 2000). 
However, dendrites are over-extended in this mutant, and the dendritic 
tree is reduced when Rho1 is over-expressed indicating that Rho1 may 
play a role in dendritic morphogenesis in fruit flies. The Rac GTPases 
are, however, required in axon guidance in Drosophila. Loss of all three 
Racs (Rac1, Rac2, Mtl) leads to defects in axon growth, guidance and 
branching, and it is likely that these effects are mediated via different Rac 
effectors (Ng, Nardine et al. 2002). The Rac GEF Trio mediates axonal 
guidance, and still life, another Rac GEF, is required for differentiation of 
axons into mature synapses (Sone, Hoshino et al. 1997; Hakeda-Suzuki, 
Ng et al. 2002).
At the Drosophila midline axons must make a decision whether to cross 
in order to reach their targets for innervation. A system of attractive and 
repulsive cues directs axons across the midline and prevents them re­
crossing. Recent work indicates that a RhoGAP, Vilse, is required for the 
repulsive response mediated by the Robo receptor in axons crossing the 
midline (Lundstrom, Gallio et al. 2004). This RhoGAP promotes the 
intrinsic GTPase activities of Rac and, to a lesser extent, Cdc42, thereby 
inactivating them. These results, combined with genetic interaction data, 
suggest a Robo signalling pathway involving Rac inactivation mediates 
the repulsive response at the midline.
The nervous system is not made up solely of neurons -  glia are required 
to ensheath axons in order for them to transmit electrical signals 
effectively. Glia in the Drosophila peripheral nervous system must first 
migrate from the lateral edge of the central nervous system to the 
periphery and then ensheath their target axons. A study of the actin 
cytoskeleton within these cells revealed dynamic rearrangements during
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this migration process and the requirement for the small GTPases Rho1 
and Rac1 for both migration and ensheathment of axons (Sepp and Auld 
2003).
1.7.8. Muscle development
Muscles are formed in flies by the fusion of myoblasts into mature 
syncitial muscle fibres, as in mammals. The Rac triple mutant fly exhibits 
defects in myoblast fusion, confirming earlier studies with dominant 
negative Rac (Hakeda-Suzuki, Ng et al. 2002). In this case it is the Rac 
GEF Myoblast city (Mbc) that is probably responsible for the regulation of 
Rac activity.
1.7.9. Eye development
Drosophila have compound eyes made from over 800 ommatidia each 
composed of eight photoreceptor cells and twelve accessory cells. The 
over-expression of Rho1, Rac1, Rac2 or Cdc42 in the eye leads to a 
rough eye caused by the disruption of photoreceptor morphology or 
organisation (Hariharan, Hu et al. 1995; Nolan, Barrett et al. 1998). In the 
case of Rho1, this is a direct result of disorganised actin in the 
photoreceptors (Hariharan, Hu et al. 1995). Further studies with Rac 
indicate its involvement in the regulation of photoreceptors by rhodopsin. 
Activated Rac is able to rescue a rhodopsin mutant in which 
photoreceptors degenerate (Chang and Ready 2000).
1.7.10.Tissue polarity
Epidermal structures such as the eye are polarised along an axis 
orthogonal to their apico-basal axis. Rho acts downstream of the Frizzled 
G-protein coupled receptor (Strutt, Weber et al. 1997) to set up this 
planar cell polarity by rearranging the actin cytoskeleton via ROK- 
mediated myosin II activation (Winter, Wang et al. 2001). This pathway 
has also proved to be important in establishment of polarity and
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convergent cell extension in the zebrafish (Marlow, Topczewski et al.
2002).
Studies with dominant negative Rac had indicated a function for this small 
GTPase in the establishment of tissue polarity (Fanto, Weber et al. 2000), 
but more recent work with loss of function triple Rac mutants contradicts 
this (Hakeda-Suzuki, Ng et al. 2002).
1.7.11 .Metamorphosis
The transition from larva to pupa towards the end of adult development is 
regulated by the steroid hormone ecdysone. A downstream effector of 
Rho1, LIM kinase, regulates ecdysone-induced gene expression during 
this transition (Chen, Gajowniczek et al. 2004). In Drosophila tissue 
culture cells this response is dependent on the actin cytoskeleton and the 
SRF transcription factor. This is the first evidence of potential 
involvement of Rho GTPases in metamorphosis.
1.8. In vitro studies complement in vivo studies
Much of the in vivo evidence of Rho GTPase function during development 
complements results from mammalian tissue culture studies. However, in 
vivo mutant studies highlight the limitations of using dominant negative 
forms of Rho GTPases for study either in vitro or in vivo since dominant 
negatives sometimes produce non-specific phenotypes not seen in 
studies with mutants and must therefore be interpreted with caution.
1.9. DRhoGEF2 functions in cellular contraction
As stated above, DRhoGEF2 functions as a GEF for Drosophila Rho1 
GTPase. The study of DRhoGEF2 function provides the backdrop to this 
thesis. DRhoGEF2 is required for cell shape changes during ventral 
furrow formation in Drosophila gastrulation, as mentioned above. Cells at 
the ventral midline constrict their apical membranes to allow invagination 
of the ventral furrow (fig. 1.5). DRhoGEF2 also induces contractile cell 
shape changes when over-expressed in Drosophila S2 cells in culture
41
(Rogers, Wiedemann et al. 2004). In both cases there is evidence that 
DRhoGEF2 is regulating myosin regulatory light chain localisation 
(Nikolaidou and Barrett 2004; Rogers, Wiedemann et al. 2004). It is likely 
that DRhoGEF2 activates DROK via Rho1. In mammalian cells ROK 
phosphorylates regulatory myosin light chain (Amano, Ito et al. 1996) 
activating acto-myosin contraction, and it is likely that DROK does the 
same.
It is also interesting to note that DRhoGEF2 associates with the plus ends 
of microtubules in S2 cells via an interaction with End-binding protein 1 
(EB1) (Rogers, Wiedemann et al. 2004). Upon over-expression of a 
constitutively active form of Cta (the Ga protein that is predicted to 
activate DRhoGEF2) DRhoGEF2 relocalises from the microtubule tips 
probably to the plasma membrane and cells round up. It is currently 
unknown whether DRhoGEF2 is localised to microtubule tips in vivo, and 
if so how this affects DRhoGEF2 and myosin localisation in apically- 
constricting cells during ventral furrow formation.
1.10. DRhoGEF2 is an RGS Rho GEF
Analysis of the primary sequence of DRhoGEF2 indicates adjacent DH 
and PH domains that are presumed to confer Rho GEF activity. The 
Drosophila genome encodes 22 predicted Rho GEFs with DH and PH 
domains. Similarly to the mammalian system, it appears that some 
Drosophila Rho GEFs are promiscuous in their activation of Rho 
GTPases whereas others are more specific. Genetic interactions imply 
that DRhoGEF2 is able to activate Rho1, but not Cdc42 or Rac1 (Barrett, 
Leptin et al. 1997), and biochemical analysis indicates that DRhoGEF2 
activates Rho1 but not Rac1, Rac2, RhoL (Rac3), Mtl, or Cdc42 
(Grosshans, Wenzl et al. 2005).
The primary sequence of DRhoGEF2 also indicates the presence of other 
putative signalling domains (fig. 1.6). The regulator of G-protein 
signalling (RGS) domain is where the Ga protein, Concertina, is believed
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to bind and thereby activate GEF activity. The existence of this domain 
places DRhoGEF2 in the family of RGS Rho GEFs.
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Figure 1.6. DRhoGEF2 putative signalling domains. DRho GEF2 is a large 
protein (~280KDa) with many putative signalling domains. PDZ: Postsynaptic 
density protein/Discs large/Zonula occludens domain, RGS: Regulator of G- 
protein signalling domain, C1: phorbol ester binding domain, DH:Dbl homology 
domain, PH: pleckstrin homology domain. N: N-terminus, C: C-terminus.
Dashed lines indicate putative signalling pathway. Not to scale.
These proteins act as a link between heterotrimeric G-proteins and Rho 
GTPases. The human orthologues of DRhoGEF2, p115 Rho GEF, 
PDZRhoGEF and LARG, exchange GDP for GTP on RhoA GTPase in 
direct response to Ga binding (Hart, Jiang et al. 1998; Rumenapp, 
Blomquist et al. 1999; Suzuki, Nakamura et al. 2003).
The primary sequence of DRhoGEF2 also indicates the presence of a 
putative phorbol ester / diacylglycerol (DAG)-binding or C1 domain. 
Protein kinase C contains such a domain and is directly activated upon 
binding diacylglycerol. The significance of this domain in DRhoGEF2 is 
not understood. The final putative signalling domain identified by primary
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sequence analysis of DRhoGEF2 is a Postsynaptic density protein/Discs 
large/Zonula occludens (PDZ) domain. This will be discussed in detail 
below.
Human
RGS Cl PH
I I -*l ~l
LARG
982aa
PDZRhoGEF
1522aa
p115RhoGEF
912aa
Fruit fly
Worm
DRhoGEF2
2559aa
CeRhoGEF
1293aa
Figure 1.7. The RGS Rho GEF Family. LARG: leukaemia associated Rho 
GEF, PDZ: PDZ domain, RGS: RGS domain, PEB: phorbol ester binding 
domain, DH:Dbl homology domain, PH: pleckstrin homology domain.
Numbers indicate protein size in amino acids. Not to scale.
1.11. The RGS Rho GEF family participate in conserved signalling 
pathways
The identification of DRhoGEF2 in Drosophila marked the beginning of 
the discovery of RGS Rho GEFs in various species. In humans the 
documented discovery of p115RhoGEF was closely followed by 
PDZRhoGEF (Fukuhara, Murga et al. 1999) which has a rat orthologue, 
GTRAP48, and LARG (Kourlas, Strout et al. 2000), which has also been 
cloned in mouse and Xenopus (Zinovyeva, Sveshnikova et al. 2004). 
Recently another member, CeRho GEF in C.elegans, has been added to 
the RGS Rho GEF family (fig. 1.7) (Yau, Yokoyama et al. 2003). The 
human orthologues of DRhoGEF2 each contain only a subset of the 
putative signalling domains, whereas CeRho GEF shares all predicted
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domains with DRhoGEF2 indicating that these domains may have been 
lost in gene duplication events during evolution.
In all cases there is genetic or biochemical evidence that the RGS Rho 
GEFs participate in a signalling pathway involving their activation by a Ga 
protein and their subsequent activation of a Rho GTPase. In the case of 
the human and Drosophila proteins there is also considerable genetic and 
biochemical data to support the existence of a signalling pathway from 
the cell surface via a GPCR to the actin cytoskeleton, resulting in the 
regulation of cell shape. In particular, in neurons it is well-established 
that lypophosphatidic acid (LPA) binding to its receptor initiates a 
signalling pathway via Gai2/13 to induce actin cytoskeleton 
rearrangements, growth cone collapse and neurite retraction 
(Kranenburg, Poland et al. 1999). Now, with the functional assignment of 
PDZRhoGEF in neurite retraction it is possible to see how the whole 
pathway fits together, and a homologous pathway is likely to exist in the 
fruit fly (fig. 1.8) (Togashi, Nagata et al. 2000).
1.12. RGS Rho GEFs are GAPs for heterotrimeric G proteins and 
GEFs for small G proteins
p115RhoGEF exhibits GAP activity towards G ai2 and G ai3 in vitro 
(Kozasa, Jiang et al. 1998). The RGS domain increases the GTPase 
activity of the Ga protein thereby generating a negative feedback on the 
signalling pathway. P115RhoGEF is also able to act as a GEF for Rho 
but not Rac, Cdc42 or Ras small GTPases (Hart, Sharma et al. 1996). 
The combined GAP/GEF activity is likely to reflect precise regulation of 
the signalling pathway from GPCRs through to Rho GTPases via a 
negative feedback system. LARG and PDZRhoGEF have been shown to 
act as Rho GEFs for RhoA, but not Rac1 or Cdc42 (Rumenapp, 
Blomquist et al. 1999; Taya, Inagaki et al. 2001).
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Figure 1.8. Putative orthologous signalling pathways. Signalling 
pathways from an extracellular ligand to the actin cytoskeleton are likely to 
be orthologous in Drosophila and humans. Adapted from (Barrett, Leptin et 
al. 1997).
LARG GAP activity has been demonstrated for both G ai2 and G ai3l and, 
similarly to p115RhoGEF, its GAP activity is restricted to G ai2/13 of all the 
heterotrimeric G proteins tested (Suzuki, Nakamura et al. 2003).
The specificity of Ga proteins in the activation of RGS Rho GEFs is 
currently under debate. Cta is a Ga protein related to both Gai2 and Gai3 
- the Drosophila genome is predicted to encode only one Ga protein of 
this class. There is no evidence to suggest that DRhoGEF2 is activated 
by other Ga proteins, although this has not been directly tested to date. 
Many of the human RGS Rho GEFs can interact with more than one G 
protein in co-immunoprecipitation experiments, but this does not 
necessarily imply that each of those G proteins activates that particular 
RGS Rho GEF. Previous studies indicate that solely G ai2 is able to 
activate LARG, but more recent studies also implicate Gaq (Booden, 
Siderovski et al. 2002; Chikumi, Fukuhara et al. 2002). This may be 
dependent on the cell type, and it should be noted that the direct 
stimulation of LARG by Gaq in vitro remains to be shown. p115RhoGEF 
can be activated by G ai3i but Gai2 inhibits this activation (Hart, Sharma et
al. 1996). The RGS domain of GTRAP48 (the rat orthologue of 
PDZRhoGEF) is able to activate RhoA when it is itself activated by 
constitutively active G ai3, but it only weakly interacts with Gdi2 (Wells, Liu 
et al. 2002). These results are summarised in Table 1.1.
Ligand
specificity
Ga
specificity
Interactors Functions
LARG LPA?
12
q??
IGF-1 
receptor 
Plexin B 
FAK 
Tec 
LARG 
PDZRhoGEF
Axon growth cone 
regulation
Actin cytoskeleton 
regulation
PDZRhoGEF/
GTRAP48
Thrombin?
13
12??
Actin 
EAAT4 
PAK4 
Plexin B 
FAK 
PDZRhoGEF 
LARG
Neurite retraction
Axon growth cone 
regulation
Actin cytoskeleton 
regulation
p115RhoGEF/
Use
LPA? 
sphingosine 1- 
phosphate?
13 p115RhoGEF
B and T cell immune 
response
Actin cytoskeleton 
regulation
DRhoGEF2
Folded
gastrulation?
Concertina?
MCC 
Mec2 
group 3 
EB1
Actin cytoskeleton 
regulation
Cell contraction
Table 1.1. The RGS Rho GEFs. Upstream activators, interactors and 
downtream effects for the RGS Rho GEFs.
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Different extracellular ligands may ultimately activate different RGS Rho 
GEFs. The use of short interfering RNAs (siRNAs) has illustrated that 
lypophosphatidic acid (LPA) stimulation of Rho signalling requires l_ARG 
whereas thrombin stimulation of Rho signalling requires PDZRhoGEF in 
prostate cancer cells (Wang, Liu et ai. 2004). In both cases the addition 
of siRNA to p115RhoGEF has no effect, although p115RhoGEF isolated 
from fibroblast cells stimulated with LPA or sphingosine 1-phosphate is 
more active than when isolated from unstimulated cells (Wells, Gutowski 
etal. 2001).
It has recently been proposed that thrombin and LPA receptors activate 
different G proteins, G ai2 and G ai3 respectively (Yamaguchi, Katoh et al.
2003). Given this, and the fact that LARG is activated by Gai2 and 
PDZRhoGEF by G ai3, it is tempting to speculate that there may be two 
distinct pathways using different receptors, Ga proteins and RGS Rho 
GEFs, that both ultimately converge on Rho. However, caution should be 
exercised since these relationships have been documented in only one 
cell type to date.
1.13. RGS Rho GEFs have distinct expression patterns
DRhoGEF2 protein is expressed primarily in epithelia during 
embryogenesis in Drosophila and is localised to the apical end of cells. 
Expression levels are elevated in tissues undergoing morphogenetic 
processes involving folding of membranes, and in the central nervous 
system (Padash Barmchi, Rogers et al. 2005). An extensive analysis of 
the expression of PDZRhoGEF, p115RhoGEF and LARG proteins has 
been carried out in murine tissues. p115RhoGEF (or Lsc as the murine 
orthologue is known) is primarily expressed in haematopoietic cells in the 
mouse (Girkontaite, Missy et al. 2001). LARG is expressed across a 
wide variety of tissues including brain, smooth muscle, spleen, intestinal 
epithelium and skin (Becknell, Shen et al. 2003). PDZRhoGEF, by 
contrast, is expressed at high levels only in the brain (Kuner, Swiercz et 
al. 2002).
The expression of PDZRhoGEF and LARG in the murine nervous system 
has been further analysed in conjunction with expression analysis of 
Ga-12/13 (Kuner, Swiercz et al. 2002). Although both PDZRhoGEF and 
LARG are widely detected in the brain and spinal cord, a striking 
difference in subcellular localisation is observed. LARG is enriched in cell 
bodies of neurons whereas PDZRhoGEF localises to neuronal 
processes. This fits with the observed interaction between PDZRhoGEF 
and the neuronal glutamate transporter, EAAT4, which is expressed at 
synaptic junctions of glutaminergic neurons (Jackson, Song et al. 2001). 
Interestingly, G ai2 primarily co-localises with LARG in cell bodies 
whereas G ai3 co-localises with PDZRhoGEF in neuronal processes. This 
could represent the proposed specificity of RGS activation by Ga 
proteins, as described above. All four proteins are also expressed in 
dorsal root ganglia of the peripheral nervous system.
1.14. Human RGS Rho GEFs are recruited to the plasma membrane 
upon activation of Ga protein signalling
p115RhoGEF localises to the cytoplasm of resting cells and relocalises to 
the plasma membrane upon activation by LPA (Wells, Gutowski et al.
2001). In epithelial cells LARG is primarily localised to lateral membranes 
with a small proportion cytoplasmically localised. PDZRhoGEF is 
localised to the plasma membrane or peri-plasma membrane in resting 
fibroblast cells (Togashi, Nagata et al. 2000). These and other studies 
are difficult to compare since they make use of different cell types and 
some study endogenous proteins, others over-expressed proteins. 
However, a consensus seems to be that p115RhoGEF is primarily 
cytoplasmically localised, whereas PDZRhoGEF and LARG are primarily 
plasma membrane or peri-plasma membrane localised in a resting cell. 
Upon stimulation of GPCR signalling (e.g. by LPA addition) the RGS Rho 
GEFs localise to the plasma membrane.
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1.15. RGS Rho GEFs have effects on the actin cytoskeleton
In mammalian fibroblasts over-expression of LARG results in the 
formation of actin stress fibres. This is abrogated by the co-expression of 
a dominant negative RhoA (Taya, Inagaki et al. 2001). p115RhoGEF 
also induces the formation of actin stress fibres when over-expressed 
(Togashi, Nagata et al. 2000). B and T cells derived from an Lsc 
knockout mouse show a profound reduction in actin polymerisation and 
improper migration compared to cells from a wild-type mouse 
(Girkontaite, Missy et al. 2001).
The over-expression of PDZRhoGEF in fibroblasts induces a 
relocalisation of actin to the cortical area beneath the plasma membrane 
and the cells round up. PDZRhoGEF interacts with actin via a short 
stretch of amino acids between the RGS and DH domains (Banerjee and 
Wedegaertner 2004). Two groups have studied the requirement for the 
different domains of PDZRhoGEF in the induction of actin-mediated cell 
shape changes in various cell lines. According to Togashi et al, the DH 
and PH domains are necessary and sufficient to induce stress fibre 
assembly, but the presence of a proline-rich domain C-terminal to the PH 
domain (fig. 1.9) is required to induce cell rounding and cortical actin 
assembly. Banerjee and Wedegaertner show that the actin-binding 
domain mediates localisation of PDZRhoGEF to the cell cortex but it may 
serve to inhibit Rho signalling since an actin-binding mutant shows 
increased levels of cell rounding. In neither case was a requirement for 
the PDZ domain in cellular localisation observed.
Studies of endogenous PDZRhoGEF localisation in a neuronal cell line 
indicate that it relocalises to the tips of retracting neurites upon addition of 
lypophosphatidic acid (LPA) (Togashi, Nagata et al. 2000). This mirrors 
the relocalisation of Rho upon LPA stimulation indicating that 
PDZRhoGEF could be interacting with Rho at neurite tips to promote 
actin reorganisation. Further evidence is provided by over-expression of
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a dominant negative PDZRhoGEF that lacks the DH/PH domains and 
inhibits LPA-induced neurite retraction and cell rounding.
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Figure 1.9. The predicted signalling and protein interaction domains of PDZ 
Rho GEF. PDZ: PDZ domain, P: proline-rich region, RGS: RGS domain, A: actin- 
binding domain, DH: DH domain, PH: PH domain, PAK4: PAK4 binding domain, 
dimer: dimerisation domain, FAK: domain of FAK phosphorylation which overlaps 
with PAK4 binding and dimer domains. Numbers refer to published amino acid 
sequence. Not to scale.
1.16. PDZRhoGEF and LARG interact with plexin B and mediate 
growth cone collapse
The direct interaction between plexin B and RGS Rho GEFs provides the 
missing link between plexin activation and Rho-mediated growth cone 
collapse (Swiercz, Kuner et al. 2002). Plexins are expressed on the 
surface of axon growth cones and mediate their targeting via interaction 
with semaphorin ligands that guide the axon. Plexin B1/2/3 share a 
canonical PDZ binding motif at their C-terminus (Thr-X-Leu-COOH) and 
the interaction is mediated via the PDZ domain of LARG / PDZRhoGEF. 
The interaction enables the plexin receptor to come to the membrane and 
respond to the semaphorin ligand since PDZ Rho GEF and LARG are 
localised at the membrane. The interaction leads to a dramatic increase 
in Rho signalling and consequent growth cone collapse, and this 
response is blocked by a dominant negative PDZRhoGEF (Perrot, 
Vazquez-Prado et al. 2002).
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1.17. LARG and possibly PDZRhoGEF are activated by the insulin­
like growth factor 1 receptor
LARG interacts with the insulin-like growth factor 1 (IGF-1) receptor via its 
PDZ domain (Taya, Inagaki et al. 2001). The IGF-1 receptor does not 
carry a canonical PDZ binding motif (see section 1.30) at its C-terminus 
(Gln-Ser-Ser-Thr-Cys-COOH). However, solely the C-terminal 20 amino 
acids were used in a yeast-2-hybrid assay that identified the interaction, 
so it does seem likely that the interaction is mediated via a classic C- 
terminus-PDZ domain interaction. The active IGF-1 receptor stimulates 
nucleotide exchange on RhoA in a cellular assay and this is inhibited by 
over-expressing solely the PDZ domain of LARG. IGF-1 stimulation also 
induces actin stress fibres, and this is partially inhibited by over­
expression of the PDZ domain of LARG. Preliminary experiments 
indicate that PDZRhoGEF may also interact with the IGF-1 receptor 
(unpublished, (Taya, Inagaki et al. 2001)).
1.18. LARG and PDZRhoGEF are regulated by phosphorylation
In some cases Rho GEF activity is regulated by phosphorylation. For 
example, the Rac GEFs Vav1 and Vav2 are tightly regulated by tyrosine 
phosphorylation (Crespo, Schuebel et al. 1997). LARG is not able to 
stimulate guanine nucleotide exchange on Rho in vitro in direct response 
to Ggi2 i although it can do so in a cellular system and in response to G ai3 
in vitro. This indicates the requirement for an extra factor in Gai2- 
mediated Rho activation by LARG. This factor is Tec, a tyrosine kinase, 
which phosphorylates LARG (but not p115RhoGEF) independently of 
Ggi2 activation and stimulates Rho signalling to a level similar to that 
achieved by G ai3 in the absence of Tec (Suzuki, Nakamura et al. 2003).
It is likely that the site of phosphorylation is within or nearby the RGS 
domain.
A separate study has shown an increase in Rho GEF activity in response 
to focal adhesion kinase (FAK)-mediated tyrosine phosphorylation of 
LARG and PDZRhoGEF (Chikumi, Fukuhara et al. 2002). In this case
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the site of phosphorylation was determined to be C-terminal to the PH 
domain. PDZRhoGEF is also phosphorylated by p21-activated kinase 
(PAK) 4 C-terminally to the PH domain. This phosphorylation abrogates 
the ability of PDZRhoGEF to promote the formation of actin stress fibres 
in cells. The PAK family of serine-threonine kinases are regulated by 
Cdc42 and this could, therefore, represent a novel method of Cdc42 
inhibition of Rho-mediated stress fibre formation.
These studies indicate that distinct signalling pathways may activate RGS 
Rho GEFs independently of GPCR-Ga pathways. Interestingly, the 
DRhoGEF2 mutant phenotype during embryogenesis in Drosophila is 
stronger than that of eta or fog mutants, indicating the existence of Cta- 
independent signals feeding in to DRhoGEF2. The PDZ and C1 domains 
of DRhoGEF2 are also indicative of Cta-independent signalling through 
DRhoGEF2. Although there is no evidence of phosphorylation events 
regulating DRhoGEF2, it will be interesting to determine what these 
additional signals are, and how they regulate DRhoGEF2 function.
1.19. RGS Rho GEFs can homo- and heterodimerise via their C- 
termini
All three human RGS Rho GEFs are able to homodimerise. At present 
there is no evidence for DRhoGEF2 doing so, although it has not 
specifically been studied. PDZRhoGEF and LARG can also 
heterodimerise with each other, although p115RhoGEF can 
heterodimerise with neither (Chikumi, Barac et al. 2004). This 
dimerisation is mediated via a region C-terminal to the PH domain (fig. 
1.9). This region is one of the least conserved amongst the RGS Rho 
GEFs and contains no obvious identifiable domains except a predicted 
coiled coil. Coiled coils are protein motifs that can mediate 
oligomerisation (Burkhard, Stetefeld et al. 2001).
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Complete deletion of the C-terminus of any of the mammalian RGS Rho 
GEFs leads to an increase in Rho GEF activity in vivo. In the case of 
p115 Rho GEF/Lsc the mutation of residues within the predicted coiled 
coil abrogates homo-dimerisation although this has no effect on Rho GEF 
activity (Eisenhaure, Francis et al. 2003). This, and the fact that deletion 
of the C-terminus of p115RhoGEF does not increase its activity in vitro, 
indicates that there are likely to be other proteins interacting with the C- 
terminus and affecting Rho GEF activity in vivo (Wells, Gutowski et al. 
2001,). Since the C-terminus is the site of FAK phosphorylation on 
PDZRhoGEF and LARG, and serves to bind PDZRhoGEF to PAK4, it is 
possible that one of these interactors inhibits Rho GEF activity. For p115 
Rho GEF C-terminal interactors have yet to be identified.
Isoforms of Lsc lacking its regulatory C-terminus are expressed in the 
mouse spleen (Eisenhaure, Francis et al. 2003). p115RhoGEF, 
PDZRhoGEF and LARG are focus-forming when over-expressed in 
human fibroblasts (Fukuhara, Chikumi et al. 2001) and deletion of the C- 
terminus significantly enhances their transforming potential (Chikumi, 
Barac et al. 2004). Again, it is possible that a factor interacting with the 
RGS Rho GEFs at the C-terminus serves to keep oncogenic potential in 
check, probably by inhibiting Rho GEF activity.
1.20. The Mutated in Colorectal Cancer (MCC) protein interacts with 
DRhoGEF2
There have been many binding partners identified for the human RGS 
Rho GEFs, but until recently none for DRhoGEF2. A yeast-2-hybrid 
screen (Fields and Song 1989) using the predicted PDZ domain of 
DRhoGEF2 yielded three potential binding partners (K. Barrett, 
unpublished). One of these, named Drosophila MCC (DMCC) due to its 
homology with human MCC, was subsequently shown to interact with 
recombinant DRhoGEF2 PDZ domain in co-immunoprecipitation 
experiments (K.Barrett, unpublished and here in chapter 5). Two of the 
human orthologues of DRhoGEF2, LARG and PDZRhoGEF, also co-
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immunoprecipitate with the human orthologue of MCC (K.Barrett, 
unpublished). Thus, the interaction is conserved across species from fruit 
flies to humans. Both human and Drosophila MCC have a classic PDZ 
target motif at their C-terminus: Threonine - X -  Leucine -  COOH (where 
X is any amino acid). It is proposed, therefore, that MCC interacts with 
RGS Rho GEF via its C-terminus in a classic PDZ-target interaction (see 
section 1.30).
1.21. The MCC gene is mutated in a variety of human cancers
MCC was originally identified as a gene mutated in patients with colon 
cancer (Kinzler, Nilbert et al. 1991a). It was initially thought to be the 
tumour suppressor gene mutated in patients with familial adenomatous 
polyposis (FAP). This disease is characterised by the development of 
multiple pre-cancerous polyps (lesions) that have a 100% chance of 
becoming cancerous if the colon is not removed. However, the gene 
mutated in patients with FAP was subsequently found to be the 
adenomatous polyposis co!i (APC) gene which lies within 500Kb of the 
MCC gene in the 5q21 region of the human genome (Kinzler, Nilbert et al. 
1991b).
The evidence for MCC as a tumour suppressor is confusing. MCC is not 
the gene involved in FAP, but it does show frequent loss of 
heterozygosity in patients with colorectal cancer and in a number of other 
cancers including oral squamous cell carcinoma, gastric carcinoma and 
breast carcinoma (Medeiros, Nagai et al. 1994; Hsieh and Huang 1995; 
Huang, Chiang et al. 1997). The interpretation of this should be treated 
with caution, however, since when MCC is heterozygously deleted the 
remaining allele is not frequently mutated in colorectal tumours (Curtis, 
Bubb et al. 1994). This suggests that MCC does not function as a tumour 
suppressor in human colorectal cancer. However, evidence from 
knockout mice suggests that murine MCC does indeed function as a 
tumour suppressor. Knockout mice that are not expressing detectable 
MCC protein develop adenocarcinomas and tumours in other organs
including lung, liver and lymphoid tissue (Lipkin 1997). In a separate 
study, mouse lung tumours were assayed for MCC mRNA levels. Levels 
were decreased compared to normal lung tissue (Oreffo, Robinson et al. 
1998). Overall, it is unclear whether MCC is acting as a tumour 
suppressor in humans but the available evidence, including the murine 
studies, indicates that there is a strong possibility that it is.
1.22. Murine MCC is expressed in intestinal epitheiia and nervous 
tissue
An antibody directed against the C-terminal 12 amino acids of murine 
MCC indicates high levels of expression in the brain (Senda, Matsumine 
et al. 1999). Expression in cerebellar neurons is throughout the cell body, 
neuronal fibres and terminals, but no nuclear staining is observed. Closer 
examination using immunoelectron microsocopy reveals an association of 
MCC with membranes, particularly organelle membranes such as 
mitochondria. It is interesting to note that MCC is expressed at high 
levels along with LARG and PDZRhoGEF in neurons of the mouse brain.
It is tempting to speculate that this co-localisation could be indicative of a 
neuronal function for the interactors.
MCC expression is also observed in the intestinal epithelium, with 
strongest expression associated with the lateral membranes. Apical 
microvilli, hepatocytes of the liver and epithelial cells of the kidney are 
also strongly reactive to the antibody. In all cases of observed MCC 
expression it is mainly associating with a membrane, either plasma or 
organelle. Upon fractionation experiments of NIH3T3 fibroblast cells the 
MCC protein detectable in the crude membrane fraction is not solubilised 
with detergents implying that it is not a transmembrane protein, but is 
likely to be part of an insoluble complex (Matsumine, Senda et al. 1996).
1.23. MCC may play a role in cell cycle regulation
The over-expression of MCC in synchronous mouse fibroblasts in culture 
prevents them from entering S-phase (Matsumine, Senda et al. 1996).
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Two mutant forms of MCC, one that was identified in a human colon 
cancer patient (Kinzler, Nilbert et al. 1991a), and another that disrupts a 
region with low homology to G protein-coupled muscarinic receptors, both 
abrogate the ability of MCC to block S-phase entry. This function may 
fulfil the tumour suppressor role that MCC is believed to possess, 
although there is no in vivo evidence for this as yet.
The same study indicated that MCC becomes phosphorylated upon 
serum stimulation of serum-starved cells. However, this phosphorylation 
is not cyclical in time with the cell cycle, so a role for MCC 
phosphorylation in regulation of the cell cycle is unlikely.
1.24. MCC has a homologue, MCC-2
MCC-2 was identified as an interactor of one of the PDZ domains of AIE- 
75, the antigen target in autoimmune enteropathy (AIE) (Ishikawa, 
Kobayashi et al. 2001). MCC-2 shares significant regions of identity with 
MCC including regions predicted to form coiled coils. The C-terminus of 
MCC-2 carries a classic PDZ target motif, Thr -  X -  Leu -  COOH, as 
MCC does. However, only MCC-2 interacts with AIE-75 in 
immunoprecipitation assays. MCC-2 is expressed in skeletal muscle, 
liver, small intestine, placenta and lungs. Interestingly, it is not expressed 
in brain tissue, therefore MCC and MCC-2 have different expression 
patterns. Since MCC-2 and MCC do not share a binding partner in AIE- 
75 and they have different expression patterns, it is likely that they have 
different or partially over-lapping functions.
1.25. The interaction between MCC and RGS Rho GEFs may 
provide a link between Rho GTPases and cancer
Since Rho proteins regulate the cell cycle and migration they may be 
misregulated in the cellular progression to cancer. The interaction 
between MCC and PDZ Rho GEF/LARG could provide a link between 
Rho GTPases and cancer. The evidence linking Rho GTPase signalling 
pathways to primary human cancer is modest but growing. The vast
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majority of studies of Rho GTPase signalling in cancer have involved the 
transformation of cells in culture. There have, so far, been few in vivo 
studies in animal models to assess the importance of Rho GTPase 
signalling in tumour growth and invasion, and this is one area where 
much more work needs to be done.
Unlike the Ras GTPases, Rho GTPases are not frequently mutated in 
tumours. One exception to this is the 5’ untranslated region of the RhoH 
gene which is frequently rearranged in Non-Hodgkins lymphoma, and is a 
target of aberrant hypermutation activity in large-cell lymphomas. 
However, it is not known how these rearrangements and mutations affect 
RhoH activity (Ridley 2004).
The over-expression of Rho GTPases has been reported in a number of 
human cancers. Over-expression of a Rho GTPase leads to the same 
outcome as a constitutively active mutation, i.e. increased levels of 
signalling. Increased levels of Rho C can stimulate metastasis and RhoC 
is over-expressed in over 90% of cases of inflammatory breast cancer, a 
highly invasive cancer (Clark, Golub et al. 2000). Farnesyl transferase 
inhibitors (FTIs), which ultimately inhibit prenylation and therefore 
association of a GTPase with the membrane, may provide a therapy for 
RhoC over-expressing tumours. However, these inhibitors may function 
by inhibition of RhoB or RhoE rather than RhoC, since RhoC is not 
farnesylated (van Golen, Bao et al. 2002). Nevertheless, this indicates 
that over-expression is an important form of misregulation of Rho 
signalling in cancer.
RhoA function is required for another small GTPase, Ras, to transform 
cells and lead to anchorage-independent growth (Coleman, Marshall et 
al. 2004). This implicates RhoA as an oncogene, and is likely to relate to 
its effects on cell proliferation (see section 1.6.5). Conversely, RhoB is a 
gene with putative tumour suppressor properties. A recent study 
indicates that RhoB is able to inhibit phosphatidylinositol 3-kinase
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signalling (Jiang, Sun et al. 2004). Since components of this pathway are 
frequently mutated in cancer this study may explain the tumour 
suppressor properties of RhoB.
Although the evidence for Rho GTPase involvement in cancer is limited, 
the evidence that Rho GEFs are misregulated in cancer is far more 
substantial. Dbl Rho GEF was originally identified as an oncogene in cell 
transformation assays (Eva and Aaronson 1985). Unlike Rho GTPases 
themselves, Rho GEFs do exhibit point mutations or deletions that lead to 
constitutive activation in human cancers.
LARG provides an example of a GEF that is misexpressed in cancer.
This gene was discovered as an in-frame fusion with the mixed lineage 
leukaemia (MLL) gene in patients with acute myeloid leukaemia (Kourlas, 
Strout et al. 2000). This fusion gives rise to an incomplete LARG protein 
lacking its PDZ domain but containing the RGS, Dbl-homology and 
pleckstrin homology domains under the control of the MLL promoter.
Another GEF, T-cell lymphoma invasion and metastasis 1 (TIAM1), 
upregulates the expression of metalloprotease inhibitors and is likely to 
inhibit metastasis. Recently, a small molecule inhibitor of Rac that 
prevents its activation in response to TIAM1 has been tested in prostate 
cancer cells in culture (Gao, Dickerson et al. 2004). This inhibitor 
prevented the proliferation, anchorage-independent growth and invasion 
phenotypes that are associated with Rac1. The fact that the Rho 
GTPases and their GEFs are implicated in metastasis is not surprising 
given their primary function in regulating the actin cytoskeleton and cell 
migration.
Cancer cells proliferate unchecked and ultimately metastasise, but in 
order for a growing tumour to be sustainable, angiogenesis is required to 
maintain oxygen and nutrient supply. Recent work indicates a novel role 
for the semaphorin-plexin partnership in the promotion of angiogenesis.
In an in vivo mouse model sema4D (a semaphorin ligand) potently
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enhances blood vessel formation, and this is plexin and Rho dependent 
(Basile, Barac et al. 2004). This opens a new area of study of Rho 
proteins in the regulation of angiogenesis in tumours.
Rho signalling is likely to become significant in the area of cancer 
therapeutics since there are already inhibitors of various Rho signalling 
pathway components available which may prove to have therapeutic 
uses. Examples include the farnesyl-transferase inhibitors mentioned 
above whose effects are rather non-specific, and small-molecule drugs 
targeting the PAK kinases and ROK kinases (Aznar, Fernandez-Valeron 
et al. 2004). Rigorous testing in animal models of these and other novel 
therapeutics will determine whether there is potential for Rho-targeted 
drugs in the clinic.
1.26. Two other proteins also interact with the PDZ domain of 
DRhoGEF2
The yeast-2-hybrid screen using the PDZ domain of DRhoGEF2 yielded 
two potential binding partners in addition to MCC. One has significant 
homology to human stomatin and C.elegans Mec-2, thus it is referred to 
as DMec-2. Mec-2 is required for the proper function of ion channels in 
neurons involved in the touch response (Goodman, Ernstrom et al. 2002). 
The third protein interacting with DRhoGEF2 PDZ domain, named 
Group3, does not have orthologues in species identifiable from Basic 
Local Alignment Search Tool (BLAST) searches (Altschul, Madden et al. 
1997). This does not necessarily mean this gene has no function in 
Drosophila -  for example the grim, reaper and head involution defective 
(hid) genes involved in apoptosis in Drosophila have functional 
mammalian orthologues with such limited sequence conservation that 
they are not picked up as orthologues in BLAST searches. The functions 
of Mec-2 and Group 3 proteins in Drosophila are under investigation.
All three proteins identified in the yeast 2-hybrid screen carry a classic 
PDZ target motif at their C-terminus: Thr -  X -  Leu -  COOH. It is likely,
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therefore, that they interact with the DRhoGEF2 PDZ domain via a classic 
PDZ domain-target interaction.
1.27. PDZ domains are protein-protein interaction modules
PDZ domains are ~90 amino acid protein modules that mediate protein 
interactions. Their name derives from some of the proteins in which they 
were initially discovered: Postsynaptic density 95, Discs large and Zonula 
occludens-1. Their structure consists of six 3 strands (pA-pF) and two a 
helices (aA and aB) which fold in an overall six-stranded p sandwich.
They can be predicted from primary sequence data on the basis of 
conserved amino acid motifs and were originally termed GLGF domains 
due to the existence of a conserved Gly-Leu-Gly-Phe motif involved in 
binding the carboxylate group at the C-terminus of their target. PDZ (or 
PDZ-like) domains have been identified in organisms as diverse as 
bacteria, plants, yeast, fruit flies and humans (Ponting 1997). Drosophila 
is predicted to have 131 proteins containing PDZ domains based on 
predictions using Simple Modular Architecture Analysis Tool (SMART) 
(Letunic, Copley et al. 2004).
1.28. PDZ-containing proteins act as scaffolds and participate in 
signalling
In many cases proteins contain more than one PDZ domain and/or 
another type of protein interaction domain (such as Src homology 3 
(SH3)) in addition to their PDZ domain, and for this reason they are often 
thought of as “scaffold” proteins that function to bring together signalling 
proteins. One protein, MUPP1, contains no less than 13 PDZ domains 
(Ullmer, Schmuck et al. 1998). In Drosophila the signalling protein InaD, 
which contains 5 PDZ domains, acts as a scaffold for proteins involved in 
photoreceptor signal transduction (Xu, Choudhury et al. 1998). The 
function of scaffolds in providing close physical proximity of the signalling 
complex machinery is likely to allow the rapid processing of signals along 
the pathway and tight regulation.
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Although PDZ domain-containing proteins may solely function as a 
scaffold, they often play more than a passive role, participating in the 
transduction of signals via enzymatic or other domains which they also 
often contain. LIM kinase is such an example with its serine-threonine 
kinase domain in addition to its PDZ domain.
The range of functions provided by PDZ domain-containing proteins is 
vast, not surprisingly given their common multi-domain structure. All 
characterised thus far are cytoplasmic (except interleukin-16), and many 
are associated with the plasma membrane. PDZ domain-containing 
proteins can generally be grouped into one of three sub-categories; those 
involved in signalling pathways as adaptors for cell surface receptors 
(including receptor tyrosine kinases and GPCRs), those involved in the 
establishment of epithelial polarity or those involved in signalling at both 
the pre- and post-synaptic sites of neurons (Nourry, Grant et al. 2003).
1.29. There are several mechanisms of interaction between PDZ 
domains and their targets
The canonical method of interaction between PDZ domain and target is 
via the C-terminus of the target. In this case the terminal amino acids 
insert into a “pocket” created by residues of the aB helix and pB strand 
(fig. 1.10). In a second, less common arrangement, the PDZ domain 
binds to an internal sequence of the target protein. For example, the 
transient receptor potential Ca2+ channel contains an internal PDZ binding 
motif that interacts with one of the InaD PDZ domains (Chevesich, Kreuz 
et al. 1997). PDZ domains can also dimerise, either with themselves 
(homo-) or with another PDZ domain (hetero-). An example of 
heterodimerisation involves amino acid residues of the nNOS PDZ 
domain forming a two-stranded p “finger” which inserts into the psd-95 
PDZ binding pocket (Tochio, Mok et al. 2000). Interestingly, the sixth 
PDZ domain of GRIP mediates homodimerisation but the crystal structure 
indicates that the peptide binding groove is not involved indicating that
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Carboxylate binding 
loop \  v
targets could
simultaneously bind, and a 
molecular complex be built 
up around the interaction 
(Im, Park et al. 2003).
Recently, a group of class II 
PDZ domains (see table
1.2) have also been shown 
to mediate interaction with 
phosphatidylinositol-3,4- 
diphosphate (PIP2), a 
plasma membrane lipid 
(Zimmermann, Meerschaert 
et al. 2002). Interestingly, 
excess PIP2 interferes with 
Figure 1.10. The PDZ-target interaction. the PDZ:target peptide
Representation of the crystal structure of part of interaction indicating that 
psd95-PDZ3 (blue) in complex with peptide perhaps the lipid binding
(yellow). Taken from (Doyle, Lee et al 1996) site overlaps with the
peptide binding site. To 
date, only a small group of class II PDZ domains have been shown to 
interact with lipids in this way, but perhaps other classes of PDZ domains 
can do the same.
1.30. The specificity of the PDZ-target interaction is determined by 
amino acid residues at the C-terminus of the target
The crystal structures of the Psd-95 PDZ domain complexed with its 
target indicate that the C-terminal 4 amino acids form specific interactions 
with the peptide-binding groove (fig. 1.10) (Doyle, Lee et al. 1996). The 
residue at the 0 position (i.e. the most C-terminal amino acid) is always 
hydrophobic in nature (e.g. leucine, valine, isoleucine), and this inserts 
into a hydrophobic pocket. In many cases, the residue at the -1 position
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points away from the interaction surface and thus does not participate. In 
this respect, the -1 position is highly variable amongst PDZ targets. 
However, there are examples of the -1 position contributing directly to the 
interaction e.g. a cysteine at the -1 position of NorpA plays a crucial role 
in its interaction with the first PDZ domain of InaD (Kimple, Siderovski et 
al. 2001).
The amino acid at the -2 position is important for binding and is used to 
classify PDZ domains based on their -2 position binding specificity (table
1.2) (Daniels, Cohen et al. 1998). Class I PDZ domains have a histidine 
residue at position aB1 (the bottom of the aB helix, fig. 1.10) which forms 
a hydrogen bond with the -2 position serine or threonine residue of the 
target. The vast majority of PDZ domains classified thus far fall into this 
class. Class II PDZ domains, by contrast, have a hydrophobic amino acid 
at the aB1 position which forms an interaction with a hydrophobic amino 
acid at the -2 position of the target. The final class, III, prefer negatively 
charged amino acids at the -2 position of the target.
It should be noted that some PDZ domains can bind multiple targets that 
place them in more than one class (Nourry, Grant et al. 2003).
1.31. The PDZ domain of DRhoGEF2 is a class I PDZ domain
In light of the fact that all three targets picked up in the yeast-2-hybrid 
screen with DRhoGEF2 PDZ domain have Thr-X-Leu-COOH at their C- 
terminus, it would seem that DRhoGEF2 is a class I PDZ domain. It does 
indeed have a histidine residue at the aB1 position, indicative of a class I 
PDZ domain (Songyang, Fanning et al. 1997).
1.32. Amino acids N-terminal to the -2 position are also important in 
the specificity of binding
Although there is promiscuity between PDZ domains and their targets, it 
is likely that some degree of specificity greater than the class system 
determines which PDZ domain protein can bind which target.
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Class
C-terminal
sequence
Interacting
protein
PDZ domain- 
containing protein
Class I
X -S orT -X -V E-S-D-V NMDAR2A, B PSD-95 (PDZ2)
E-T-D-V Shaker-type K+ channel
D-S-W-V p0071 Erbin
o-catenin. ARVCF
X-S orT-X-L D-S-S-L |i2-adrenergic receptor NHERF or EBP50
Q-T-R-L GKAP Shank pr ProSAP
Class II
X-H'-X-T E-Y-Y-V Neurexin CASK
E-F-Y-A Syndecan CASK, syntenin
S-V-E-V EphB2 PICK1
D-V-P-V ErbB2 Erbin
Class III
X-D or E-X-H' V-D-S-V Melatonin receptor nNOS
G-E-P-L KIF17 mLINlO or Mintl or X11
Table 1.2. The classification of PDZ domains. PDZ domains are classified 
based on the C-terminal motif to which they bind. Taken from (Nourry, Grant 
et al. 2003).
Since the group of class I PDZ domains is large (at least 70 across 
species), and since more than one PDZ-containing protein is present in a 
single cell, it is likely that there are further means of regulating specificity 
of binding. Subcellular localisation could play a major role in determining 
whether a PDZ domain interacts with one target or another, but the fact 
that most PDZ domain proteins are associated with the plasma 
membrane indicates that there are likely to be further modes of 
regulation.
An elegant study using a peptide library approach determined that PDZ 
domains were generally selective for up to 7 amino acid residues from the 
C-terminus (i.e. up to the -6 position) (Songyang, Fanning et al. 1997). 
The solution structure of the second PDZ domain of human phosphatase 
hPTP1 E indicates that target residues up to the -5 position are involved in 
binding the PDZ domain (Kozlov, Banville et al. 2002). In this case, the
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pB-pC loop mediates interaction with the amino acid at the -5 position 
providing a new region of focus in the determination of PDZ-target 
specificity. A synthetic peptide library screening approach with this same 
PDZ domain suggested that up to the - 8 position may be involved in 
binding (Songyang, Fanning et al. 1997).
1.33. PDZ domains can be engineered to bind a specific C-terminal 
target sequence
An elegant mutagenesis screen using a yeast-2-hybrid approach 
identified novel PDZ domain sequences that can bind specific C-terminal 
target peptides (Schneider, Buchert et al. 1999). These were then 
verified in a mammalian cell system. In two cases, orphan PDZ targets 
were used as bait for mutagenised PDZ domains in order to identify 
specific residues required for binding. Most residues identified were in 
the carboxylate binding loop, the pB strand or aB helix (fig. 1.10). 
However, some residues were in regions outside the binding groove 
indicating that these can contribute to specificity.
A second approach used computational predictions based on known 
structural information to mutate a PDZ domain from class I to class II 
(Reina, Lacroix et al. 2002). In this case the specificity of interactions 
was verified in yeast-2-hybrid experiments, “affinity purification” using an 
immobilised PDZ domain, and in one case a protein pull-down. When the 
PDZ domain was mutated to bind a new target that differed only in the -1 
and -3 positions (i.e. was of the same class), no less than 6 amino acid 
changes were predicted. In order to turn a class I binder into a class II 
binder, 7 amino acid changes were made, the most critical being the 
mutation of the aB1 position histidine residue into a leucine in order to 
accommodate the hydrophobic amino acid at the -2 position of the target. 
Similarly to the findings by Schneider et al, the vast majority of mutations 
affected the carboxylate binding loop, the pB strand or aB helix.
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In a further study, three different PDZ domains were tested for their ability 
to bind library peptides and showed differing degrees of promiscuity 
towards target sequences (Wiedemann, Boisguerin et al. 2004). The 
SNA1 (a-1 syntrophin) PDZ domain recognises a much larger set of C- 
terminal sequences than the ERBIN (ErbB2 interacting protein) PDZ 
domain. This may reflect their different biological functions in vivo since 
SNA1 is a scaffolding protein whose function is likely to be in the 
construction of large protein complexes, whereas ERBIN is a suppressor 
of the Ras/Raf pathway.
These studies are interesting in determining the critical residues required 
for binding, and are beginning to map out regions that determine 
specificity of binding. However, there is still a long way to go before the 
specificity of binding in vivo is understood.
The PDZ-mediated interaction between MCC and RGS RhoGEF forms 
the basis of study for this thesis. Since the interaction appears to be 
conserved from flies to humans it is likely to be of significance to 
organismal development and survival.
1.34. The hypothesis for this thesis
The work in this thesis is based on the following hypothesis:
The Drosophila melanogaster orthologue of human MCC interacts 
with DRhoGEF2 during development, and this interaction affects 
DRhoGEF2 signalling and Drosophila development
MCC is a potentially interesting protein to study due to its predicted 
tumour suppressor function in humans. There are no known interactors 
for MCC1 in humans, and its exact mechanism of action as a tumour 
suppressor is unknown. DRhoGEF2 interactions are interesting to 
analyse since DRhoGEF2 mutants have a stronger phenotype than eta or 
fog mutants. This indicates that there may be other signalling pathways
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feeding in to or out of DRhoGEF2, in which DMCC (Drosophila 
melanogaster MCC) could participate. Preliminary study of human MCC 
in mammalian tissue culture cells indicates that it may affect the actin 
cytoskeleton (K. Barrett, unpublished data), which could imply a link with 
Rho signalling. These factors make the interaction between DRhoGEF2 
and DMCC an interesting one to study.
Drosophila melanogaster was chosen as a model organism to study MCC 
and its interaction with RhoGEF due to the existence of only one MCC 
orthologue (thereby overcoming redundancy problems), and the ease of 
genetic and cell biology analysis.
1.35. The aims of this study
In order to prove or disprove the above hypothesis, this study looks to 
achieve two main aims. The first is to characterise the function of MCC in 
Drosophila development, and the second is to better understand the 
relationship between DRhoGEF2 and DMCC. The work can be broadly 
grouped into three areas:
1) MCC gene and protein analysis (chapter 3)
2) Analysis of MCC loss- and gain-of-function (chapter 4)
3) Analysis of MCC interaction with DRhoGEF2 (chapter 5)
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2. Materials and methods
2.1. Polymerase Chain Reaction (PCR)
25pmol of each primer, 0.2mM dNTP mix, and 1mM MgCI2, were used 
unless otherwise stated. Different standard PCR programmes were used 
for genomic DNA or plasmid DNA template. For genomic DNA, the 
following programme was used:
1) 95 °C 2 minutes
2) 95 °C 30 seconds
3) {annealing temperature + 10 °C} -  2°C each cycle 30 seconds
4) 72 °C extension time
5) go back to step 2, repeat 5 times
6) 95 °C 30 seconds
7) annealing temperature 30 seconds
8) 72 °C extension time
9) go back to step 6, repeat 29 times
10 )72 °C  10 minutes
11 )10 °C  HOLD
For plasmid DNA, the following programme was used:
1 )9 5 °C  2 minutes
2) 95 °C 30 seconds
3) annealing temperature 30 seconds
4) 72 °C extension time
5) go back to step 2, repeat 29 times
6) 72 °C 10 minutes
7) 10 °C HOLD
The extension time was determined by the polymerase, following 
manufacturers instruction. Polymerases used included HOTStart Taq 
(Qiagen), Pfu Turbo (Stratgene), Expand long-template polymerase
(Roche), Taq (Qiagen). The annealing temperature used was 1 °C lower
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than the lowest melting temperature of the primers (for a list of primers 
used see Appendix 2). Generally, 150ng of DNA template were used 
per PCR. PCR products were checked by gel electrophoresis, purified 
using Qiaquick gel extraction kit (Qiagen) and sequenced where 
necessary (MWG Biotech).
2.2. Restriction digestion and ligation of DNA
Unless otherwise stated, 1pg DNA was digested using 5 units of 
restriction enzyme (New England Biolabs) at 37°C for 2 hours. Vector 
DNA was dephosphorylated by addition of 1 unit calf intestine 
phosphatase (Fermentas Life Sciences) to the digestion reaction and a 
further hour incubation at 37°C. Vectors used for cloning included: 
pGEMT Easy (Promega), pFASTBAC-Act5C (kindly donated by Buzz 
Baum), pBluescript (Stratagene), PCR Blunt (Invitrogen), pUASp (Rorth 
1998). Digests were run on agarose gels and the DNA cleaned using 
Qiaquick gel extraction kit (Qiagen). Ligations were carried out using T4 
DNA ligase (Invitrogen) according to manufacturer’s instructions.
2.3. Transformation of bacteria
An aliquot of competent bacteria (Turbo cells, Invitrogen) was defrosted 
on ice. 50ng DNA was added and the mixture tapped gently. The 
mixture was incubated on ice for 5 minutes, heat-shocked at 42°C for 45 
seconds, then placed immediately back on ice for 2 minutes. SOC 
medium (0.5% yeast extract, 2% tryptone, 10mM Na Cl, 2.5mM KCI, 
10mM MgCI2 20mM M gS04, 20mM glucose) was added and the bacteria 
grown at 37°C for one hour. The bacteria were plated onto agar plates 
containing the relevant antibiotic and incubated at 37°C overnight.
Blue/white screening was performed where relevant using agar plates 
with 20mg/ml X-gal and 100mg/ml Isopropyl bD-thiogalactopyranoside 
(IPTG) smeared onto the surface.
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2.4. Diagnostic PCR
PCRs of twelve bacterial colonies were performed using appropriate 
primers both sides of the multiple cloning site. PCR products were run on 
a 1% agarose gel. A small amount of each colony was transferred to a 
new agar plate before the tip was dipped in the PCR mix. The agar plate 
was incubated for ~8 hours to generate new colonies. Colonies giving 
the predicted PCR product size were selected for mini-prep.
2.5. Isolation of plasmid DNA from bacteria
Bacterial colonies were individually picked using a metal wire loop.
These were used to inoculate LB broth (2% tryptone, 0.5% yeast extract, 
10mM NaCI) cultures which were grown at 37 °C overnight. The Wizard 
plus SV Minipreps kit (Promega) was used to isolate the plasmid DNA on 
a small scale, and the Qiagen maxi prep kit on a large scale.
2.6. Generation of RNAi hybrid construct
The cDNA and genomic DNA pieces were generated by PCR. These 
were cloned through various intermediates and finally into the Not I and 
Xba I sites of pUASp (Rorth 1998).
2.7. Microinjection of the hybrid RNAi construct to generate 
transgenic flies
Transgenic flies were generated by P-element transformation (Rubin and 
Spradling 1982). One hour egg collections were performed using yw 
adult flies in an egg-laying cage. Embryos were dechorionated in 50% 
bleach for two minutes followed by three washes in dH20 . Embryos were 
lined up on agar and transferred to double-sided sticky tape on a glass 
slide. Voltalef oil (Atochem) was used to cover the embryos and 1.5pg/pl 
DNA injected into the posterior end at either 3:1 or 5:1 ratio of UAS-MCC 
RNAi: Turbo transposase.
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2.8. Selection and balancing of RNAi transgenic flies
Surviving adult flies were crossed to yw flies. Second generation flies 
that had mw+ eyes (i.e. pale yellow through to red) were selected and 
individually crossed back to yw. Males were also crossed to X, second 
and third chromosome balancer virgins once they had fertilised the 
females of the previous cross. All subsequent generations were crossed 
back to balancers to determine on which chromosome the insertion(s) 
lay. Lines were maintained as balanced stocks or homozygotes if viable 
as such.
2.9. Transgenic RNAi and UAS-MCC crosses to GAL4 lines
pUASp-MCC RNAi or pUAST-MCC lines were crossed to various GAL4 
drivers at 25°C (table 2.1). Flies were scored soon after hatching. All 
RNAi, over-expression, and GAL4 lines were homozygous viable, 
therefore all progeny carried both insertions and were scored 
phenotypically.
2.10. RNA extraction for RT-PCR
20 adult flies were rapidly homogenised with a pestle in 700pl (1 volume) 
guanidium hydrochloride solution in a 1.5ml Eppendorf tube. An equal 
volume of 50% phenol:50% chloroform was added and mixed well by 
vortexing. The sample was centrifuged at 12,000 x g for 5 minutes at 
4°C. The upper, aqueous phase was transferred to a new tube. The 
RNA was precipitated by addition of 0.02 volumes 1M acetic acid and 0.5 
volumes 100% ethanol. Following gentle mixing the sample was 
incubated at -20°C for at least 3 hours. The RNA was pelleted by 
centrifugation at 14,000 x g for 10 minutes at 4°C. The pellet was 
redissolved in 0.5 volumes guanidium hydrochloride solution and re­
precipitated as above. To the RNA pellet 1 volume of 100% ethanol was 
added to wash.
87
Driver name Expression pattern Reference
{tubP-GAL4}LL7 Ubiquitous (Lee and Luo 1999)
{GawB}elavU155 All nervous system tissues 
from stage 12
(Lin and Goodman 
1994)
{GAL4-wg.M}MA1 Wingless (striped) 
expression pattern in 
embryos
(Hays, Gibori et al. 
1997)
{GAL4-ey.H} Eye (Hazelett, Bourouis et 
al. 1998)
{se v E P-G AL4. B} Eye (Therrien, Wong et al. 
1999)
GMR-GAL4 Eye (Moses and Rubin 
1991)
Da-GAL4 Ubiquitous (strong) (Georgias, Wasser et 
al. 1997)
Table 2.1. GAL4 drivers.
Following centrifugation at 14,000 x g for 5 minutes at 4°C the pellet was 
air dried for approximately 5 minutes and resuspended in DEPC-treated 
ddH20. The sample was stored at -20°C for short-term storage and - 
80°C for long term storage.
Guanidium hydrochloride solution 
5mM DTT
7.5M guanidium hydrochloride 
25mM sodium acetate, pH 7.0 
0.5% N-lauryl sarcosinate
2.11. Reverse transcription and PCR
Reverse transcription was carried out using the Single Strand RT-PCR kit 
(Invitrogen) following manufacturer’s instructions including DNase I 
treatment prior to reverse transcription. Reactions were primed using 
oligo dT.
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DEPC-treated ddH2Q:
0.1% diethyl pyrocarbonate in 
ddH20
left overnight and autoclaved
2.12. Probe generation for whole mount in situ hybridisation
3M9 probe DNA in the pBluescript vector with T7 and SP6 RNA 
polymerase priming sites was digested with appropriate restriction 
enzymes to generate sense (control) and anti-sense probes by in vitro 
transcription using the DIG RNA labelling kit (Roche).
2.13. In situ hybridisation
An overnight collection of embryos was dechorionated in 50% bleach and 
washed thoroughly with ddFhO before being transferred to a 
polypropylene tube containing equal volumes of fixative and heptane, and 
shaken at room temperature for 30 minutes. The lower phase (fixative) 
was removed and an equal volume of methanol added. Devitellinsation 
was achieved by shaking vigorously in heptane/methanol for 30 seconds. 
The devitellinised embryos sank to the bottom of the methanol phase and 
were recovered to a fresh tube.
The embryos were washed three times with methanol and rehydrated 
gradually into 4% paraformaldehyde in PBS followed by re-fixing in 4% 
paraformaldehyde for 20 minutes at room temperature. They were then 
washed in PTw three times for 5 minutes each at room temperature and 
incubated in an equal mix of PTw and hybridisation solution for 10 
minutes, followed by a further 10 minute incubation in pure hybridisation 
solution. Pre-hybridisation was carried out at 55°C for one hour. The 
probe was boiled for 10 minutes at 100°C then placed on ice for 1 minute. 
Fresh hybridisation solution containing probe at 500pg/pl was added and 
the embryos were incubated in probe overnight at 55 °C.
Washes at 55 °C in hybridisation solution for 20 minutes were followed by 
subsequent washes in gradually increasing concentration of PTw. The 
embryos were washed in pure PTw twice at room temperature followed 
by two washes in PBT. They were then incubated for one hour in 1: 2500 
anti-digoxigenin antibody (Roche) at room temperature followed by four 
washes with PBT and three with detection buffer at room temperature. 
The embryos were transferred to a glass dish to facilitate visualisation
and incubated in detection buffer containing 3.75 pg/ml Nitro blue 
tetrazolium chloride and 1.88 pg/ml 5-Bromo-4-chloro-3-indolyl 
phosphate, toluidine salt. Once the colour reaction was complete, the 
embryos were washed three times with PBS then placed in an Eppendorf 
tube in 70% glycerol to clear overnight.
Fixative Hybridisation Buffer
4% paraformaldehyde 50% deionised formamide
60mM Na2H P 0 4 
40mM NaH2P 0 4
PTw 
1 x PBS
0.1% Tween 20 
50mM MgCI2 
0.1% Tween 20
PBT 
1 x PBS
0.1% Bovine serum albumin 
0.2% Triton X-100
2.14. Plasmid rescue of P(lacW) insertions
Genomic DNA was extracted from twenty flies and digested with Xba (5’ 
end of P-element rescued) or ECoRI (3’ end of P-element rescued). The 
restriction enzyme was heat-inactivated at 70°C for 10 minutes and the 
volume was made up to 200pl with ddH20 . The restriction fragments 
were ligated overnight at 4 °C using T4 DNA ligase. The DNA was 
precipitated by addition of 40ng tRNA, 2 volumes 100% ethanol and 0.1
5x  SSC
100pg/ml denatured phenol- 
chloroform extracted salmon 
sperm DNA 
100pg/ml heparin 
0.1% Tween 20
Detection Buffer 
100mM NaCI 
100mM Tris-CI pH 9.5
volumes 3M sodium acetate. The precipitation reaction was incubated at 
-20°C for 30 minutes and centrifuged at 13,000 x g for 30 minutes at 4°C. 
The supernatant was removed and the pellet washed with 70% ethanol 
followed by air drying and resuspension in ddH20.
The DNA was transformed into bacteria, colonies were grown up as mini 
preps and sequencing reactions carried out. The resulting sequence was 
lined up against the Drosophila genome using BLAST in order to 
determine the site of P-element insertion.
2.15. P-element hop genetics
Drosophila with a PllacW™] P-element were obtained from the Szeged 
Stock Centre (stock no. 070116). After three generations in quarantine 
these were crossed with a source of transposase (Robertson, Preston et 
al. 1988) in order to generate flies with P-element insertions at new 
positions.
Cross 1
6 9
yw ; Ki pp A2-3 X vw : PriacV\r*l
yw TM3 Sb, Ser
Cross 2
Mosaic-eyed male flies were selected and these were crossed to a third 
chromosome balancer stock:
S 9
vw : P H acW ^ X w . TM2 Ubx
Ki pp A2-3 w TM6C Sb
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Cross 3
Males with mw+ were selected and crossed again to the third 
chromosome balancer stock in order to balance the new P-element 
insertions:
s $
w : PM acW ^l X w ; TM2 Ubx
TM 2 Ubx or TM6CSb w TM6C Sb
Flies with insertions on chromosomes other than the third were de­
selected after cross 3 due to the presence of both balancer chromosomes 
and mw+. Flies were maintained as balanced stocks during PCR 
screening.
2.16. Genetic interaction studies
M c c 12,3 represent different MCC alleles e.g. the P1 insertion, P4 
insertion etc.. RG 21,2,3 represent different DRhoGEF2 alleles e.g. 
DRhoGEF241, DRhoGEF2Px6 etc (see table 5.3).
1) Heterozygous DRhoGEF2 with heterozygous DMCC.
Cross 1:
c? ?
vw X w : + : M CC1
w + TM6C Sb
Cross 2:
$
vw : M C C 1 X w ; RG21 ; +
+ w CyO +
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2) Hom ozygous D R hoG E F2 with heterozygous D M C C .
Cross 1:
s $
w ; RG21 ; + X w ; If ; MCC1
CyO + w CyO TM6C Sb
Cross 2:
6 $
w ; RG22; + X w : RG21 : MCC1
CyO + w CyO +
3) Homozygous DRhoGEF2 with homozygous DMCC.
Cross 1:
c? $
w ; RG21 ; + X w ; If ; MCC1
CyO + w CyO TM6C Sb
Cross 2:
s $
w : RG22 : MCC" X w : RG21 : MCC1
CyO + w CyO +
2.17. Genomic DNA isolation for PCR screening
Single flies from each line were pooled in groups of twenty for genomic 
DNA isolation. The flies were homogenised in 250pl homogenisation 
buffer and an equal volume of lysis buffer was added and mixed by 
inversion. RNase A was added to 25pg/ml, mixed by inversion, and 
incubated at 37°C for 15 minutes. Proteins were precipitated by addition 
of proteinase K to 400pg/ml, which was mixed by inversion, and 
incubated at 37°C for 30 minutes. 1 volume of 50% phenol/50% 
chloroform was added and mixed vigorously by shaking. The sample
was centrifuged at 13,000 x g for 10 minutes at 4°C and the upper 
aqueous phase recovered to a fresh tube. The phenol/chloroform 
extraction was repeated. 0.7 volumes of pure chloroform was added, 
mixed by inversion and the sample was centrifuged at 13,000 x g for 10 
minutes at 4°C. The upper aqueous phase was recovered to a fresh 
tube.
2.5 volumes of 100% ethanol was added, mixed by inversion, and the 
sample was centrifuged at 13,000 x g for 5 minutes at 4°C. The pellet 
was washed with 70% ethanol. The pellet was air-dried for 5-10 minutes, 
resuspended in ddH20  and stored at 4°C.
Homogenisation buffer:
10mM Tris-CI pH 7.5 
60mM Na Cl 
10mM EDTA 
0.15mM spermine 
0.15mM spermidine 
5% sucrose
2.18. Digoxigenin-DNA labelling of probes for Southern blotting
Probes were labelled by random primer labelling following manufacturer’s 
instructions using the DIG DNA Labelling and Detection Kit (Roche).
1.5pg probe DNA was used in the labelling reaction. The labelled DNA 
was precipitated using 0.5M LiCI and 3.75 volumes ice-cold 100% 
ethanol. The sample was incubated at -20°C for 30 minutes then 
centrifuged at 13000 x g for 15 minutes at 4°C. The pellet was washed 
with ice cold 70% ethanol, dried at 45°C for 10 minutes and redissolved in 
TE.
Lvsis buffer:
300mM Tris-CI pH 9.0 
100mM EDTA 
0.626% SDS 
5% sucrose
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2.19. Dot blot test
A dot blot test was performed to determine the concentration of the 
labelled probe. A series dilution (from undiluted to 1 in 100,000) of the 
labelled probe and the control labelled probe was performed in ddH20 .
1 pi of each dilution was dot-blotted onto a Hybond-N nylon membrane 
(Amersham Life Sciences). The control labelling reaction and the control 
pre-labelled DNA were also blotted. The DNA was fixed to the 
membrane by UV cross-linking using the UV Stratalinker 2400 
(Stratagene) at 120 Joules/cm2.
The membrane was washed in maleic acid buffer with agitation for 15 
minutes at room temperature followed by incubation in 1 x blocking 
solution for 30 minutes with agitation. It was then incubated in 1:5,000 
anti-DIG-AP antibody (Roche) in 1 x blocking solution for 30 minutes 
followed by two 15 minute washes with washing buffer then a 5 minute 
incubation in detection buffer. Spots were detected by incubation in 
detection buffer containing 3.75 pg/ml Nitro blue tetrazolium chloride and 
1.88 pg/ml 5-Bromo-4-chloro-3-indolyl phosphate, toluidine salt in the 
dark. The reaction was stopped by addition of excess ddH20  and the 
membrane was air-dried.
2.20. DNA digestion and denaturation for southern blot
1.5pg genomic DNA was digested for 2 hours at 37°C with a suitable 6- 
base cutter restriction enzyme. The DNA was run on a 1 % agarose gel 
containing ethidium bromide at 40V for approximately 8 hours. The DNA 
was visualised under ultraviolet light to check digestion was complete. 
The gel was incubated in denaturing solution for 30 minutes followed by 
neutralising solution for 30 minutes at room temperature with agitation.
Denaturing Solution: .Neutralising Solution;
1.5M NaCI 
1M Tris-CI pH 8.0
1.5M Na Cl 
0.5M NaOH
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2.21. Transfer of DNA to membrane and probe hybridisation
The DNA was transferred overnight from gel to Hybond -N  nylon 
membrane (Amersham Life Sciences) as in (Sambrook J 1989) and 
cross-linked to the membrane as for dot blot. The membrane was rinsed 
in 3 x SSC and placed in a glass hybridisation bottle. The membrane 
was pre-hybridised at 42°C for 2-4 hours in hybridisation solution with 
rotation. Hybridisation solution was removed and replaced with fresh 
solution containing 100ng probe. Hybridisation was carried out at 42°C 
overnight.
2.22. Stringency washes and detection
The probe solution was drained off and stored for future use at -20°C.
The membrane was washed flat with agitation with excess wash solution 
1 at room temperature. The membrane was washed flat with agitation in 
excess wash solution 2 at 68°C. All subsequent steps were performed at 
room temperature unless otherwise stated. The membrane was 
incubated in 1 x blocking solution for 30 minutes with agitation followed 
by 30 minute incubation in 1:5,000 anti-DIG-AP antibody in 1 x blocking 
solution. It was then washed twice with washing buffer followed by a 5 
minute incubation in detection buffer. 125pM Disodium 3-(4-meth- 
oxyspiro {1,2-dioxetane-3,2’-(5,-chloro) tricyclo [3.3.1.13 7] decan}-4- 
yl)phenyl phosphate (CSPD) in detection buffer was added and incubated 
at 37°C for 10 minutes. The membrane was exposed to photo-sensitive 
film for ~30 minutes and developed.
20X SSC:
3M NaCI 
0.3M Na citrate
pH 7.5 (pH adjusted using solid NaOH) 
Wash solution 1:
2 X SSC 
0.1% SSC
Maleic Acid Buffer:
0.1M maleic acid 
0.15M NaCI
10 X Blocking Solution:
10% blocking reagent (Roche) 
in maleic acid buffer
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This is diluted 1 in 10 with 
maleic acid buffer to produce 
working solution
Wash solution 2 
0.1XSSC  
0.1% SDS
Washing Buffer: 
Maleic acid buffer 
0.3% Tween 20
Detection Buffer: 
0.1M Tris-CI pH 9.5 
0.1M NaCI
Hybridisation Solution:
50% formamide 
1x Denhardt’s (0.02% Ficoll 
(type 400), 0.02% 
polyvinylpyrolidone, and 0.02% 
bovine serum albumin)
1% SDS 
5 X SSC
5% blocking reagent 
0.1M sodium phosphate buffer 
100ug/ml denatured salmon 
sperm DNA
2.23. Storing, stripping and re-probing the membrane
The membrane was stored at -20°C in sealed plastic casing. To strip the 
membrane of probe it was briefly rinsed in ddH20  and incubated twice in 
strip buffer (0.2M Na OH, 0.1% SDS) for 15 mins at 37°C. The 
membrane was rinsed thoroughly in excess 2 x SSC, incubated in 
hybridisation solution as before, and hybridisation with a second probe 
carried out.
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2.24. Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
(SDS PAGE)
A 7.5% separating gel and stacking gel were prepared as described 
(Sambrook J 1989). The gel was loaded with protein samples and run at 
95V until the blue marker dye had migrated to the bottom of the gel.
2.25. Transfer and Immunoblotting
Protein samples were transferred to nitrocellulose membrane as 
described (Sambrook J 1989). Following transfer the membrane was 
washed twice with TBS Tween for 5 minutes followed by blocking solution 
for 30 minutes. Primary antibody in blocking solution was added to a final 
concentration of 1:1000 (anti-myc9E10) or 1:10,000 (anti-T7 tag) and the 
blot incubated overnight at 4°C with gentle shaking. The blot was washed 
3 times for 10 minutes each at room temperature with TBS Tween. Goat 
anti mouse-HRP secondary antibody (DAKO) was added in blocking 
solution at 1:2000 and incubated at room temperature for 1 hour. The 
blot was washed 3 times for 10 minutes each at room temperature with 
TBS Tween. The blot was developed and visualised following 
manufacturer’s instructions using ECL blotting detection reagents 
(Amersham Biosciences).
TBS Tween:
10mM Tris-CI pH 8.0 
150mM Na Cl 
0.1% Tween 20
2.26. Stripping and reprobing membrane
The membrane was washed briefly in TBS Tween, strip buffer was added 
and incubated with shaking for 30-60 mins at 65°C. The membrane was 
washed several times in TBS Tween before proceeding to block and 
antibody incubation as above.
Blocking solution:
5% milk powder (Tesco) in 
TBS Tween
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Strip buffer:
2% SDS
62.5mM Tris-CI pH 6.8 
100mM (3-mercaptoethanol
2.27. Tagged DRhoGEF2 and MCC construct preparation
Full-length DRhoGEF2 was previously cloned into pUASp with a T7 tag at 
the N-terminus (K. Barrett). pFASTBAC-act5C was generated by 
replacement of the polyhedron promoter of pFastBac 1 (Invitrogen) with 
the actin 5C promoter, and was a kind gift from Buzz Baum. pFastBac- 
act5C-myc was generated by annealing two oligos (MWG) to create the 
myc tag with an upstream Kozak sequence and sticky restriction sites on 
each end (appendix 2).
200pmol of each primer were annealed in restriction enzyme buffer (New 
England Biolabs) in a PCR machine using the following program: 90°C for 
5 minutes, 70°C for 10 minutes, -2°C each minute until 4°C. The newly 
double-stranded DNA was phosphorylated using 10 units polynucleotide 
kinase (Fermentas) in a forward reaction following manufacturer’s 
instruction. The fragment was ligated into restriction-digested pFastBac- 
act5C. MCC constructs were generated by RT PCR followed by cloning 
into pGEMT Easy vector (Promega). PCR using primers with appropriate 
restriction sites was used to transfer MCC constructs from pGEMT easy 
into pFastBac-act5C-myc. Mutant MCC constructs in pCMV vector were 
provided by Kathy Barrett. These were sub-cloned into pFASTBAC- 
act5C-myc.
2.28. Transfection and lysis of Drosophila cells
S2 cells were grown at high density in Schneider’s medium with 10% fetal 
calf serum and transfected according to manufacturer’s instructions using 
Fugene transfection reagent (Roche). At 2 days post-transfection cells
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were spun down at 1000 rpm and lysed by pipetting up and down in 
standard lysis buffer
Lvsis Buffer:
20mM Tris-CL pH 7.5 
1% NP40 
150mM NaCI 
1mM PMSF 
10pg/ml leupeptin 
10pg/ml aprotinin
2.29. Full-length protein co-immunoprecipitation
A 10cm dish of cells was transfected as above using 6pg DRhoGEF2,
6pg actin-GAL4, 6pg MCC DNA. Cells were lysed in 400pl lysis buffer. 
Where phosphatase inhibitors were added the lysis buffer included 1 mM 
sodium orthovanadate, 20mM sodium fluoride and 12.5mM sodium 
pyruvate. The sample was centrifuged at 10,000 rpm for 5 minutes at 
4°C. 20 pi post-nuclear supernatant samples were transferred to a new 
tube and 20 pi 2 x sample buffer added and mixed. These were stored at 
-20°C. The remaining lysate was transferred to a new tube and EDTA 
and GTPyS (Upstate) were added where appropriate to 1mM and 100pM 
concentrations respectively, and the sample incubated at 30°C for 5 
minutes with agitation. The reaction was stopped by the addition of 
magnesium chloride to a final concentration of 60mM.
2 x sample buffer:
100mM Tris-CI pH 6.8 
4% SDS
0.2% bromophenol blue 
20% glycerol 
5mM DTT
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Bead preparation - 40 pi protein G beads (Autogen Bioclear) per sample 
were spun down at 1,000 x g and washed three times with cold PBS. 20 
pi per sample were used for clearing. Primary antibody was added to the 
remaining 20 pi per sample (mouse anti-myc 9E10 (Santa Cruz 
Biotechnology) was used at 1:1000, mouse anti-T7 tag (Novagen) was 
used at 1:5000) and the beads were incubated with end-over-end mixing 
at 4 °C for 30 minutes.
The lysate was cleared by end-over-end incubation with 20 pi pre-washed 
protein G beads at 4 °C for 30 minutes. Following clearing the beads 
were spun down and the lysate recovered to a fresh tube. 20 pi antibody- 
conjugated beads were added to the lysate and the sample was end- 
over-end mixed for at least 1 hour at 4 °C.
The beads were washed 3 times with 1 ml lysis buffer. Each wash 
involved addition of wash buffer, brief end-over-end mixing followed by 
centrifugation at 14,000 rpm for 1 minute at 4 °C. Beads were 
resuspended in 20 pi 2 x sample buffer, boiled at 100 °C for 5 minutes, 
spun down and the supernatant loaded onto a 7.5% SDS PAGE gel (or 
stored at -20 °C). The blot was immunoblotted with the appropriate 
antibody to test for immunoprecipitation and co-immunoprecipitation.
2.30. Recombinant PDZ domain production
The PDZ domain of DRhoGEF2 was cloned into the PET28c vector 
(Novagen). BL21 cells (Novagen) were transformed with the construct 
and a single colony was used to inoculate 50ml LB broth. The culture 
was incubated with shaking at 37°C until the ODeoo reached 0.6 when 
IPTG was added to a final concentration of 1mM. The culture was grown 
for a further 3 hours and the bacteria were then spun down at 10,000 x g 
for 10 minutes. The pellet was resuspended in 4ml ice-cold 20mM Tris-CI 
pH 7.5. rLysozyme (Novagen) was added to a final concentration of 
50KU/gram bacterial pellet and the cell suspension was sonicated on ice 
using a microtip with amplitude 60 for 10 second bursts until the
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visocosity was significantly reduced (approx 1 0 x 1 0  second bursts). The 
sample was centrifuged at 14,000 x g for 10 minutes to separate the 
insoluble phase which was discarded. The soluble supernatant was 
passed through a resin column and purified according to manufacturer’s 
instructions using the His Bind Purification Kit (Novagen). Samples were 
run on SDS-PAGE gels and stained with Coomassie blue as described 
(Sambrook J 1989).
2.31. PDZ domain co-immunoprecipitation
60mm plates of S2 cells were transfected as above with individual MCC 
constructs. Cells were lysed in 200pl standard lysis buffer and 20pl was 
kept as whole cell lysate. Protein A beads were prepared as above and 
the lysate was cleared using T7-conjugated beads as above. 500ng 
recombinant PDZ domain was incubated with T7-conjugated beads for 
1 hour at 4°C prior to addition to the cleared cell lysate, followed by 
overnight incubation at 4°C. The samples were washed as above, run on 
an SDS-PAGE gel and immunoblotted.
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3. Results — DMCC expression analysis
3.1. Introduction
When considering the function of MCC in Drosophila development a good 
place to begin analysis is to determine where and when the gene is 
expressed and determine the nature of the protein products resulting from 
gene expression. Sequence analysis of the mRNA transcribed from a 
gene allows prediction of the primary sequence of the resulting protein, 
and this protein sequence can be used to make predictions about 
function. Analysis of the conservation of a protein across species can 
also provide information. If a protein is expressed across many species, 
and particularly if it has functional domains that are well-conserved, this 
indicates that the protein is very likely to play an important role in survival 
of the species.
The expression pattern of a particular mRNA gives clues as to the 
expression pattern of the protein (the two do not necessarily coincide 
exactly), and can provide information as to the likely function of the 
protein. If an mRNA is only expressed in one particular tissue, for 
example, it is highly likely that the corresponding protein will be 
functioning in that tissue, and some inference of function may be 
possible. In this chapter the structure and expression of the Drosophila 
MCC gene is explored.
3.2. The protein encoded by the predicted gene CG6156 interacts 
with DRhoGEF2 PDZ domain
A yeast-2-hybrid screen using the DRhoGEF2 PDZ domain identified the 
protein product of a mRNA produced by the CG6156 locus of the 
Drosophila genome as a potential PDZ target (K. Barrett, unpublished). 
This gene is predicted to encode two mRNA isoforms corresponding to 
cDNAs G H 12452 and GH21874 (subsequently referred to as cDNAa and 
cDNAb respectively), which were obtained from a Berkeley Drosophila 
Genome Project (BDGP) adult head cDNA library.
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The mRNAs corresponding to cDNAa and cDNAb are compromised of 7 
exons and 6 exons respectively, the difference being that the first intron is 
not removed during exon splicing of mRNAb (fig. 3.1). This intron 
contains a STOP codon in frame with the mRNAa transcription start site 
and it is therefore predicted that the protein encoded by mRNAb will 
begin at the next downstream methionine which is just into the second 
exon. The two mRNAs also have slightly different sites of 3’ cleavage 
and poly-adenylation but this is not expected to lead to a difference in 
protein sequence. mRNAa and mRNAb are predicted to encode proteins 
of 630 and 565 amino acids respectively with identical protein sequence 
except the 65 amino acid N-terminus of mRNAa that is absent in mRNAb 
(appendix 1). It is possible that a 19 amino acid polypeptide is also 
produced from mRNAb as a result of translation up to the STOP codon in 
the first intron.
mRNAa (B and C spliced) ~2.5Kb
mRNAb (read through from B to C) ~2.6Kb
299 301329 769 797
STOP STOP STOP
Exon B: 1-117 of CG6156 
Exon C: 185-434 of CG6156 
Exon D: 492-821 of CG6156
Exon E: 877-1010 of CG6156 
Exon F: 1073-1374 ofCG6156 
Exon G: 1436-2205 of CG6156 
Exon H: 2205-3002 of CG6156
Figure 3.1. CG6156 mRNAs. mRNAa and mRNAb encode proteins with 
different N-termini. Blue boxes denote exons , red flags denote methionine 
(ATG) residues and STOP arrows denote stop codons. Numbers in exon 
boxes indicate size in bp. Numbers in table refer to bp of CG6156 published 
sequence (appendix 1). Not to scale.
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3.3. The predicted protein encoded by CG6156 has sequence 
homology to human MCC
cDNAa and cDNAb do not have significant sequence homology to DNA 
sequences from either Drosophila or other species as determined using 
Basic Local Alignment Sequence Tool (BLAST) (Altschul, Madden et al. 
1997). However, the predicted protein encoded by mRNAa (referred to 
as DMCCa from here onwards) has significant primary sequence 
homology to the human MCC1 protein in two regions (fig. 3.2). An 
arginine residue frequently mutated in human patients with colon cancer 
(Kinzler, Nilbert et al. 1991) is conserved in the fly protein.
A BLAST search using DMCCa identifies MCC2 as well as MCC1 (table 
3.1). The reciprocal search using MCC1 picks up DMCC, but a search 
using MCC2 picks up nothing in Drosophila. This indicates that there is 
only likely to be one MCC gene in Drosophila, and that it has greater 
sequence similarity to MCC1 than MCC2.
Fly 16 s v q q l e n r v r d l t q r l q q a e r q  _
++ L+ + + L +RLQQ ER+
-LTESNTEREICHKR 
L E + C +
- LEWSQAHECRIT 64 
E + +E RIT
Human: 24 ALASLKGDIVELNKRLQQTERERDLLEKKLAKAQCEQSHLMREHEDVQERTTLRYEERIT 83
Fly : 65 EMHCVIAELSKKLRSKQDHVIMEEQE 90
E+H VIAEL+KK+ Q I EE E 
Human: 84 ELHSVIAELNKKIDRLQGTTIREEDE 109
34% identity 
51% similarity
Fly : 280 DLERLQRRVEQLEMRNTMLALTLDECKEHTEHLYLLCGKYESNAVALQLALNCSDRAIEA 339
+ ERL R + E L+ +N +L +TL+ECK + E + +L GKYESNA AL+LAL S + + IEA 
Human: 399 ETERLNSRIEHLKSQNDLLTITLEECKSNAERMSMLVGKYESNATALRLALQYSEQCIEA 458
Fly
Fly
340 YDVMLALLESKLALLGEKSVA----------------------  -AEESiRSVEAVARHLLA 377
Y+++ AL E L A A + I++ E A+ LL
Human: 459 YELLLALAESEQSLILGQFRAAGVGSSPGDQSGDENITQMLKRAHDClKTAENAAKALLM 518
378 RLDSEKN VCENSLGPWQHNINLGPEDAPKTGRPWC----- ADDDNRLRYHVSKLKG 428
+LD v s+ pw+ + + c +d+ rl+ ++ +lk f  47 /o similarity
519 KLDGSCGGAFAVAGCSVQPWESLSSNSHTSTTSSTASSCDTEFTKEDEQRLKDYIQQLKN 57 8
Fly : 429 RRSNVQHTIVSLESPFSDIYERKRLALEKEHELRSADKKSPIDLETAVIMQEILELRDSN 488
R+ V+ T + + LES D + + + + +DLE AV + MQE + + + + +
Human: 579 DRAAVKLTMLELESIHID---------- PLSYDVKPRGDSQRLDLENAVLMQELMAMKEEM 629
Fly : 489 LQLKTKM 495 
+ LK + + 
Human: 63 0 AELKAQL 63 6
J
Figure 3.2. Regions of sequence identity between human MCC1 and 
Drosophila metanogaster MCCa protein. Yellow highlights identical 
residues, red highlights Arg 506 of the human protein which is mutated in 
some colon cancer patients. Numbers refer to published amino acid 
sequences (appendix 1). Adapted from BLAST search result.
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3.4. MCC has other species orthologues
DMCCa has predicted orthologues in other Drosophila species and in 
mammals including the mouse and orang-utan (table 3.1). A BLAST 
search does not identify any predicted orthologues in the nematode worm 
or yeast.
All of the species in Table 3.1 (except Drosophila pseudoobscura, the 
crab-eating monkey, orang-utan, and non-animal species) have 
DRhoGEF2 protein orthologues identified in a BLAST search. In addition, 
DRhoGEF2 has orthologues in species for which there are not predicted 
MCC orthologues including the mosquito (Anopheles gambiae), the 
nematode worms (Caenorhabditis elegans and Caenorhabditis briggsae), 
the frog {Xenopus laevis) and the pufferfish (Tetraodon nigroviridisj.
At least some of those animals that do not have identifiable orthologues 
of either DMCC or DRhoGEF2 have not had their genomes completely 
sequenced to date, and there could, therefore, be orthologues that are 
unidentifiable by BLAST at present.
Figure 3.3 illustrates the degree of homology between DMCC and its 
orthologues. The region of DMCC from amino acid residues -280-500 
has the highest degree of homology across species. This region includes 
sections of two predicted coiled coils and the conserved arginine residue 
(see fig. 3.5).
3.5. MCC has a conserved PDZ target m otif at its C-terminus
Sequence analysis reveals that DMCCa, Drosophila mRNAb predicted 
protein (DMCCb) and human MCC (HsMCC) all have a consensus 
(threonine/serine-X-leucine) PDZ target motif at their C-terminus (where 
X represents any amino acid) (fig. 3.4).
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Protein name Identity Similarity C
terminus
Fruit fly (Drosophila 
pseudoobscura)
GA19398
(720aa)
77% 85% PETTL
Honey bee (Apis 
meUifera)
Similar to MCC 
(1254aa)
28% 46% KRANG
Human (Homo sapiens) MCC (829aa) 27% 47% NETSL
Orang-utan (Pongo 
pygmaeus)
Similar to MCC 
(766aa)
27% 47% NETSL
House mouse (Mus 
musculus)
Similar to MCC 
(1303aa)
26% 46% EEISN
Crab-eating monkey 
(Macaque fasicularis)
Similar to MCC 
(829aa)
27% 46% NETSL
Red jungle fowl (Gallus 
gallus)
Similar to MCC 
(1454aa)
35% 56% NETSL
Brown rat (Rattus 
norvegicus)
Similar to MCC 
(1133aa)
25% 41% NETSL
Red jungle fowl (Gallus 
gallus)
Similar to 
AIEBP (MCC2) 
(685aa)
22% 44% PCMRL
Cyanobacteria (Nostoc 
sp. PCC 7120)
Chromosome
segregation
protein
(1208aa)
25% 48% SNTSA
Head blight fungus 
(Fusarium graminearum)
FG00382.1
(1459aa)
22% 41% RWLGG
Human (Homo sapiens) AIEBP (MCC2) 
(703aa)
26% 44% GDTFL
Chimpanzee (Pan 
troglodytes)
Similar to MCC^ 
(688aa)
27% 48% NETSL
Rice blast fungus 
(Magnaporthe grisea)
MG00594.4
(2056aa)
24% 46% NNATE
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Table 3.1. DMCC potential orthologues. (previous page). A protein BLAST 
search using DMCCa predicted protein was performed. Results are ranked with 
lowest BLAST e-value first. Numbers in parentheses following protein name 
denote protein length in amino acids (aa).
Color Key for Hlignnent Scores
50-80 80-200 >=200
0 100 200 300 400 500 GOO
7-9 { :
10
12
13
14
18
1-4 Drosophila melanogaster 10 Orangutan MCC 15 Red jungle fowl MCC2
5 Drosophila pseudoobscura 11 Mouse MCC 16 Cyanobacteria chromosome 
segregation protein
6 Honey bee MCC 12 Macaque monkey MCC 17 Head blight fungus unknown 
protein
7-9 Human MCC 13 Red jungle fowl MCC 18 Human MCC2
Figure 3.3. MCC similarity across species. Results of BLAST using 
DMCCa protein. Colours denote degree of homology between DMCC and 
species orthologues. Scores are arbitrary units.
This PDZ binding motif is conserved in the “similar to MCC” proteins of 
the crab-eating monkey, the orang-utan, the chimpanzee, the brown rat 
and the red jungle fowl (table 3.1). Neither the house mouse nor the 
honey bee “similar to MCC” proteins are predicted to contain a PDZ 
target motif at their C-termini. Drosophild pseudoobscurd MCC contains 
exactly the same motif (threonine-threonine-leucine) at its C-terminus as 
DMCCa.
All the species which have DRhoGEF2 predicted orthologues and DMCC 
predicted orthologues including the human, the honey bee, the red jungle 
fowl, the house mouse, the brown rat and the chimpanzee have predicted 
PDZ domains in a DRhoGEF2 orthologue (as determined by Simple
Modular Architecture Research Tool (SMART) analysis (Letunic, Copley 
et al. 2004)).
-9 -8 -7 -6 -5 -4 -3 -2 -1 0
G H N H V P E T T L Fly
S R P H T N E T S L Human
Figure 3.4. Fly and human MCC both have a classic C-terminal PDZ target 
sequence: T-X-L-COOH. Numbers denote amino acid position from the C- 
terminus which is position 0.
As noted above, of these the honey bee and the house mouse “similar to 
MCC” proteins do not carry a predicted PDZ target motif at their C- 
terminus. Therefore, at the current time, the species with an identifiable 
PDZ-containing-Rho GEF and a C-terminal target-containing-MCC are 
Drosophila melanogaster, red jungle fowl, brown rat, chimpanzee and 
human.
In addition, the nematode worm, frog and pufferfish have predicted PDZ 
domains in their DRhoGEF2 orthologues.
DMCCa
Arg
V/X//A V A // /J I/ / / / 7 7 7
19
HsMCCI
133 220 291 '38 8  431
Arg
563 \  659 717 821
Figure 3.5. MCC has a repeat coiled coil structure. Blue regions indicate 
coiled coils. Dashed regions indicate significant sequence identity (fig. 3.2). 
Numbers denote amino acid sequence (appendix 1). Not to scale.
1 1 0
3.6. MCC proteins have a predicted repeat coiled coil structure
SMART predicts HsMCC and DMCCa to each contain five coiled coils 
(fig. 3.5). The two regions of significant sequence identity cover parts of 
regions predicted to form coiled coils. Arg506 does not fall within a 
predicted coiled coil region.
3.7. RT PCR analysis reveals that there are two additional 
Drosophila MCC isoforms
Previous work had indicated that there may exist, in addition to mRNAa 
and mRNAb, further mRNAs encoded by the CG6156 locus (V. Finnerty, 
personal communication). To address this possibility, reverse 
transcriptase PCRs were performed to amplify two novel cDNAs (figs.
3.6 and 3.7). The primers were designed to cover an exon from an 
upstream predicted gene that may be upstream of the CG6156 exons in a 
novel mRNA splice form, and a short sequence immediately following 
exon E that may be included in a separate splice form. For primer 
sequences see appendix 2. The primers used in the RT PCRs were:
cDNAa: MCC RT PCR_2 & MCC RT PCR_4
novel “cDNAc”: MCC RT PCR_1 & MCC RT PCR_4
novel “cDNAd”: MCC RT PCR_1 & MCC RT PCR_3
The two novel cDNAs each include an exon of C G 18496 (and a short bit 
of genomic sequence upstream of that) which was predicted by the 
BDGP to be a distinct gene upstream of CG6156 (fig. 3.7). Using the 
primers designed for the RT PCR, cDNAc and cDNAd are predicted to be 
3292bp and 1757bp long, respectively (appendix 1). It is possible that 
the mRNAs corresponding to these cDNAs are longer at the 5 end than 
cDNAc/d, although the primers used were based on the 5’ terminus as 
predicted previously (V. Finnerty, personal communication).
I l l
3.0Kb-----
2.5Kb-----
2.0Kb
1.5Kb
1.0Kb-----
Figure 3.6. Additional MCC mRNA isoforms. cDNAs were generated by 
reverse transcription using RNA isolated from wild-type embryos followed by 
PCR using primers illustrated in figure 3.7. The first lane of each triplet (1, 4,
7) has reverse transcriptase present in the reaction, the middle lane (2, 5, 8) 
has no reverse transcriptase (control), and the final lane is a PCR using 
genomic DNA as template (3, 6, 9). 1-3: Primers MCC RT PCR_2 & MCC RT 
PCR_4, 4-6: Primers MCC RT PCR_1 & MCC RT PCR_4, 7-9: Primers MCC 
RT PCR_1 & MCC RT PCR_3.
Since 5’ RACE was not performed here for mRNAa or mRNAb, it is 
possible that they actually extend back to include exon A (the indicated 
start site in fig .3.7 was based on sequencing of the cDNAs obtained from 
the BDGP). If they were to include exon A, mRNAa would share a start 
translation site with mRNAc. For mRNAb the start translation site would 
remain unchanged due to the stop codon in the read-through from exon A 
to B. However, these mRNAs (and therefore proteins) would still be 
distinct from mRNAc since they include exon B.
The mRNA corresponding to cDNAd is predicted to encode a truncated 
protein due to a lack of removal of the intron between exons E and F
cDNAa cDNAc
1 2 3 4 5 6
cDNAd
7 8 9
I  3.0Kb
I   2.5Kb
I   2.0Kb
i   1.5Kb
I  1.0Kb
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which contains a stop codon (fig. 3.7). This protein is predicted to 
contain three coiled coils and the conserved arginine residue, but to lack 
the C-terminal two coiled coils and the PDZ target motif at its C-terminus. 
The RT PCR primers were designed just 3’ of the translation stop codon, 
therefore the in vivo mRNA corresponding to cDNAd is likely to be 
significantly longer and include a 3’ untranslated region. All the PCR 
products were confirmed by sequencing. From this point onwards, the 
predicted proteins encoded by mRNAc and mRNAd will be referred to as 
DMCCc and DMCCd respectively.
mRNAc -  2.8Kb
mRNAd -1  2Kb
mRNAa (B and C spliced) -2 .5K b
mRNAb (read through from B to C) - 2 .6Kb
1 "
STOP STOP STOP
CG 18496 CG 6156:M CC CG 6171
Exon A: 177bp upstream sequence Exon E: 877-1010 of CG6156
plus 1-287 of CG 18496 Exon F: 1073-1374 of CG6156
Exon B: 1-117 of CG6156 Exon G: 1436-2205 of CG6156
Exon C: 185-434 of CG6156 Exon H: 2205-3002 of CG6156
Exon D: 492-821 of CG6156
Figure 3.7. DMCC mRNAs. There are likely to be at least 4 mRNAs 
transcribed from the MCC gene locus. Boxes and letters denote exons (sizes 
in bp inside). Red flags denote methionine residues (ATG’s) and STOP 
arrows denote stop codons. Orange arrows indicate MCC RT PCR primer 
positions. Not to scale.
Further RT PCRs were carried out to determine whether other mRNAs 
were being transcribed (fig. 3.8). Using primers MCC RT PCR_2 and 
MCC RT PCR_3 it was possible to show that there is unlikely to be 
expression of a truncated mRNA that does not remove the intron between
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exons E and F and that begins at the same locus as cDNAa and cDNAb, 
since the cDNA corresponding to such an mRNA was not generated by 
RT PCR (lanes 4-6, fig. 3.8). Although there is PCR product in all three 
lanes, this is due to genomic DNA contamination since it is the size of the 
genomic PCR product and is present in the lane with no reverse 
transcriptase present in the reaction.
An RT PCR to test whether MCC mRNAs run into the downstream 
predicted gene (CG6171) was carried out using primers MCC RT PCR_6 
and MCC RT PCR_5 (lanes 1-3, fig. 3.8). This also proved to be 
negative, indicating that the 3’ end of the CG6156 locus predicted in the 
Drosophila genome annotation is likely to be correct.
3.5K b
3 .0K b 3.0K b
2 .5 K b 2.5K b
2 .0K b 2.0K b
1.5K b 1.5Kb
1.0K b
7 5 0 b
1.0K b
750bo
Figure 3.8. Lack of expression of further MCC mRNAs. cDNAs were 
generated by reverse transcription using RNA isolated from embryos followed by 
PCR using primers illustrated in figure 3.7. The first lane of each triplet (1, 4) 
has reverse transcriptase present in the reaction, the middle lane (2, 5) has no 
reverse transcriptase, and the final lane is a normal PCR using genomic DNA as 
template (3, 6). 1-3: Primers MCC RT PCR_6 & MCC RT PCR_5. 4-6: Primers 
MCC RT PCR_2 & MCC RT PCR_3.
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3.8. DMCCc has five predicted coiled coils
DMCCc has the same five predicted coiled coils as DMCCa/b since their 
sequences are identical from exon C onwards (fig. 3.7). The short 
section encoded by the additional N-terminal exon of DMCCc and 
DMCCd does not contain any predicted functional domains.
3.9. All four mRNAs are transcribed during embryogenesis
The RT PCR analysis of MCC mRNAs used RNA extracted from mixed 
embryos at all stages of development (an overnight embryo collection). It 
must, therefore, be the case that all four mRNAs are transcribed at some 
time during embryogenesis, although it is not possible to ascertain from 
the RT PCR at what stage of embryogenesis they are expressed.
3.10. MCC mRNA is expressed in the developing embryonic central 
nervous system
In order to gain clues as to the potential function of MCC an in situ 
analysis of MCC mRNA expression during Drosophila embryogenesis 
was carried out. The probe generated for the in situ used primers “in 
situ_V’ and “in situ_2” (appendix 2). This probe covers 201 to 2172bp of 
mRNAa and should recognise all four mRNA isoforms (fig. 3.9).
mRNAc
mRNAd
mRNAa
mRNAb
329 301 769 797177
STOPSTOP
In situ probe
Figure 3.9. The in situ probe covers all four mRNAs.
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Antisense probe Sense probe (control)
Stage 5, lateral view Stage 5, lateral
Stage 8, lateral view Stage 9, lateral
Stage 12/13, lateral view Stage 12, lateral
Stage 13, dorsalStage 13, dorsal view
Stage 17, lateral viewStage 17, lateral view
Figure 3.10. MCC mRNA expression. An overnight collection of embryos was 
used for in situ analysis. Sense (control) and antisense DIG-labelled RNA 
probes and standard staining procedures were used (see Materials and 
Methods). Anterior is to the left.
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E xpression  p r o f i le  o f CG6156
time point (hours)
1 2 3 4 S £7 8 S It 11*111 12* 121 13* 131 14* 141
developmental stage
Figure 3.11. BDGP embryonic microarray expression data for CG6156. Total 
RNA was isolated from embryos and labeled cRNA samples were prepared 
following standard Affymetrix protocol. 36 Drosophila GeneChips were hybridized 
and scanned with Affymetrix equipment. Scanned array images were analyzed 
using Affymetrix and dChip analysis software. Y axis units are arbitrary. The color 
of the bar indicates the result of Affymetrix absent/present call that attempts to 
estimate whether a given gene is or is not expressed in the interrogated sample. 
Green indicates present (expressed), blue indicates marginal, red indicates absent. 
Taken from the BDGP website.
There is very low or no mRNA expression seen during stages 1-11 of 
embryogenesis (fig. 3.10). This fits with microarray expression data from 
the BDGP (fig. 3.11). From stage 12 onwards expression is observed in 
what appears to be a general epidermal staining pattern with high 
expression in the central nervous system (CNS), and possibly the anterior 
midgut, foregut and posterior midgut at stage 13 (fig. 3.12). Expression 
then becomes restricted to the central nervous system and the larval 
brain hemisphere from stage 14 onwards until the embryo hatches (fig. 
3.13). There is no expression observed in the peripheral nervous system 
(PNS) or the salivary gland.
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foregut
C N S  and midgut stainingmidgut segmental CNS  
staining
Figure 3.12. MCC may be expressed in the embryonic gut. A is a stage 
12/13 embryo showing MCC in situ staining using the antisense probe. B is a 
reporter antibody staining of a stage 13 embryo from an enhancer trap line, 
1(2)01381, exhibiting CNS, foregut, midgut and hindgut expression (BDGP 
data taken from FlyView - http://pbio07.uni-muenster.de/FlyView/Home.html) 
to compare with A.
Closer analysis of the central nervous system staining reveals a 
segmental “spotty” pattern that is strongest on both sides of the midline 
(although there m ay also be a regular, fainter, spotty staining at the 
midline) (fig. 3 .13).
According to microarray time course data, C G 6156 expression decreases 
during the larval stages but increases once again during metamorphosis, 
and persists in the adult fly (fig . 3 .14). Expression is higher in adult 
males than fem ales.
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lateral viewdorsal view
ventral view
*  *
CNS staining
Strong segmental midline staining PNS staining
Figure 3.13. MCC expression in the central nervous system. A, B and C
are stage 17 embryos showing MCC in situ staining. D and E are antibody 
staining of similar stage embryos from enhancer trap lines 10942 (D) and 
1(2)09327 (E) exhibiting strong midline staining and CNS staining (D) and 
peripheral nervous system and CNS staining (E) (taken from FlyView - 
http://pbio07.uni-muenster.de/FlyView/Home.html) to compare with C.
3.11. D iscu ss io n  and  co n c lu s io n s
3.11.1 . M C C  g en e and  p ro te in  s tru c tu re
The M CC protein is conserved through evolution from the ancestral line 
that led to both Drosophila and humans. The interaction between MCC  
and D R hoG EF2 via the P D Z domain m ay be conserved in the fruit fly, rat, 
fowl, chim panzee and human. It is also possible that further species 
whose genom es are currently incompletely sequenced have a conserved 
interaction betw een these two proteins. Although it is currently very 
difficult (or at the least tim e-consum ing) to test the interaction between
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MCC and Rho GEF for all these species, it is likely that the interaction is 
conserved across all species since two species widely separated in 
evolution -  fruit fly and human -  conserve the interaction. The implication 
of this conservation of interaction during evolution is that it is important for 
species survival from fruit flies to humans.
3 .0
2.0
.2 1.0
*t.
CMxw
,2-1.0
- 2.0
-3 .0
Tine course data
10 20 30 40 50
O Embryo
*  Larvae
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60 70
sample
Figure 3.14. CG6156 expression from embryo to adult. Microarray time 
course for CG6156 expression during development. The Y axis represents 
arbitrary units. The X axis effectively represents time but is not a linear 
scale. Data taken from: flygenome.yale.edu -  see (Arbeitman, Furlong et al. 
2002) for methods.
It is interesting to note that an arginine residue that is frequently mutated 
in human patients with colorectal cancer is conserved in fruit flies and 
humans. This residue is thought to be required for MCC-mediated cell 
cycle regulation since its mutation to an alanine residue leads to an 
inability of MCC to block the cell cycle between the G1 and S phases 
(Matsumine, Senda et al. 1996).
Analysis of the primary sequence of the DMCC gene indicates that the 
protein shares the same predicted five coiled coil structure as the human 
MCC1 protein. Coiled coils are formed from bundles of a-helices wound 
into a superhelix. They mediate subunit oligomerisation of a large 
number of proteins. This can be either homo- or hetero-oligomerisation, 
and it is possible that MCC interacts with itself or something else via one 
or more of these coiled coils.
Coiled coils can exhibit a number of important properties from extreme 
thermostability to a means of dynamic protein folding in response to 
signalling (Burkhard, Stetefeld et al. 2001). MCC’s coiled coils are of the 
short heptad-repeat variety, which are found in a variety of transcription 
factors and some signalling proteins. For example, the NIMA/Nek kinase­
like regulator of chromosome condensation-like 1 (NERCC1) protein 
contains a coiled coil that mediates homodimerisation and is required for 
autophosphorylation (Roig, Mikhailov et al. 2002). Perhaps further study 
of the nature of the coiled coils of MCC, and whether they do indeed 
mediate oligomerisation, will reveal a function relevant to DRhoGEF2- 
mediated signalling.
3.11.2. MCC mRNA expression
There are at least four different mRNAs encoded by the MCC gene locus, 
and two of these include part of an upstream exon of what is predicted to 
be a distinct gene. It is possible that these four mRNAs are expressed in 
different tissues of the developing embryo and they may perform different 
or overlapping functions. The in situ analysis here did not distinguish 
between these different mRNAs since the probe is able to recognise all 
four. It would be interesting to use smaller probes specific to one or more 
of these mRNAs to determine whether they do exhibit different 
expression patterns. However, since the probe recognised all four 
mRNAs it is unlikely that any is expressed beyond the pattern revealed in 
figure 3.10.
The in situ analysis indicates that there is undetectable MCC mRNA 
expression in the early stages of embryogenesis such as gastrulation, 
when we know that DRhoGEF2 is expressed and is functioning. It is 
possible that DMCC protein is maternally-loaded, and this would not be 
visualised by the in situ analysis. An antibody against DMCC would be 
required to determine whether there is DMCC maternal protein loading. 
There is no in situ staining detected in the salivary glands, another tissue 
where DRhoGEF2 functions to promote epithelial folding (Nikolaidou and
121
Barrett 2004). This would imply that DMCC probably does not function in 
the G-protein mediated signalling pathway involving DRhoGEF2 which 
regulates cell shape changes and epithelial sheet folding.
DRhoGEF2 protein is expressed in the CNS during embryogenesis 
(Padash Barmchi, Rogers et al. 2005), therefore expression will overlap 
with DMCC at the later stages of embryogenesis. 8% of Drosophila 
embryos with one DRhoGEF2 null allele and one dominant negative 
allele have mild commissural defects in the central nervous system (W. 
Wei Tee and K. Nikolaidou, personal communication). Homozygous null 
embryos hatch into larvae that exhibit reduced locomotion during the 
larval stages and only 27% survive to adulthood (K. Nikolaidou, personal 
communication). The musculature of these larvae appears to be normal 
(K. Nikolaidou, personal communication), and it is possible that they have 
a nervous system defect leading to the “sluggish” larval phenotype. It is 
possible that DMCC and DRhoGEF2 function together in nervous system 
development.
The fact that DMCC is expressed in the CNS from stage 12/13 may 
indicate an involvement in neuronal differentiation since it is at stage 13 
that neurons begin to differentiate and set up the classic tram-track 
pattern of axon fascicles (fig. 3.15). The strongest DMCC staining 
appears to be outside this tram-track, and is therefore likely to be in the 
ventral nerve cord where the ganglion mother cells and neurons reside 
(fig. 3.15). It is of interest to note that PDZRhoGEF and LARG, human 
orthologues of DRhoGEF2, are both expressed in the brain and spinal 
cord of mice (Kuner, Swiercz et al. 2002). It is also interesting to note 
that MCC is postulated to be involved in cellular differentiation in mice 
based on its in vivo expression pattern and increased expression in PC12 
cells in culture in response to nerve growth factor (NGF) treatment to 
induce differentiation (Senda, Matsumine et al. 1999). There is currently 
no evidence for DRhoGEF2 involvement in neuronal differentiation.
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neuroblasts  
ganglion mother cells/ neurons 
mesectoderm/derivatives
Figure 3.15. The development of the central nervous system. CenBr: 
brain, plOA/pOOA: inner/outer optic anlage, cn: connectives, co: commissures, 
VenNC/vg: ventral nerve cord, mp: midline glial cells, OL: optic lobe, af: 
anterior fasicle, pf: posterior fascicle, mg: midgut, myo: myoblasts, pn: 
peripheral nerve, tp: tracheal pit. Dorsal is up, anterior is left. Numbers 
represent embryonic stages. Taken from (Hartenstein 1993)
It will be necessary to use an antibody against MCC protein in order to 
determine the exact nature of the CNS cells expressing MCC. A 
polyclonal antibody has been generated, but it proved to be non-specific 
both in embryo staining (no CNS staining but the yolk stained strongly, 
data not shown) and Western blot analysis (various dilutions of antibody 
were tested on S2 cells over-expressing MCC, a large number of bands 
were visible but none corresponded to MCC, data not shown).
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4. Results -  DMCC functional analysis
4.1. Introduction
The manipulation of expression levels has been used extensively in 
Drosophila and other organisms to study the function of genes. The 
artificial increase or decrease (or complete knock out) of expression of a 
gene will normally lead to changes in mRNA and protein levels, and in 
many cases lead to a phenotype that can be visualised and 
characterised. With the vast array of Drosophila phenotypic data 
available, often the phenotype of a mutant can be used to place the gene 
in a specific signalling pathway or at least to ascertain that it is involved in 
a specific developmental process.
In this chapter the function of the MCC gene is investigated further by the 
manipulation of mRNA expression levels, generation of an MCC mutant, 
and phenotypic analysis. mRNA levels are manipulated by both over­
expression using the GAL4-UAS system, and knock down of expression 
using RNAi. The mutant is generated by the hopping of a P-element, 
identified by PCR, and confirmed by Southern hybridisation.
4.2. The GAL4-UAS system
The GAL4-UAS system makes use of a yeast transcription activating 
factor, GAL4, and the DNA sequence to which it binds, Upstream 
Activating Sequence (UAS), to regulate gene expression. This system 
can be used in Drosophila to ectopically express a gene of interest in a 
tissue of interest (Phelps and Brand 1998). The gene of interest is fused 
downstream of a UAS and this is crossed to a fly carrying a GAL4 gene 
under the control of a promoter or enhancer. This gives rise to 
expression of the gene of interest in a specific tissue or set of tissues as 
determined by the promoter driving GAL4 expression. Large numbers of 
Drosophila GAL4 lines have been generated (“GAL4 drivers”) to enable 
expression of a gene in almost any tissue desired.
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4.3. Over-expression of MCC using the GAL4-UAS system
The GAL4-UAS system was used to ectopically express the MCC gene in 
various tissues. The GAL4 drivers used are described in table 2.1 of 
Materials and Methods. Three different UAS-MCC constructs were used 
for over-expression (gratefully received from V. Finnerty, Emory 
University, GA): UAS-DMCCc, UAS-DMCCd and UAS-MCC1.
4.4. Over-expression of MCC leads to no obvious developmental 
phenotype
Since MCC is expressed in the central nervous system, the elav-GAL4 
driver was used to over-express both DMCC and HsMCC specifically in 
nervous tissues. Over-expression of MCC in nervous tissues gives rise 
to viable flies with no visible phenotype (fig. 4.1). In order to test whether 
ectopic expression of MCC produces a phenotype, over-expression of 
MCC specifically in the eye using the sevenless-GAL4 or eyeless-GAL4 
drivers was carried out, or in the wing using the wingless-GAL4 driver 
(not shown). Ectopic expression using these drivers also results in no 
obviously visible phenotype (fig. 4.2).
Over-expression in the eye using the Glass Multimer Reporter (GMR)- 
GAL4 driver results in flies with rough eyes due to disruption of the 
ommatidial architecture. However, GMR-GAL4 flies themselves have 
rough eyes so the effect is not specific to MCC over-expression (fig. 4.2). 
The eyes did not appear to be more or less rough when MCC was over­
expressed.
In order to test whether ectopic expression of MCC in any tissue gives 
rise to a phenotype, MCC was ubiquitously over-expressed using the 
tubulin-GAL4 driver. This driver over-expressing MCC has no effect on 
viability (table 4.1) and gives no obviously visible phenotype (fig. 4.1).
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Figure 4.1. Over-expression of DMCC and MCC1 in Drosophila.
Male (left) and female flies resulting from crosses to cause over-expression of 
MCC. A: Tubulin GAL4 x UAS-DMCC, B: Tubulin GAL4 x UAS-MCC1, C: Elav- 
GAL4 x UAS-DMCCc, D: Elav-GAL4 x UAS-MCC1. Over-expression of DMCCd 
is not shown but flies looked identical to DMCCc.
4.5. The use of RNA interference to compromise MCC function
RNA interference (RNAi) technology is used to compromise gene 
expression in order to study gene function. dsRNA corresponding to a 
gene of interest is introduced into the system provoking an RNAi 
response that degrades the dsRNA and leads to the additional specific 
destruction of mRNA for that particular gene. The use of RNAi was first 
shown in the worm (Fire, Xu et al. 1998). The exact molecular nature of 
this response is not entirely understood, but it has been shown to exist in 
various systems including both Drosophila and mammalian cells in 
culture, and in Drosophila embryos (Hannon 2002).
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Figure 4.2. Over-expression of MCC specifically in the Drosophila eye.
The UAS-MCC constructs were over-expressed specifically in the eye using the 
Sev-GAL4 or GMR-GAL4 driver. A: sevGAL4 x UAS-DMCCc, B: sev-GAL4 x 
UAS-DMCCd, C: ey-GAL4 x UAS-DMCCc, D: ey-GAL4 x UAS-DMCCd, E: 
GMR-GAL4, F: GMR-GAL4 x UAS-DMCCc, G: GMR-GAL4 x UAS-DMCCd, H: 
GMR-GAL4 x UAS-MCC1.
Tub-G AL4 TM 3, Sb
UAS-DM CCc (116) 49% (120) 51%
UAS-DM CCd (126) 50% (123) 50%
UAS-HsM CC (145) 52% (135) 48%
Table 4.1. Ubiquitous over-expression of MCC. Drosophila crosses were 
performed at 25°C and emerging adults scored from 10 days onwards until all 
had emerged. Percentages are the percentage number of flies of each 
genotype resulting from the cross. Numbers in parentheses are actual number 
of adult flies.
4.6. G eneration o f a UAS-MCC RNAi DNA construct
An RNAi construct was generated as a “flipback” cDNA:genomic DNA 
hybrid (Kalidas and Smith 2002). An earlier attempt was made to 
generate a cDNA:cDNA flipback construct, but it was not possible to sub­
clone this using bacteria probably due to the secondary structure formed
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by the DNA. The advantage of the genomic DNA:cDNA hybrid is that, at 
the DNA level, there is less opportunity for secondary structure formation, 
but, once splicing has occurred to produce the mature mRNA, secondary 
structure can form.
Genomic DNA
INTRONS
T
I Reverse cDNA 
I
EXON E EXON F EXON F EXON E DNA
Exon splicing
mRNA
Flipback
dsRNA
RNAi Response
Figure 4.3. Hybrid genomic DNA:cDNA construct. Introns are removed 
during the mRNA maturation process and the RNA flips back on itself to create 
the dsRNA species that activates the RNAi response. Exon lettering as in fig.
3.7 of chapter 3. Not to scale.
A region covering two and a half exons of CG6156 genomic sequence 
(from 777 to 1442bp of the published genomic sequence (appendix 1)) 
was fused to the corresponding reverse complement sequence of cDNA 
(fig. 4.3). The first five nucleotides of exon G plus a restriction site act as 
a linker between the genomic and cDNA pieces. Both fragments were 
generated by PCR (fig. 4.4) and sub-cloned into pUASp which was 
chosen since it enables expression in the germline and very early stage 
embryos, and can be used to express MCC-RNAi in a tissue of choice
using the GAL4-UAS system (Rorth 1998). This vector contains the 
elements required for P-element mediated stable insertion into the 
Drosophila genome (Rubin and Spradling 1982).
Not I 
Gen for
Transcribed strand
Un-transcribed strand
Gen rev 
ECoR I
ECoRI 
cDNA rev
Pstl 
cDNA int rev
Un-transcribed strand
Transcribed strand
cDNA int for 
Pstl
cDNA for 
Xba I
Figure 4.4. Generation of the genomic (A) and reverse cDNA (B) pieces of 
the RNAi hybrid construct. The reverse complement full-length mRNAc 
sequence was scanned using DNA Strider to check for intron splice donor sites 
(GTnnGT) revealing many such sites. The cDNA piece of the hybrid was 
selected due to it encompassing only one intron donor site. This piece was 
made in two parts by PCR with the intron splice donor site mutated to a Pst I 
restriction site which was used to join the two parts together. Restriction sites 
were also introduced via primers (appendix 2) at both ends of the complete 
cDNA piece to enable joining to the genomic piece and ligation into the pUASp 
vector. The genomic piece of the hybrid was generated by PCR using primers 
containing restriction sites to enable joining to the cDNA piece and ligation into 
the pUASp vector. Blue arrows represent PCR primers. Not to scale.
4.7. Generation of transgenic UAS-MCC-RNAi flies and crossing to 
GAL4 drivers
-3000 early embryos were injected with the pUASp-MCC-RNAi construct 
and from these -100 individual transgenic lines were obtained. These 
lines were mainly homozygous viable and maintained as such. A
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selection was crossed to various GAL4 drivers in order to activate 
expression of the MCC-RNAi construct and thereby compromise MCC 
gene expression. The GAL4 drivers used include two that give ubiquitous 
expression and one that gives CNS expression. Four transgenic UAS- 
RNAi lines that carried insertions on different chromosomes were used:
RNAi65, RNAi98 -  insertion(s) on 3rd chromosome 
RNAi46 - insertion(s) on 2nd chromosome 
RNAi29 - insertions on X and 2nd chromosomes
4.8. Flies expressing an MCC-RNAi construct are viable with no 
visible phenotype
Flies that expressed the RNAi construct ubiquitously under the control of 
either the tubulin GAL4 or daughterless-GAL4 (data not shown) drivers 
were viable and had no visible phenotype (table 4.2). Flies that strongly 
expressed the construct in the nervous system (under the control of the 
elav-GAL4 driver) were also viable with no visible phenotype (data not 
shown).
Tubulin-GAL4 TM3, Sb
RNAi65 (156) 51% (149) 49%
RNAi8* (136) 50% (139) 50%
RNAi46 (124) 51% (119) 49%
RNAi29 (148) 52% (137) 48%
Table 4.2. MCC RNAi expression studies. Drosophila crosses were 
performed at 25°C and emerging adults scored from 10 days onwards until all 
had emerged. Percentages are the percentage number of flies of each 
genotype resulting from the cross. Numbers in parentheses are actual number 
of adult flies.
4.9. Strategy for generation of an MCC mutant
In parallel with generating transgenic RNAi flies, a second strategy was 
employed to knock out MCC gene function in Drosophila. It was hoped
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that, by taking a two-pronged approach to gene knockdown (i.e. RNAi 
and mutagenesis), a phenotype could be assessed more rapidly, and 
useful reagents generated in the process.
The generation of mutants has been used for many years to study the 
function of proteins. Since the phenotype of an MCC mutant fly is 
unknown, and is not certain to be lethal, a reverse genetics approach was 
applied. Reverse genetics starts with a gene and moves towards finding 
a phenotype associated with that gene. The strategy for finding a 
phenotype associated with the MCC gene involved making a mutant 
using the technique of P-element hopping.
4.10. P-elements are mobile transposons in Drosophila that can be 
used for mutagenesis
P-elements are large (up to ~10Kb) pieces of DNA that are able to 
transpose themselves around the Drosophila genome inserting more or 
less randomly into a chromosome (O'Hare and Rubin 1983). These 
elements can be used for mutagenesis of Drosophila genes by screening 
for insertion of a P-element into a gene of interest (Bellen, Levis et al. 
2004). The insertion of such a large piece of DNA into a gene (or 
upstream regulatory region) is very likely to disrupt expression of that 
gene, and in most cases leads to complete abolition of gene expression 
and a resulting null phenotype. The strategy of P-element insertion 
mutagenesis was chosen for MCC mutagenesis since the technique is 
well-characterised and there is a P-element within the vicinity of the MCC 
gene available.
4.11. The P-element starting point
P-elements are more likely to hop locally than to hop long distances along 
a chromosome or move chromosomes (Tower, Karpen et al. 1993). In 
order to maximise the chances of a P-element hop resulting in an 
insertion into the MCC gene, a fly line with a P-element as close to the 
MCC gene as possible was used as the P-element starting point. This
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line carries a P(lacW) P-element (Bier, Vaessin et al. 1989) -7.8Kb 
upstream of the CG6156 locus in the 88F1 region of the 3rd chromosome 
right arm (fig. 4.5). This P-element is not within any predicted genes but 
does lie in a relatively gene-rich region. This insertion is called PO 
throughout this chapter.
3’ PO insertion
CG18496 CG6171 
5' CG5073 CG6136 CG14868 | CG6156 \
Hi 1— — I --------- ►
-7.8 Kb
Figure 4.5. Location of the original insertion (PO). Purple boxes 
represent 31 bp inverted terminal repeats of P-element. Not to scale.
Drosophila carrying the PO insertion are homozygous viable with a 
distinctive phenotype. This phenotype is characterised by bristles on the 
thorax that are three-quarters of the normal length (fig. 4.6).
The posterior scutellar bristles are often, but not always, kinked and have 
the appearance of being knotted together. Since the PO insertion is not 
within a predicted gene (it is between CG14867 and CG5073), it is likely 
that its insertion affects the expression of a gene some distance away, 
perhaps by affecting the function of an enhancer, resulting in the bristle 
phenotype.
A plasmid rescue making use of the ampicillin resistance gene within 
P(lacW) (fig. 4.7) was performed to confirm the published insertion site in 
the PO line. Plasmid rescue involves restriction digestion of genomic 
DNA, ligation to circularise fragments and transformation into bacteria 
under antibiotic selection. DNA from twelve bacterial colonies were 
sequenced (six in each direction) and all gave the predicted insertion site 
indicating that there are not likely to be other P-element insertions 
present in this line and that the predicted insertion site is correct. The PO 
line was crossed to a source of transposase, and resulting new insertion
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lines were balanced for subsequent screening (see Materials and 
methods for details of the crosses).
kinked posterior scutellar bristles
Figure 4.6. The PO bristle phenotype, yw ; P(lacWmw)88F1
1 0 0 0  2 0 0 0  3000  4 0 0 0  5 0 0 0  6 0 0 0  7 0 0 0  8 0 0 0  9 0 0 0  1 0 0 0 0  1 1 0 0 0
I________I________I________ I________I________ I________I________ I________ I________ I________ L_
BamHI
Hindlll EcoRI EcoRI Xbal Hindlll
|  l a c Z Y  H s p 7 0 B t >  | whi fce
P5' PJ'
-4  P{±acW} ►
 Y  ^  V -- V----- *-- <./“V----- ^ ^
Figure 4.7. P(lacW). lacZY: E.coli |3-galactosidase gene, Hsp70Bb:
Drosophila heat shock protein 70Bb, white: mini-white gene, ampR: ampicillin 
resistance gene. Numbers represent base pairs. Relevant restriction sites are 
indicated. Taken from Flybase.
4.12. PCR screening of P-element insertions
In order that no phenotypic assumptions were made, a PCR strategy was 
used to screen all lines for insertions into the MCC gene. P-element 
primers were designed for both ends of the P-element just internal to the
terminal repeats (fig. 4.8). Genomic primers were designed so that the
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PCRs covered the complete CG6156 locus, the CG18496 locus and most 
of the upstream region that forms the start of mRNAc and d (fig. 4.8, see 
appendix 2 for primer sequences). The PCRs tested both ends of the P- 
element in combination with all the genomic primers.
Flies were grouped into pools for PCR screening. To test the sensitivity 
of the PCR, one PO fly was pooled with increasing numbers of OreR flies 
and a P-element/genomic primer combination used in a PCR. It was 
determined that one PO fly in a pool with 19 wild-type flies could be 
detected by PCR, therefore flies were grouped in pools of 20. Pooling 
into numbers greater than this resulted in a decrease in sensitivity that 
made the PCR unreliable (data not shown).
A
LacW5’ LacW3’
* - LacZ Mini-white AmpR
5'1  1 1 I I n ■  13
1.8Kb 2.0Kb
D ~  - . .....-
G10
Taq2/1
G9
i—
CG 18496
ICG 6156 CG 6171
Figure 4.8. Primer positions for PCR screening. A: P(lacW) primer 
positions, purple boxes represent 31 bp terminal repeats in P-element. B: 
genomic primer positions. Not to scale.
PCRs were run in 96-well format with the 12th column used exclusively for 
controls (table 4.3). Taq 3 and Taq 4 were additional primers designed 
approximately 2Kb from each end of the PO insertion for use in control 
PCRs to make sure the P-element primers were working. It was 
assumed that at least one of the twenty flies in each pool would still have 
a P-element at the original insertion site in order for this control to work. 
The genomic DNA extracted from each pool of twenty was run on an 
agarose gel to check quality and concentration before being subjected to 
PCR.
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Genomic DNA 
1-20
21-
40
41-
GO
61-
80
81-
100
101-
120
121-
140
141-
160
161-
ISO
181-
200
201-
220
Controls
riQ + laMA/A' .....W + |ar\A/R' 4- Ton 9oy  ^ lacvvo w 0 3  ^ laCVVO t  I aqz
G9 + lacW3' __ .....w G9 + lacW3‘ + Taq4vjw * wvvj  ..... W
G10 + lac W 5 '.. G10 + lacW5' + Taq3w
w G10 + lacW3' + Taq1G10 + lac W3 w
T0-4  . lo^VA/C... ..... w Taq1 + lacW5' + P10I aqi + lacwo
Tan1 + larVAAT ....... Taq1 + lacW3' + Taq4i a q  i T icK sW O
Tan 9 + IflrWS!.... w Taq 2 + lacW5'+ Taq 3i cnq £. T laVrfVVvJ...
Taq2 + lacW3'..... .....w Taq2 + lacW3' + G9
Table 4.3. 96-well PCR screening. The genomic DNA indicated in the top row 
(e.g. 1-20) was added to each of the 8 wells in the below column and thereby 
tested with all primer combinations. A genomic DNA prep was chosen at 
random for each control.
4.13. A single insertion into MCC
Approximately 1500 lines were screened by PCR. Of these only one pool 
of 20 gave a positive result. A band of approximately 1,4Kb was visible 
on the PCR screening gel in the lane corresponding to the primer pair 
G10 + LacW5’ (fig. 4.9).
The genomic DNA from all 20 lines was extracted individually and PCRs 
identified one line carrying the insertion (not shown). The PCR product 
was sequenced and indicated an insertion within exon D, 623bp into 
mRNAa (fig. 4.10). This insertion (named P1) is predicted to affect the 
expression of all four mRNAs. Flies carrying this insertion are 
homozygous lethal.
4.14. P1 is not a “clean” insertion
Although the primer pair G10 + LacW5’ gave a PCR product, the LacW3’ 
primer did not give a PCR product with the Taq1 primer. A number of 
other genomic primers to the right of the Taq1 primer were tested in 
combination with the LacW3’ primer, but none of these gave a PCR 
product (data not shown). This implies that the 3’ end of the P-element 
and/or the 3’ end of CG6156 may be deleted in this insertion line.
137
P1 insertion
Figure 4.9. P1 insertion discovery. Genomic DNA from pools of 20 
P-element hop flies was extracted and subjected to PCR using 
primers that covered the MCC gene. Image shows part of the 
screening gel for lines 641-720.
mRNAc ~ 2.8Kb
mRNAd ~1.2Kb
mRNAa (B and C spliced) ~2.5Kb
mRNAb (read through from B to C) ~2.6Kb
G10
5' P1 3'
t&zm SQ E 3  KE3H u£j I
Taq1
B *  C
I f"
CG 18496
STOP STOP
CG6156:MCC
STOP
Figure 4.10. P1 insertion position. The P1 insertion is within exon D (the 
third exon of CG6156). Not to scale.
4.15. Molecular analysis of the P1 insertion
138
In order to determine the extent of any possible deletion of the P1 P- 
element, PCRs were performed using primers internal to the P-element in 
combination with the G10 primer (fig. 4.11). PCRs up to and including 
the “8.8out” primer gave PCR products of the predicted size indicating 
that at least 8.8Kb of the P-element is present (fig. 4.12). A PCR using 
the LacW3’probe1 primer did not give PCR product indicating that less 
than 10.5Kb is likely to be present (the faint band on the gel in lane 3 was 
likely to be loading spill-over from lane 2 since subsequent PCRs with this 
primer combination gave no product - personal communication, E. 
Batchelor).
Breakpoint
region
I-----------►
LacW3'
7.8in Probe2
LacW5' —*  —*  LacW3'
probel 2.8out 3.8out 4.8out 5.8out 6 8out 7.8out 8.8out probel
Lacw 3'
LacZ | Mini-white , AmpR 3’
i - i i  ~ n
0 K b  4 K b  8 K b
CG 18496 CG6156 P-element
Figure 4.11. Molecular mapping of the P1 P-element deletion. Primers 
were designed to cover the whole P-element. Not to scale
Since more than 8.8Kb but less than 10.5Kb of the P-element is present, 
the breakpoint is likely to occur within the ampicillin resistance gene. 
Plasmid rescue experiments did not amplify the P1 insertion confirming 
that the ampicillin resistance gene is not intact. However, colonies were 
obtained, all of which corresponded to the PO insertion, indicating that this 
is still present in the P1 line. This also indicates that there are unlikely to 
be further intact insertions in this line since all 18 colonies that were 
sequenced (10 in one direction, 8 in the other) corresponded to the 
original insertion. The P1 flies have darker eyes than the original 
insertion line which could be indicative of two insertions each with a mini­
white gene.
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Lane 1: G10 + 7.8out 
Lane 2: G10 + 8.8out 
Lane 3: G10 + LacW3’probe1 
Lane 4: LacW3’probe2 + G9 
Lane 5: LacW3’probe2 + Gen4Kb 
Lane 6: LacW3’probe2 + Gen8Kb 
Lane 7: LacW3’probe2 + Gen12Kb 
Lane 8: LacW3’probe2 + Gen16Kb 
Lane 9: LacW3’probe2 + Gen20Kb 
Lane 10: LacW3’probe2 + Gen24Kb 
Lane 11: LacW3’probe2 + Gen28Kb
Figure 4.12. Determining the extent of deletion of the P-element in P1 
and investigating a possible 3’ genomic deletion. Genomic DNA was 
extracted from flies carrying the P1 insertion and subject to PCR using primers 
internal to the P-element in combination with the G10 primer (figs. 4.8 and 
4,11).
Breakpoint
region
|------- ---------- ►
LacW3'probe2 Gg Gen4Kbr- Gen8Kb* - Gen12KbC Gen 16Kb *— Gen20Kb Gen24Kb Gen28Kbr-
h H  1 H I------ 1 ~~H H ~ ~ H H I
P-element CG6156 CG5063 CG5044 CG5038 CG31392 Surf4 CG6128 FK506-bp1
CG6171 IdlCp CG6194 CG6196 CG31301 Aats-Ser Sra-1
Figure 4.13. Molecular mapping of the P1 insertion line deletion. Primers
were designed to cover the region up to 28Kb to the right of CG6156. Not to 
scale.
It is possible that the deletion event removing the 3’ end of the P-element 
also removed some of the 3’ end of CG6156 and possibly chromosome to 
the right of this also. To address this possibility, PCRs were performed 
using a “LacW3’probe2” primer that is the reverse complement of the 
“8.8out” primer (fig. 4.11) in combination with a number of genomic 
primers at the 3’ end of the CG6156 locus and up to 28Kb to the right of 
the 3’ end of CG6156 (fig. 4.13). PCRs using primers up to and including 
the Gen28Kb primer were all negative, indicating that up to 28Kb to the 
right of the 3’ end of CG6156 may be deleted in addition to the 3’ end of
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the P-element (fig. 4.12). The faint band in lane 9 was not seen in 
subsequent PCRs with the same primer pair and can probably be 
attributed to non-specific PCR priming. As can be seen in figure 4.13, 
the region to the right of CG6156 is very gene (or predicted gene) -rich, 
therefore any deletion is likely to remove a large number of genes.
In another attempt to determine the extent of the deletion molecularly, 
restriction digestion of genomic DNA from the P1 line was followed by 
ligation to circularise fragments. The selected restriction enzymes cut 
within the P-element 5’ of the breakpoint, but do not cut again within the 
P-element and would then cut somewhere within the genomic DNA to the 
right of the P-element (fig. 4.14).
Using primers internal to the P-element, PCRs were attempted across the 
breakpoint in an inverse PCR (e.g. for Apal using primers 7.8out + 
LacW3’probe2). However, these PCRs did not produce product (fig. 
4.15). Since the original PO insertion, which is still present in the P1 line, 
should have given PCR product and did not, it would seem that this 
technique was not successful.
4.16. The deletion does not extend as far as the easter gene
In order to narrow down more quickly the extent of the deletion in the P1 
line, a genetic complementation approach was used. The MCC gene sits 
in the 88F1 region of the 3rd chromosome right arm. The easter gene is 
the nearest gene locus to the right of CG6156 for which there is a mutant 
available, easter lies approximately 33Kb downstream of the 3’ end of 
CG6156. The P1 line was crossed to two easter mutant alleles (ea1 and 
ea14), both of which are homozygous lethal at 25°C.
LacW3’probe2
breakpoint
7.8out 8.8out
Genomic DNAP-element
CG6156
Apal ECoRI
Nsil Sacll
restriction cut
ligation
LacW3’probe2 / 8.8out7.8out
site of ligation breakpoint
Figure 4.14. Strategy for sequencing to the right of the P1 insertion to 
determine the extent of deletion. Restriction digestion of genomic DNA 
from the P1 line was followed by ligation to circularise fragments. The 
selected restriction enzymes cut within the P-element 5’ to the breakpoint, 
but do not cut again within the P-element and would then cut somewhere 
within the genomic DNA to the right of the P-element. The resulting 
circularised fragments were subject to PCR using primers internal to the P- 
element. Apal, ECoRI, Nsil and Sacll were all used in separate reactions.
The P1 line complements both alleles indicating that the easter gene is 
not deleted in the P1 line (table 4.4). This, combined with the PCR 
results, leads to the conclusion that the right-hand breakpoint of the 
deletion is between 28Kb and 33Kb to the right of the 3’ end of CG6156.
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Figure 4.15. Ligation and PCR to the right of the P-element in P1 line. For
methods see fig. 4.14 legend. 1: Apal digestion, PCR using 7.8out + 
LacW3’probe2 primers. 2: ECoRI digestion, PCR using 8.8out + LacW3’probe2 
primers. 3: Nsil digestion, PCR using 8.8out+ LacW3’probe2 primers. 4: Sacll 
digestion, PCR using 8.8out + LacW3’probe2 primers. 5: Apal digestion, PCR 
using primers 4.8out + LacW5’probe2. 6: Control PCR with P1 genomic DNA 
using primers G10 + 5.8out, 7: Control PCR with P1 genomic DNA using 
primers G10 + 8.8out.
E l TM6C. Sb
ru \ h \ th \  st1, cu1, ea1 35% (59) 25% (44)
TM8, Sb, e 40% (70) 0
E l TM6C. Sb
ru \ st1, ea14, spz3, ca1 29% (60) 39% (81)
TM1 32% (66) 0
Table 4.4. easter complementation analysis. Drosophila crosses were 
performed at 25°C and emerging adults scored from 10 days onwards 
until all had emerged. Percentages are the percentage number of flies of 
each genotype resulting from the cross. Numbers in parentheses are 
actual number of adult flies.
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4.17. Conclusions from the P1 line analysis
Based on the analysis and discussion in section 4.27.4 (see below), the 
overall conclusion is that the CG6156 gene has been disrupted in the P1 
line and will be very unlikely to produce functional protein, but that 
additional genes are also likely to have been disrupted/deleted and not be 
producing protein. The homozygous lethality associated with this line 
cannot, therefore, necessarily be attributed to MCC disruption.
4.18. Broadening of the PCR screening
Since the P-element hop that had produced P1 had not generated a 
clean MCC mutant, a new strategy was employed. The hop lines were 
once again screened by PCR, but this time to search for insertions close 
to, but not within, the MCC gene itself. It was hoped that insertions would 
be identified that could be used for imprecise P-element excision in order 
to remove the MCC gene and a small section of intervening DNA, or to 
provide a position closer to MCC as the starting point for a second hop. 
Screening was carried out using the same genomic DNA preps as 
previously. New primers were designed to cover a ~2Kb region on each 
side of CG6156 (fig. 4.16) and these were used in PCRs with the primer 
at each end of the P-element, as before.
-2Kb ~2Kb
A
r ~ ' \
5 ’gen G11 G8 3 ’gen
— ■  h - \ h
\
CG CG 18496
I
CG 6156
/  /  \  
CG 6171 CG 5063 IdlCp
Figure 4.16. Broad screening genomic PCR primers. Not to scale
This round of screening identified one further insertion. A PCR product of 
approximately 2.2Kb was observed using primers G8 and PlacW3’ (fig. 
4.17). This was narrowed down to one particular line, and the insertion 
was named P2.
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P2 insertion
 ■ ----------  3Kb
 ■  2Kb
Figure 4.17. P2 insertion discovery. Genomic DNA from pools of 20 P- 
element hop flies was extracted and subjected to PCR using primers that 
covered the region either side of the MCC gene. Screening gel for lines 1-80.
This insertion is predicted to be within the IdlCp gene based on the size of 
the PCR product (fig. 4.18). Flies carrying the P2 insertion are 
homozygous viable with the same homozygous phenotype as the PO 
insertion.
G8 PlacW3’Y  P2 insertion
m  h ..... r ' 1 ]□??
CG6156
/  /  • 
CG 6171 CG 5063 \ c p
Figure 4.18. The P2 insertion.
4.19. The P2 insertion may be incomplete
Similarly to the P1 insertion, the P2 insertion appeared to be incomplete 
and/or there had been a genomic deletion. No PCR product was 
generated using the primer at the 5’ end of the P-element and any of a 
number of genomic primers that should have given PCR product if an 
intact P-element were present. A plasmid rescue was performed, but 
once again all sequence corresponded to the original insertion, indicating 
that this is still present in the P2 line. This indicated that any deletion of
the P-element in P2 was likely to have removed the ampicillin resistance
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gene, and also indicated that there were likely to be no further intact 
insertions in this line except the PO insertion. The eye colour of the P2 
line was the same as the PO line, indicating that the mini-white gene 
within the P2 P-element was unlikely to be intact.
4.20. The second hop
Despite the fact that the second insertion may be incomplete (and 
therefore the P2 P-element may not be competent to hop), a second hop 
was carried out using the P2 insertion line in an attempt to get a clean 
insertion into the MCC gene. It was predicted that even if the P2 insertion 
itself could not hop, the PO insertion that is still present in this line could 
hop and therefore more insertions would be generated. Once again, 
approximately 1500 fly lines were screened for an insertion into the MCC 
gene (the 2Kb either side of the gene was not re-screened), and one 
further insertion was identified by PCR (fig. 4.19). This insertion (named 
P3) gave a PCR product of 500-700bp with the G9 + LacW5’ primers.
P3 insertion
■500bD
Figure 4.19. Discovery of the P3 insertions. Genomic DNA from pools of 20 
P-element hop flies was extracted and subjected to PCR using primers that 
covered the MCC gene. Screening gel for lines 181-300.
146
4.21. Two distinct lines
As with the two previous insertions, the precise line carrying the insertion 
was identified by genomic DNA extraction of the 20 possible lines and
individual PCRs. In the 
case of the P3 insertion it 
was determined that two 
lines within the cohort of 
20 gave PCR product 
with the G9 + LacW5’ 
primers (fig. 4.20). The 
size of the PCR products 
for the two lines is subtly 
different indicating that 
they are likely to be two 
separate lines rather 
than a duplication of the 
same line. These 
insertions are therefore 
called P3 and P4. Both 
P3 and P4 lines are 
homozygous viable with the same bristle phenotype as the homozygous 
PO line in each case (fig. 4.21).
It was also determined by PCR that the P2 insertion is still present in the 
P3/4 lines, and that the PO insertion is still present in the P2 line and the 
P3 line (fig. 4.22). The PCR to test for the PO insertion in the P4 line did 
not give a product despite the P4 line having the same homozygous 
phenotype as the PO original insertion line.
P3 P4
750bp
500bp
Figure 4.20. Isolation of the P3 and P4 
insertion lines. Genomic DNA from all 20 P- 
element hop flies was extracted and subjected to 
PCR using primers G9 and LacW5’.
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Figure 4.21. The P3 and P4 homozygous phenotype. A: P3 line, B: P4 line, 
C: PO line. All images are of homozygotes.
4.22. The P3/4 P-element may be incomplete
Once again, the P-element insertion in MCC gave PCR product with 
primers at one end of the insertion (5’ end), but not the other. As for the 
P1 insertion, the extent of the remaining P-element was mapped using a 
genomic primer (G9) in combination with the LacW5’ primer. Once again, 
at least 8.8Kb of the P-element is still present at the insertion site, but the 
extreme 3’ end of the P-element appears to have been deleted (E. 
Batchelor, personal communication). Figure 4.23 is a map of the P- 
element insertions generated by the P-element hops as predicted by the 
PCR results.
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PO insertion? P2 insertion?
Figure 4.22. Testing for the presence of the original P-element insertions.
Genomic DNA from the individual lines was tested for the PO insertion using 
primers PlacW5’ + Taq3, and for the P2 insertion using primers G8 + PlacW3’.
4.23. Verifying the insertions
PCR can amplify DNA in a non-specific manner and generate a product 
that is not desired. In order to confirm that insertions are indeed present 
in each of the lines at the positions indicated in figure 4.23 a Southern 
blot analysis was carried out. Southern blotting is a method to identify 
particular DNA sequences of interest within a large number of DNA 
fragments such as restriction digestion products of genomic DNA. Here, 
two probes were used for the Southern blotting (fig. 4.24).
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P2 line
CG 18496 0^6156
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CG 18496 CG6156
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CG 6171 CG 5063 IdlCp
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CG6156 CG 6171 CG 5063 IdlCp
Figure 4.23. The P-element insertions as predicted by PCR analysis. The
PO insertion is not shown.
If a P-element has inserted into the region covered by the probe, different 
and/or additional bands to the wild-type bands should be visualised on 
the Southern blot. Two different restriction enzymes were used to 
generate fragments for the Southern analysis in the hope that bands 
distinct from the balancer chromosome wild-type bands would be clearly 
visible with at least one enzyme. The band sizes predicted by identifying 
restriction sites in the BDGP genomic sequence are depicted in figure 
4.25.
MCC 3’gen
r v  ^  ^
ir
CG 1L 96 CG 6156 Cg / i 71 CG 5063 IdlCp CG5044
Figure 4.24. Probes for the Southern blot analysis. DIG-labelled probes 
were generated using standard methods (see Materials and Methods). The 
MCC probe covers the whole of CG6156 and CG18496, and was generated 
using primers G9 + G10. The 3’gen probe used primers G8 + gen4Kb and 
covers a region of ~4Kb directly to the right of CG6156. Not to scale.
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CG 18496 CG 6156 CG6171
Figure 4.25. Prediction of approximate wild-type band sizes for the 
Southern blot analysis. A: BamHI digestion, B: Hindlll digestion.
Green line indicates MCC probe, orange line indicates 3’gen probe, red 
arrows indicate restriction enzyme cut sites. Not to scale.
The Southern blot clearly indicates extra bands in the P1 and P4 insertion 
lines, confirming the presence of a P-element within the MCC gene locus 
in each case (fig. 4.26). The P3 genomic DNA digested with Hindlll was 
unfortunately degraded (lane 4). However, the P3 insertion does not 
show any extra bands with BamHI (lane 4) (nor with ECoRI -  not shown). 
This indicates that the P3 insertion line almost certainly does not carry a 
P-element within MCC.
In order to analyse a potential deletion of genomic DNA to the right of the 
3’ end of CG6156 in the P1 and P2 lines, the Southern blot was stripped 
and re-probed with the 3’gen probe (fig. 4.27). Blotting with this probe 
revealed no extra bands in addition to the predicted wild-type bands for 
the P2 line. This probably indicates that the P2 line does not carry a P- 
element at the predicted position. However, it is possible that an insertion 
at this point happens to give a new band(s) of the same size as the wild- 
type bands and is therefore not distinguishable. Analyses of the bands 
produced by the P3 or P4 lines (which are predicted by PCR to carry the 
P2 insertion, fig. 4.22) confirm that there is no insertion at the P2 
predicted insertion site.
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2.3Kb
2.0Kb
Figure 4.26. Southern blot of P-element insertions using the MCC probe.
Total genomic DNA was extracted from the P-element insertion lines, digested 
with either BamHI or Hindlll and subjected to Southern blot analysis using the 
MCC probe. P1 heterozygous flies and P2, P3 and P4 homozygous flies were 
used. OreR and PO homozygous flies were used as controls. M: DIG-labelled 
markers, 1: OreR, 2: P0/P0, 3: P1/TM3, 4: P3/P3 5: P4/P4 6: P2/P2 7: 
Df(3R)ea/TM3.
A detailed analysis of the bands on the Southern blots and conclusions 
resulting from the analysis is provided in sections 4.27.2 -4.27.5 at the 
end of this chapter. In summary, the P4 insertion appears to be a clean 
insertion into MCC.
4.24. The P1 line is viable over the P4 line
Crossing P1 with P4 produced viable flies with no visible phenotype other 
than the bristle phenotype associated with the PO insertion (table 4.5, fig.
4.28). Similarly, control crosses of P2 with either P1 or P4 produced the 
PO homozygous phenotype, as did crosses of P1, P2 or P4 with PO (data 
not shown).
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4.25. The P1 and P4 lines complement deficiencies that take out 
MCC
The P1 and P4 lines were tested for complementation with two deficiency 
lines. These lines are both predicted to have removed the CG6156 and 
CG18496 genes, and all the genes from the 3’ end of CG6156 up to and 
including easter (all these genes lie within 88F1):
Df(3R)ea (BL 383) -  predicted breakpoints: 88E7-13;89A1 
Df(3R)Exel6174 (BL 7653) -  molecularly predicted to delete all genes 
from 88F1-88F7
Both lines are viable over both of these deficiencies with no visible 
phenotype (table 4.5, fig. 4.28).
BamHI Hindlll
M1 2 3 4 5 6 7  M 1 2 3 4 5 6 7
23Kb — • 23Kb — IS
9.4Kb — 
6.5Kb —
** m m
9.4Kb — 
6.5Kb —
m — m . . .
4.4Kb — 4.4Kb —
•
2.3Kb — 
2.0Kb —
2.3Kb — 
2.0Kb —
Figure 4.27. Southern blot of P-element insertions using the 3’gen probe.
Total genomic DNA was extracted from the P-element insertion lines, digested 
with either BamHI or Hindlll and subjected to Southern blot analysis using the 
3’gen probe. M: DIG-labelled markers, 1: OreR, 2: PO/PO, 3: P1/TM3, 4: P3/P3, 
5: P4/P4, 6: P2/P2, 7: Df(3R)ea/TM3.
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4.26. Fertility defects
Although there was no phenotype observed in homozygous adults of the 
P4 line, it is possible that this insertion could lead to a defect in 
oogenesis, spermatogenesis, or some other process associated with 
fertility. If this were the case, phenotypes would only become visible in 
the second homozygous generation. In order to test this, an attempt was 
made to keep the P4 line as a homozygous stock.
P4 TM6C, Sb
P1 (118) 31% (134) 36%
TM6C, Sb (124) 33% 0
Df(3R)ea TM3, Ser
P1 (97) 49% (101)51%
TM3, Sb, Kr-GFP 0 0
Df(3R)Exel6174 TM6B, Hu
P1 (77) 50% (78) 50%
TM6C, Sb 0 0
Df(3R)ea TM3, Ser
P4 (101)39% (98) 38%
TM6C, Sb 0 (58) 23%
Df(3R)Exel6174 TM6B, Hu
P4 (108) 49% (112) 51%
TM6C, Sb 0 0
Table 4.5. P-element complementation analysis.
Drosophila crosses were performed at 25°C and emerging 
adults scored from 10 days onwards until all had emerged. 
Percentages are the percentage number of flies of each 
genotype resulting from the cross. Numbers in parentheses 
are actual number of adult flies.
The P2 line was used as a control with the same genetic background as 
P4 but lacking a P-element insertion in MCC. The PO line can be
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maintained as a homozygous stock and was also used as a control. 
Neither P2 nor P4 flies could be maintained as a homozygous stock.
This may imply that the P2 line carries a P-element insertion somewhere 
in the genome that is affecting fertility since P2/P2 homozygous flies are 
viable, but their progeny are not. This is presumably also present in the 
P4 line. P2 homozygous females do lay eggs but no larvae hatch from 
these eggs implying that they are either not fertilised, or are not 
competent to be fertilised.
Figure 4.28. Complementation analysis of P-element lines. For details of 
methods see table 4.5 legend. A: w/+ ; P1/P4, B: w/+ ; P1/Df(3R)ea, C: w/+ ; 
P4/Df(3R)ea.
The P4 and P2 lines were also crossed to the P1 line and attempts made 
to generate progeny from interbreeding P1/P4 or P2/P4. Table 4.5 
illustrates the results of these crosses. The lack of progeny from all of 
these crosses indicates that any fertility defect is not associated with an 
insertion in MCC, but is likely to be a separate mutation on the 
chromosome that is present in the P1, P2 and P4 lines but not the PO 
line.
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Line Larvae?
PO/PO YES
P4/P4 X
P2/P2 X
P1/P4 X
P1/P2 X
P2/P4 X
Table 4.6. Fertility crosses for P-element 
insertions. Crosses were carried out at 25°C. 
Each line was inter-bred with itself and the food 
observed for churning (associated with larval 
feeding) and adult emergence. X indicates 
churned medium was not observed.
4.27. Discussion and conclusions
4.27.1. RNAi and UAS-MCC expression studies
The lack of phenotype observed with the UAS over-expression crosses 
could indicate that there is a technical problem with the construct or that 
MCC over-expression has no effect on development. It is possible that 
the fly lines had lost the UAS insertions. They were tested by PCR with a 
primer internal to the hsp70 gene in combination with one internal to the 
MCC gene, and one internal to the white gene in combination with one 
internal to the MCC gene (both the hsp70 and white genes are present in 
PUAST, the vector used to make these transgenic lines), and all lines 
tested positive for the insertion. Another possibility is that the expression 
level achieved is not sufficiently high to give a phenotype. To circumvent 
this possibility, the crosses were also carried out at 29°C to achieve high 
GAL4 expression levels and therefore high MCC expression levels. This 
still produced no visible phenotypes.
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There can be insertion position effects on expression levels of P-element 
mediated injected constructs (Spradling and Rubin 1983). It is possible 
that expression levels at some UAS-MCC insertion loci are very low, and 
therefore multiple insertions are required to provide sufficient over­
expression levels to produce a phenotype. All lines have at least one 
insertion on the third chromosome, but it is not known whether multiple 
insertions are present. Lastly, it may be that the UAS construct is simply 
not functioning (i.e. it is not expressing MCC in response to GAL4 binding 
to the UAS). It would be possible to test this by carrying out an in situ of 
embryos carrying a GAL4 construct and UAS-MCC construct that would 
lead to ectopic MCC expression that could be assayed by use of the 
MCC probe. For example, using a wingless-GAL4 driver, a striped in situ 
pattern would be indicative of the UAS construct functioning correctly.
The final possibility is that over-expression of MCC produces no 
phenotype. If MCC is involved in blocking the cell cycle in its role as a 
tumour suppressor it is possible that its over-expression would have no 
cellular effect, and an effect would only be seen when the gene function 
was taken away. However, in this regard one would expect there to be a 
phenotype when using RNAi or in a mutant.
The RNAi construct covered exons E and F and should, therefore, lead to 
degradation of all four mRNAs since they all include at least part of these 
exons. The lack of phenotype could be due to similar technical reasons 
as for the UAS over-expression construct. In this regard crosses were 
also performed at 29°C. Fly lines with dark red eyes (potentially 
indicative of multiple mini white genes and therefore multiple insertions), 
and one with insertions on multiple chromosomes were chosen for the 
RNAi analysis in an attempt to select lines achieving high expression 
levels of the construct. RNAi constructs are often prone to difficulties with 
achieving high protein knock-down levels. Without an antibody it is not 
possible to ascertain the efficacy of the flipback RNAi construct used
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here. However, it may be possible to visualise a knock down of mRNA 
levels either by in situ, Northern analysis or RT PCR.
4.27.2. P-element hopping (general comments)
Deletion of the 3’ end of the P-element appeared to occur with both the 
P1 and P4 insertions. It is possible that the P-element in the PO line that 
was the starting point for the hops is defective in some way that leads to 
a deletion of its extreme 3’ end when it hops. Deletions are commonly 
associated with P-element hops and may solely involve regions internal 
to the P-element or in addition remove genomic DNA in the region of 
insertion (Staveley, Heslip et al. 1995).
4.27.3.Southern blotting (general comments)
The Southern blot revealed an interesting phenomenon when analysing 
the wild-type bands for OreR (lane 1, fig. 4.26). There appeared to be an 
extra band of approximately 2.7Kb in the BamHI digestion. This band 
could represent a polymorphism of the chromosome in the region of 
MCC. A polymorphism is a sequence difference observed between 
different chromosomes in the wild-type population. A single organism 
may have one chromosome with one version of the polymorphism and 
the homologous chromosome with a different version. If the 
polymorphism happens to remove or insert a restriction site this will be 
seen with Southern blotting using the corresponding restriction enzyme. 
The polymorphism is most obvious when a 5’gen probe is used (fig.
4.29). The polymorphism is also seen in the TM3 balancer chromosome 
(lanes 3 and 7 of fig 4.29). In this case an extra band is also observed 
with Hind III, indicating that there is also a polymorphism affecting a Hind 
III site (fig. 4.26).
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Figure 4.29. Polymorphism to the left of the MCC gene. Total genomic 
DNA was extracted from the P-element insertion lines, digested with either 
BamHI or Hindlll and subjected to Southern blot analysis using the 5’gen 
probe. M: DIG-labelled markers, 1: OreR, 2: PO line, 3: P1/TM3, 4: P3/P3, 5: 
P4/P4, 6: P2/P2, 7: Df(3R)ea/TM3.
4.27.4. P1 insertion analysis
The P1 line is homozygous lethal. The insertion is located within the third 
exon of the CG6156 predicted gene. This exon is upstream of the end of 
mRNAd, therefore no stable MCC mRNAs are likely to be produced from 
the P1 insertion chromosome.
The Southern analysis confirms the presence of a P-element in the region 
indicated by the PCR product sequencing. The PCRs indicate that the 3’ 
end of the P-element and/or the 3’ end of CG6156 (and genes to the 
right) may be deleted, but that at least 8.8 Kb and less than 10.5Kb of the 
P-element is present. The inverse PCRs designed to enable sequencing 
across the breakpoint were not successful possibly due to inefficient 
ligation. They should have given a PCR product from the PO insertion 
that is present in the P1 line but they did not, indicating that the technique 
was not working.
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The Southern analysis confirms that the 3’ end of CG6156 has been 
deleted since there are no extra bands corresponding to this part of the 
MCC probe with either BamHI or Hindlll unless they all happen to be the 
same size as the wild-type bands (which is unlikely). The BamHI bands 
suggest that a large proportion of the P-element is present in the P1 line 
since the extra band is large at -13Kb (fig. 4.26). The genome contains 
many BamHI sites (on average 1 every 3.8Kb in the MCC region), but the 
P-element contains only one BamHI site almost at the 3’ end. Based on 
the PCR analysis, and the fact that the plasmid rescue gave no colonies 
corresponding to the P1 insertion, it is likely that the P-element is 
incomplete and that the breakpoint is 3’ of 8.8Kb and 5’ of 10.5Kb within 
the P-element. The BamHI site giving rise to the -13Kb fragment is, 
therefore, likely to be genomic and the fragment will include -8.8Kb of the 
P-element (fig. 4.30).
Unfortunately, due to P1 being homozygous lethal, the Southern analysis 
tells us little about a potential deletion of genomic DNA to the right of 
CG6156 since the wild-type bands are always present. The only 
information we have about this is the genetic analysis with the easter 
mutants that indicate that the easter gene is intact within this line. 
Therefore, the conclusion from analysis of the P1 line is that the P- 
element has inserted within the third exon of CG6156 and that the part of 
CG6156 downstream from the insertion point has been deleted from the 
genome along with a section of the chromosome that does not reach as 
far as the easter gene.
The homozygous lethality of P1 does not fit with its viability over both 
deficiencies that take out all genes from CG6156 to easter. If deletion of 
the 3’ end of CG6156 itself or any of the other genes removed in the P1 
line were to give rise to a homozygous lethal phenotype, it would be 
expected that the combination of P1 /deficiency would be homozygous 
lethal too. There are several possible reasons for this discrepancy. One 
explanation is that the deficiencies have not been accurately mapped.
Df(3R)ea breakpoints have been mapped cytologically, a technique with a
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high degree of error. Df(3R)Exel6174 has been mapped molecularly 
which should ensure accuracy of claimed deleted genes. However, re­
mapping of the deficiency would be required to confirm this data. The 
deletion in the deficiency could be confirmed by either a Southern blot or 
PCR approach. If either of these deficiencies do not remove CG6156 
and/or any other genes that have been deleted in the P1 line, they could 
be viable in combination with P1.
~2.9Kb -7 .6Kb-4.4K
CG 18496 CG 6156 CG6171
-4 .4Kb ~13Kb
P1 insertion
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CG 18496 CG 6156 
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XKb
I
gene to the left of easter 
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H Z Z X  I h
C G '18496 CG 6156 CG 6171 CG 5063 IdlCp CG5044
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Figure 4.30. Hypothesis for P1 and P4 insertion outcomes and resulting 
Southern bands. A-C: BamHI digestion, D-F: Hindlll digestion. A, D: wild- 
type chromosome (e.g. balancer), B, E: P1 insertion chromosome, C, F: P4 
insertion chromosome. Red arrows indicate restriction enzyme cut sites. Not 
to scale.
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A second possible reason why P1 is homozygous lethal but viable over 
the deficiencies is that there is another P-element insertion somewhere in 
the genome that leads to homozygous lethality. If this were the case it 
would presumably have a non-functional ampicillin resistance gene (as 
the P1 insertion does) since the plasmid rescue only gave colonies with 
sequence corresponding to the original insertion. It is possible that the 
combination of PO and P1 insertions gives rise to lethality, which would 
explain why the P1 line, which carries both insertions, is homozygous 
lethal but viable over the deficiencies. However, both deficiencies are 
predicted to remove the insertion point of PO, so it seems unlikely that it is 
the combination of PO and P1 that gives rise to lethality. It is more likely 
to be a third insertion elsewhere in the genome.
The overall conclusion of P1 line analysis is that the CG6156 gene has 
been disrupted and will be very unlikely to produce functional protein, and 
that additional genes are likely to have been disrupted/deleted and not be 
producing protein. The homozygous lethality associated with this line 
cannot necessarily be attributed to MCC disruption.
4.27.5. P4 insertion analysis leading to the conclusion that an
MCC mutant has no obvious phenotype
The P4 line is homozygous viable with the same phenotype as the PO 
line. The P4 insertion is predicted by the size of the PCR products to be 
located within exon H (see fig. 4.10) just to the right of the stop codon 
used in DMCCd. It is possible that mRNAd is expressed in the P4 line. 
The RT PCR in chapter 3 did not define the 3’ end of mRNAd, but it is 
likely that it continues after the stop codon with a 3’ UTR. The likelihood 
is, therefore, that the P4 insertion line is not able to produce stable 
mRNAs since the coding region would be separated from the 3’ 
untranslated region and site of polyA tail addition, which are needed to 
confer stability (Wickens, Anderson et al. 1997). The P4 insertion is 
viable over both deficiencies (although, as discussed above, these may 
not remove CG6156).
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PCRs indicate that the 3’ end of the P-element and/or the 5’ end of 
CG6156 (and upstream genes) may be deleted but that at least 8.8 Kb of 
the P-element is present in the P4 line. The Southern analysis confirms 
the predicted region of P-element insertion. Confusingly, the BamHI 
analysis of the P4 line apparently shows wild-type bands in addition to the 
non-wild type band of approximately 5.5Kb. A likely explanation for this is 
that the P-element has inserted between the two closely spaced BamHI 
sites towards the 3’ end of the MCC gene (fig. 4.30). These are located 
only 266 bp apart and from the size of the PCR product using the G9 + 
PlacW5’ primers (between 500 and 750bp) it is possible that the P- 
element has inserted between them. This would give rise to wild-type 
size bands in addition to the extra band. Sequencing of the PCR product 
would confirm this.
The Southern analysis of P4 using BamHI indicates that less than 5.5Kb 
of the P-element is present since P(lacW) contains only one BamHI site 
almost at its 3’ end and a 5.5Kb band is observed. However, digestion 
with Hindlll gives a very large band of approximately 16Kb which is larger 
than a combination of both the P-element and the whole CG6156 gene 
(the P-element contains Hindlll sites at both its 5’ and 3’ ends). These 
two facts are contradictory, and there must be something more 
complicated going on. One hypothesis would be that the P-element has 
gained a BamHI site approximately 5.5Kb from its 3’end giving rise to the 
5.5Kb BamHI site (we know that the P-element in the P1 insertion does 
not contain a BamHI site at this position) (fig. 4.30). P-elements move 
via a cut-and-paste mechanism which is prone to errors and internal 
deletions are common (Staveley, Heslip et al. 1995). P-elements also 
replicate themselves, another error-prone process that may result in 
sequence alternations. Either an internal deletion or replication error may 
have given rise to a novel BamHI site. The fact that the 5.5Kb band is 
weak in intensity indicates that it is likely to correspond to the probe 
hybridising to the small region of CG6156 that is to the right of the P4 
insertion. There is no other extra band corresponding to the 5’ end of
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CG6156/CG18496. This could be indicative of a deletion of the 5’ end of 
MCC or of a BamHI site immediately to the left of the P4 insertion giving 
rise to a wild-type band size. If this BamHI site were sufficiently close to 
the end of the P-element there would only be a very small section of 
sequence that the probe would hybridise to, and therefore the band 
corresponding to that small section may be present on the gel but not 
visible with the probe. Depending on the extent of the 3’ deletion of the 
P4 insertion (which is likely to be small based on the size of the Hindlll 
fragment), it is possible that this band is the same size as one of the other 
bands on the blot (most likely the 5.5Kb or 2.9Kb bands) and is therefore 
not visible or that it is too faint to be seen for reasons just described.
The analysis of the P4 line using Hindlll confirms that the 5’ end of 
CG6156 is present since the ~16Kb fragment is dark, and that the P- 
element is likely to be mostly intact. Similarly to BamHI, the frequency of 
Hindlll sites is high within the genome (in the MCC region they occur on 
average one every 3.25Kb), and therefore a large fragment is indicative 
of a mostly intact P-element insertion since the P-element only has two 
Hindlll sites -  one at each end.
In conclusion, in the P4 line a P-element missing only its extreme 3’ end 
has inserted in the seventh exon of CG6156. This insertion is not likely to 
produce functional protein from the MCC locus, but no other genes 
should be directly affected (unless the P-element is within an enhancer of 
another gene). An MCC mutant, therefore, has no homozygous 
phenotype (the P4 line does, of course, have the background PO 
phenotype). It is important to confirm that the P4 line does not express 
functional protein. Without an antibody against Drosophila MCC this is 
impossible.
4.27.6. Complementation analysis
The fact that P1 is homozygous lethal but is viable over the P4 insertion 
indicates that mutation of a gene other than MCC is giving rise to the
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homozygous lethality since both P1 and P4 lines are unlikely to be 
producing functional MCC protein of any form. As discussed above, it is 
possible that an additional P-element insertion elsewhere in the genome 
is giving rise to P1 homozygous lethality.
There is a Drosophila line available that carries a P-element insertion 
within CG18496 (Bloomington stock 18571). This line is homozygous 
viable, and both the P1 and P4 insertions are viable over it (data not 
shown). This insertion would be predicted to disrupt expression of 
mRNAc and mRNAd. This is further evidence for lack of phenotype of an 
MCC mutant, although mRNAa and mRNAb may be expressed normally 
in this line.
4.27.7. Lack of phenotype
The lack of phenotype for an MCC mutant indicates that MCC protein has 
no obvious function during Drosophila development. The lack of 
phenotype seen with the mutant correlates with the lack of phenotype 
seen with RNAi analysis. In order to absolutely confirm lack of gene 
expression in the P-element lines, an antibody against MCC could be 
used to illustrate lack of MCC protein. It is just possible that an mRNA 
may be produced from either P1 or P4 lines that runs into the P-element 
and is stable. However, this is unlikely in itself, and would be even more 
unlikely to produce a stable and functional in-frame protein. Certainly in 
the case of the P1 insertion, any protein produced would contain only a 
short section of amino acids of MCC origin, and would be unlikely to be 
functional.
It is possible that the P-element mutant has a phenotype that is not 
obviously visible such as a behavioural phenotype associated with MCC 
CNS expression. This may not affect CNS development perse  but affect 
its function once it is developed, and give rise to a subtle behavioural 
phenotype that could only be observed in specialised behavioural studies.
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If MCC were acting as a tumour suppressor one might expect a visible 
phenotype, perhaps involving overgrowth when the gene is mutated, such 
as is seen with the leukaemia associated tumour suppressor (LATS) 
mutant (Xu, Wang et al. 1995). No overgrowth phenotype is observed, 
and therefore indicates that MCC is unlikely to be acting as a “tumour 
suppressor” in Drosophila. This does not mean, however, that MCC does 
not act as a tumour suppressor in higher organisms. The fact that MCC 
is expressed in tissues other than the central nervous system in higher 
organisms such as the mouse may indicate additional roles for MCC in 
those organisms.
If DMCC were functioning in the signalling pathway involving DRhoGEF2, 
a DMCC mutant would be expected to show a phenotype similar to the 
DRhoGEF2 mutant phenotype. Since this is not the case, it is unlikely 
that DMCC is functioning in the signalling pathway involving DRhoGEF2.
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5. Results -  DMCC and DRhoGEF2 interaction analysis
5.1. introduction
Although it is unlikely that DMCC participates in the signalling pathway 
involving DRhoGEF2 leading to cell shape changes based on the 
expression and mutation analyses presented in chapters 3 and 4, 
DRhoGEF2 may have other functions for which DMCC is required. 
Alternatively, DRhoGEF2 could be influencing any function DMCC may 
have. In this chapter the interaction between DRhoGEF2 and DMCC is 
investigated in order to understand whether DMCC influences 
DRhoGEF2 function, or vice versa.
The yeast 2-hybrid result (Introduction) indicates a possible interaction 
between the DRhoGEF2 PDZ domain and DMCC. However, yeast 2- 
hybrid studies can give false positives, and confirmation of the interaction 
is required, which is presented here. The fact that the interaction is likely 
to be mediated via the DRhoGEF2 PDZ domain is interesting as it opens 
up questions of specificity. For example, does DMCC only interact with 
DRhoGEF2 PDZ domain or other PDZ domains too and what, 
molecularly, is required for the interaction? These issues are begun to be 
addressed here.
The functional interaction between DRhoGEF2 and DMCC is investigated 
by a genetic approach. Despite the fact that mutation of DMCC does not 
lead to a phenotype per se (chapter 4) it is possible that the DMCC 
mutant alleles could enhance or suppress a DRhoGEF2 phenotype 
indicating that a genetic interaction exists between DRhoGEF2 and 
DMCC.
5.2. Interaction between the isolated DRhoGEF2 PDZ domain and 
DMCC
In order to confirm the yeast 2-hybrid result, a co-immunoprecipitation 
strategy was used. The DRhoGEF2 PDZ domain and DMCC were
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generated as fusion proteins with N-terminal tags. The recombinant PDZ 
domain co-immunoprecipitated DMCC from a Drosophila S2 cell lysate 
(fig. 5.1).
+
250KDa
160KDa -----
105KDa -----
■ *------ DMCCa
75KDa
50KDa mmh—  >9°
35KDa
IP: T7
Blot: myc9E10
Figure 5.1. DMCCa co-immunoprecipitates with DRhoGEF2 PDZ domain.
The recombinant PDZ domain was generated using a bacterial recombinant 
expression system which provides a T7 tag at the N-terminus. Full-length 
DMCCa was cloned into a modified pFASTBACI vector (Invitrogen) which has 
the Act5C promoter in place of the Polh promoter, and provides a myc tag at 
the N-terminus. The Act5C promoter within pFASTBAC-Act5C gives high 
expression levels when transfected into Drosophila culture cells. pFASTBACI - 
Act5C-myc-DMCCa was transfected into Drosophila Schneider S2 cells and 
cells were lysed prior to addition of the recombinant PDZ domain and 
immunoprecipitation with an anti-T7 antibody. The membrane was blotted with 
the anti-myc9E10 antibody. - no PDZ domain, + with PDZ domain.
The bright band at ~50KDa in figure 5.1 is due to the secondary anti 
mouse-IgG antibody recognising the mouse T7 antibody used to 
immunoprecipitate the PDZ domain.
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5.3. Conservation of PDZ-binding motif
The three potential DRhoGEF2 PDZ targets identified in the yeast 2- 
hybrid screen (MCC, group 3 and Mec-2) all have a Threonine -  X -  
Leucine -  COOH motif at their C-terminus. This is a classic PDZ-binding 
motif (see Introduction). All three targets also have a proline residue at 
the -4 position (table 5.1). There does not appear to be conservation of 
residues at the -1 or -3 positions, nor positions immediately N-terminal to 
the proline up to the -8 position. This motif is hereafter referred to as 
PXTXL.
Tarqet -8 -7 -6 -5 -4 -3 -2 -1 0
MCC Gin Asn His Val Pro Glu Thr Thr Leu
Mec-2 Leu Asp Ala Trp Pro Lys Thr Asn Leu
Group-3 Val Ala Asp Ala Pro Iso Thr Asp Leu
Table 5.1. C-terminal amino acid residues of DRhoGEF2 predicted PDZ 
targets. 0 indicates the C-terminus.
5.4. Requirement of C-terminal residues for interaction
Since all DRhoGEF2 PDZ targets identified in the yeast 2-hybrid screen 
carry a PXTXL motif at their C-terminus, it is possible that the proline, 
threonine and leucine residues are necessary for binding to the 
DRhoGEF2 PDZ domain. In order to test the requirement of these 
residues for interaction with DRhoGEF2 PDZ domain, they were each 
individually mutated by site-directed mutagenesis of the the MCCa 
isoform to an alanine residue (K. Barrett). They were tested, as 
previously, for interaction with DRhoGEF2 PDZ domain using a co- 
immunopreciptation approach (fig. 5.2).
Neither the DMCCap^ A nor the DMCCaL^ A mutants co-immunoprecipitate 
with the DRhoGEF2 PDZ domain. The DMCCaT~*A mutant co- 
immunoprecipitates less effectively than wild-type DMCCa. DMCCd, 
which lacks the C-terminal PXTXL motif, and which was expressed at
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very high levels (fig. 5.2, lane 6, blot C) also co-immunoprecipitates with 
DRhoGEF2 PDZ domain. This is likely to be due to excessively high 
expression levels and not represent a real interaction.
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Blot: myc
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DMCCd
Figure 5.2. The proline and leucine residues are required for binding to 
DRhoGEF2 PDZ domain. DMCCa, DMCCap^ \  DMCCaT^ A and DMCCaL^ A 
were individually cloned into pFASTBACI-Act5C-myc and expressed in 
Drosophila S2 cells. Recombinant DRhoGEF2 PDZ domain with an N-terminal 
T7 tag was used for the IP. A: IP using anti-T7, blot using anti-myc9E10. 1: 
DMCCa, 2: DMCCa, 3: DMCCap^ A, 4: DMCCaT^ A, 5: DMCCaL^ A, 6: DMCCd,
7: untransfected control. B: IP using anti-T7, blot using anti-T7. Lanes as in A.
C: Whole cell lysates (WCL), blot using anti-myc9E1°. 1: DMCCa, 2: DMCCa. 3: 
DMCCap^ A, 4: DMCCaT^ A, 5: DMCCaL^ A, 6: DMCCd, 7: untransfected control. 
D: IP using T7, blot using a rabbit anti-myc antibody (anti-mycrab). Lanes as in 
A.
5.5. Bioinformatics to identify further PXTXL proteins
If DRhoGEF2 does interact with targets based on sequence specificity for 
PXTXL at the C-terminus, it would be interesting to determine how many 
potential binding partners for DRhoGEF2 exist in Drosophila. A TXL- 
COOH motif occurs in 116 (PATSCAN) (appendix 3) or 123 (D.Sims, 
personal communication) proteins of the Drosophila proteome. This list is 
likely to include a large number that interact with PDZ domain proteins
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since TXL is a classic C-terminal motif for a PDZ target protein. A PXTXL 
motif occurs in six of these (table 5.2).
Name/ID -4 -3 -2 -1 0
MCC / CG6156 Pro Glu Thr Thr Leu
mec-2 / CG7635 Pro Lys Thr Asn Leu
group-3 / CG9795 Pro lie Thr Asp Leu
capricious / CG11282 Pro Val Thr Glu Leu
CG5539 Pro Gly Thr lie Leu
CG3777 Pro Gin Thr Gly Leu
Table 5.2. PXTXL-COOH proteins of the Drosophila proteome (BLAST 
analysis).
Therefore, if the DRhoGEF2 PDZ domain does select specifically for 
PXTXL in its binding partners, there are only six proteins within the cell 
with which it could potentially interact (see sections 5.9.2-5.9.4 for 
discussion of DRhoGEF2 PDZ domain specificity).
5.6. Interaction between full-length DRhoGEF2 and DMCC
In order to test the interaction between DRhoGEF2 and DMCC in a more 
physiologically relevant manner, the full-length proteins were over­
expressed in Drosophila S2 cells and co-immunoprecipitation attempted 
following cell lysis (fig. 5.3).
Full-length DRhoGEF2 does not co-immunoprecipitate with DMCCc when 
the two full-length proteins are co-transfected in Drosophila S2 cells 
under the conditions tested (fig. 5.3). The addition of phosphatase 
inhibitors to push the system to an “active” phosphorylated state does not 
promote co-immunoprecipitation between DRhoGEF2 and DMCC, nor 
does treatment with GTPyS to lock G-proteins in an active state (data not 
shown), although co-transfection was not very efficient for these 
experiments (see section 5.9.1),
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Figure 5.3. Full-length DRhoGEF2 does not co-immunoprecipitate with 
DMCC in S2 cell lysates. Three constructs were co-transfected into S2 cells: 
pAct5C-GAL4, pUASp-T7-DRhoGEF2 and pFASTBAC1-Act5C-myc-DMCCc 
as indicated. The pAct5C-GAL4 construct was used to express DRhoGEF2 
from pUASp. The efficiency of co-expression was not high. In order to 
optimise this plasmids were co-transfected in different ratios and into different 
cell types (not shown). A 1:1:1 ratio transfected into Drosophila S2 cells was 
determined to be optimal and used here, although efficiency of co-transfection 
was still rather low. Anti-myc9E10 was used for immunoprecipitation and co- 
immunoprecipitation was tested by blotting with anti-T7 antibody. A: IP using 
anti-myc, blot using anti-T7, Pi’s -  phosphatase inhibitor cocktail, B: IP using 
anti-myc, blot using anti-myc, Pi’s -  phosphatase inhibitor cocktail, C: whole 
cell lysate blot using anti-T7.
There are various possible reasons why MCC was not shown to co- 
immunoprecipitate with full-length DRhoGEF2, and these are discussed 
in section 5.9.1, It is possible that the two proteins do interact in vivo, but 
that the conditions used in the experiments here are not conducive to 
binding. However, confirmation of MCC binding to full-length DRhoGEF2 
would be required to illustrate that the interaction does happen in a cell.
5.7. Genetic interaction between DRhoGEF2 and DMCC
In order to test in another manner whether DMCC and DRhoGEF2 
proteins are interacting in vivo a genetic interaction analysis was 
performed. Genetic interaction analysis involves the use of loss-of-
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function or gain-of-function mutations in a specific gene that give a certain 
phenotype, and looks for modification of this phenotype by mutation in a 
distinct gene. In this case a phenotype caused by DRhoGEF2 loss of 
function was used in an assay for enhancement/suppression of 
phenotype by presumed loss-of-function mutations in MCC (the P- 
element insertions described in chapter 4). There were various 
DRhoGEF2 alleles used in the genetic interaction experiments (table 
5.3).
Allele Molecular abnormality Comment
DRhoGEF241 (4.1) Breakpoint between amino acids 763 
and 885 (between PDZ and C1 domains)
null
DRhoGEF2Px6 (Px6) 2132bp insertion in intron 1 hypomorph
DRhoGEF2Px10 (Px10) 860bp insertion in intron 1 weak
hypomorph
DRhoGEF265 (6.5) Arg1687Cys dominant
negative
Table 5.3. DRhoGEF2 alleles. (Nikolaidou and Barrett 2004)
The combination of a DRhoGEF2 null allele {DRhoGEF?41) and 
hypomorphic allele (DRhoGEF2Px6) gives rise to a distinctive phenotype 
in Drosophila, most notably in the wings (fig. 5.4). The combination of a 
null allele (DRhoGEF241) and a much weaker hypomorph 
(DRhoGEF2Px10) gives rise to a low penetrance phenotype of folded 
wings. These phenotypes are, of course, only seen in surviving flies - 
previous work has indicated that the viability to adulthood of 4.1/Px6 is 
30% and 4.1/Px10 is 70% (Nikolaidou and Barrett 2004).
There were three different types of interaction experiment performed (for 
details of the crosses see section 2.16, Materials and methods):
1) Heterozygous DRhoGEF2 with heterozygous DMCC e.g. 
w ; 4.1/+ ; P1/+ vs w ; 4.1/+ ; +/+
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2) Homozygous DRhoGEF2 with heterozygous DMCC e.g. 
w ; 4.1/Px6 ; P1/+ vs w ; 4.1/Px6 ; +/+
3) Homozygous DRhoGEF2 with homozygous DMCC e.g. 
w ; 4.1/Px6 ; P1/P4 vs w ; 4.1/Px6 ; +/+
Figure 5.4. DRhoGEF2 null I hypomorph phenotypes. A: 4.1/Px6 - wing 
length difference is a weak phenotype for this genotype. B: 4.1/Px6 - wing 
stump is a stronger phenotype resulting from a folded wing getting stuck in the 
pupal case and being ripped off during adult eclosure. C: 4.1/Px10 - normal 
wings. D: 4.1/Px10 - slightly folded wing is a strong phenotype for this 
genotype.
Each experiment provides a progressively more sensitive background 
than the previous. It was hoped that DMCC mutation may enhance the 
phenotype of a weakly sensitive background but give rise to lethality in a
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more sensitive background (for example a phenotype may be observed 
with experiment 1, and total lethality observed in experiment 2).
4.1 ; + CyO ; +
+ ; R1 26% (68) 19% (49)
+ ; + 28% (72) 27% (69)
4.1 ; + CyO ; +
+ ; R4 29% (89) 18% (56)
+ ; + 28% (86) 25% (77)
4.1 ; + CyO ; +
+ ; P3 23% (57) 17% (42)
+; + 28% (69) 31% (76)
6.5; + CyO ; +
+ ;P1 9% (26) 18% (54)
+; + 45% (132) 27% (80)
6.5 ; + CyO ; +
+ ;P4 7% (12) 26% (42)
+ ; + 43% (69) 24% (39)
6.5; + CyO ; +
+ ; P3 13% (38) 22% (62)
+ ; + 41% (118) 24% (68)
Table 5.4. Combination of heterozygous DRhoGEF2 with 
heterozygous DMCC. For details of crosses see section 2.16 of Materials 
and methods. Drosophila crosses were performed at 25°C and emerging 
adults scored from 10 days onwards until all had emerged. Percentages 
are the percentage number of flies of each genotype resulting from the 
cross. The expected percentage for each genotype is 25%. Numbers in 
parentheses are actual number of adult flies. P3 is a line with the same 
genetic background as P4 and is used here as a control (see sections 
4.21-4.24 of Chapter 4).
The combination of DRhoGEF241 with a single DMCC allele does not 
lead to a decrease in viability compared to a wild-type allele (e.g. 26% 
versus 28% for P1) (table 5.4). There were no phenotypes observed for
this combination. Combining DRhoGEF26 5with DMCC does lead to a 
decrease in viability compared to wild-type (e.g. 9% versus 45% for P1).
Px6; P1 CyO ; P1 Px6 ; + CyO ; +
4.1 ; + 2% (4) 23% (38) 4% (6) 24% (40)
CyO ; + 23% (38) 0 24% (40) 0
Px6 ; P4 CyO ; P4 Px6 ; + CyO ; +
4.1 ; + 1 % (2) 17% (34) 5% (10) 30% (59)
CyO; + 17% (34) 0 30% (59) 0
Px6 ; P3 CyO ; P3 Px6 ; + CyO ; +
4.1 ; + 4% (8) 22.5% (60) 5% (12) 18% (40)
CyO ; + 22.5% (60) 0 18% (40) 0
Px10 ; P1 CyO ; P1 Px10 ; + CyO ; +
4.1 ; + 7% (12) 19% (33) 23% (40) 16.5% (29)
CyO; + 19% (33) 0 16.5% (29) 0
Px10 ; P4 CyO ; P4 Px10 ; + CyO ; +
4.1 ; + 13% (34) 20.5% (53) 13% (34) 16% (41)
CyO ; + 20.5% (53) 0 16% (41) 0
Px10 ; P3 CyO ; P3 Px10 ; + CyO ; +
4.1 ; + 9% (16) 22% (39) 8% (14) 20% (36)
CyO ; + 22% (39) 0 20% (36) 0
Table 5.5. Combination of homozygous DRhoGEF2 with heterozygous 
DMCC. For details of crosses see section 2.16 of Materials and Methods. 
Drosophila crosses were performed at 25°C and emerging adults scored from 
10 days onwards until all had emerged. Percentages are the percentage 
number of flies of each genotype resulting from the cross. The expected 
percentage for each genotype is ~16.7% taking into account the homozygous 
lethality of CyO. Numbers in parentheses are actual number of adult flies. It 
was not possible to distinguish between the different DRhoGEF2 alleles, hence 
the total number for the two genotypes (e.g. 4.1/CyO ; P1/+ and Px6/CyO ; 
P1/+) was divided by two to give the number of adult flies and resulting 
percentage in each class. P3 is a line with the same genetic background as P4 
and is used here as a control (see sections 4.21-4.24 of Chapter 4).
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However, the same is true when the control P3 allele is used (13% versus 
41%), which indicates that it is not due to DMCC disruption. Again, there 
were no phenotypes observed. It is likely that there is another 
mutation/chromosomal aberration present on the P1, P3 and P4 
chromosomes that is interacting with DRhoGEF26 5 leading to a decrease 
in viability. It is also noticeable that the CyO balancer chromosome also 
gives a slight decrease in viability which leads to the >25% percentages 
for the other genotypes.
Given that there are 8 possible genotypes for each cross in table 5.5 
(homozygous DRhoGEF2 with heterozygous DMCC), each genotype 
would be expected to show a percentage viability of 12.5%. However, 
homozygous CyO is always lethal and therefore the percentage expected 
increases to ~16.7% for each genotype that survives. The combination of 
4.1/Px6 leads to a significant decrease in viability with only 4-5% of flies 
surviving to adulthood. Given that the expected percentage of flies is 
16.7% this is a percentage viability to adulthood of 26.9%, which fits with 
previous work that indicated the viability to adulthood of 4.1/Px6 is ~30% 
and 4.1/Px10 is 70% (Nikolaidou and Barrett 2004). Similarly, 4.1/Px10 
has a decreased viability with an average of 14.5% of flies for that 
genotype surviving to adulthood which corresponds to a percentage 
viability to adulthood of 87%, which is rather higher than previously 
observed.
The addition of a DMCC allele to the combination of 4.1/Px6 does appear 
to decrease viability slightly when compared to the control (average 1.5% 
versus 4%). However, for the 4.1/Px10 combination the same was not 
true, with the viability of 4.1/Px10 in combination with P4 giving greater 
viability than with P3 (13% versus 9%), and with P1 giving a very similar 
figure to the P3 control (7% versus 9%). These differences could be 
merely due to the fact that the total number of adult flies for each 
experiment was not high (approximately 200). In order to see a statistical 
difference between two genotypes that produce very low numbers of
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adults a much larger number of flies must be generated. The phenotypes 
observed in the flies that do make it to adulthood are no more or less 
severe with a DMCC allele than without (fig. 5.5).
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Figure 5.5. Phenotypes of flies homozygous mutant for DRhoGEF2 and 
heterozygous mutant for DMCC. For details of crosses see section 2.16,
Materials and Methods. Adults were collected soon after emergence for 
imaging. Images here are representative of typical phenotypes observed. P3 
is a line with the same genetic background as P4 and is used here as a control. 
A: 4.1/Px6 ; +/+, B: 4.1/Px6 ; P1/+, C: 4.1/Px6 ; P4/+, D: 4.1/Px6 ; P3/+, E: 
4.1/Px10 ; +/+, F: 4.1/Px10 ; P1/+, G: 4.1/Px10 ; P4/+, H: 4.1/Px10 ; P3/P4.
The number of possible genotypes for the crosses in table 5.6 is 16, 
therefore taking into account the homozygous lethality of CyO, the 
expected percentage viability for each genotype is ~8.3%. In this 
experiment the percentage viability of 4.1/Px6 ; +/+ ranged from 1 to 8%. 
4.1/Px6 in combination with two DMCC alleles decreases this viability to 
zero. However, the control P3 allele in combination with either P1 or P4 
and 4.1/Px6 is also not viable. Therefore, once again, the decrease in 
viability must be due to a mutation on the P1, P3 and P4 chromosomes 
other than DMCC.
The combination of 4.1/Px10 with two DMCC alleles leads to a similar 
decrease in viability to zero. However, one 4.1/Px10 ; P3/P4 fly did
survive until adulthood, and this had a more severe wing phenotype than
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is normally seen for4.1/Px10 (fig. 5.5). Although this could indicate that 
MCC is genetically interacting with DRhoGEF2, crosses using much 
larger numbers of flies will need to be carried out to determine if there is a 
statistically significant decrease in viability as a result of DMCC alleles.
5.8. Discussion and conclusions
5.8.1. Molecular interaction between DRhoGEF2 and DMCC
DMCCa interacts with the DRhoGEF2 PDZ domain both in a yeasty- 
hybrid experiment (K. Barrett, personal communication) and in an in vitro 
co-immunoprecipitation experiment (fig. 5.1). False positive interactions 
are common place in yeast 2-hybrid screens (Serebriiskii, Estojak et al. 
2000). However, the fact that the recombinant DRhoGEF2 PDZ is able to 
pull DMCC from a cell lysate indicates that they are indeed able to 
interact. It also indicates that, if they do interact in vivo, the PDZ domain 
of DRhoGEF2 is sufficient for interaction.
Having determined that DMCC can interact with the DRhoGEF2 PDZ 
domain, the question then is why the two proteins did not give a positive 
interaction when full-length DRhoGEF2 was used (fig. 5.3). It is possible 
that within a “resting” cell the two proteins do not interact, but that, upon 
activation of a signalling pathway, they come together. This could be the 
pathway that likely activates DRhoGEF2 (see fig. 1.8 of Introduction), or 
a completely different pathway that feeds in to DRhoGEF2. DRhoGEF2 
is a large protein, and it is possible that it folds into a conformation that 
shields the PDZ domain from interaction with targets until it receives a 
signal that enables it to adopt a binding conformation (fig. 5.6). Deletion 
of the C-terminus of any of the human orthologues of DRhoGEF2, 
p115RhoGEF, LARG and PDZ RhoGEF, increases their activity 
indicating that they may exist in an inactive form which could be the result 
of an intramolecular inhibition (see section 1.19 of Introduction). The 
human RhoGEFs homodimerise, and, although there is currently no 
evidence for this, it is possible that DRhoGEF2 does the same. This 
intermolecular interaction could prevent other interactors from binding.
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Px6 ; P1 CyO ; P1 Px6 ; + CyO ; +
4.1 ; P4 0 9% (19) 3% (7) 14% (30)
CyO ; P4 9% (19) 0 14% (30) 0
4.1 ; + 2% (4) 10% (22) 4% (8) 13% (29)
CyO ; + 10% (22) 0 13% (29) 0
Px6 ; P1 CyO ; P1 Px6 ; + CyO ; +
4.1 ; P3 0 5% (9) 2% (4) 16% (27)
CyO ; P3 5% (9) 0 16% (27) 0
4.1 ; + 5% (8) 8% (14) 1 % (2) 16% (28)
CyO ; + 8% (14) 0 16% (28) 0
Px6 ; P3 CyO ; P3 Px6 ; + CyO ; +
4.1 ; P4 0 8% (9) 3% (4) 11% (13)
CyO ; P4 8% (9) 0 11% (13) 0
4.1 ; + 3% (4) 11% (13) 8% (10) 13% (16)
CyO ; + 11% (13) 0 13% (16) 0
Px10 ; P1 CyO ; P1 Px10 ; + CyO ; +
4.1 ; P4 0 8% (14) 6% (10) 13% (23)
CyO ; P4 8% (14) 0 13% (23) 0
4.1 ; + 5% (8) 9% (16) 8% (14) 10% (18)
CyO ; + 9% (16) 0 10% (18) 0
Px10 ; P1 CyO ; P1 Px10 ; + CyO ; +
4.1 ; P3 0 5% (6) 7% (8) 13% (15)
CyO ; P3 5% (6) 0 13% (15) 0
4.1 ; + 11% (12) 7% (8) 11% (12) 9% (10)
CyO; + 7% (8) 0 9% (10) 0
Px10 ; P3 CyO ; P3 Px10 ; + CyO ; +
4.1 ; P4 0.4% (1) 7% (18) 8% (20) 9% (22)
CyO ; P4 7% (18) 0 9% (22) 0
4.1 ; + 8% (20) 9% (22) 12% (30) 8% (20)
CyO ; + 9% (22) 0 8% (20) 0
Table 5.6. Combination of homozygous DRhoGEF2 with homozygous 
DMCC. (previous page). For details of crosses see section 2.16, Materials 
and methods. Percentages are the percentage number of flies of each 
genotype resulting from the cross. Numbers in parentheses are actual number 
of adult flies. The expected percentage for each genotype is ~8.3% taking into 
account the homozygous lethality of CyO. It was not possible to distinguish 
between the different DRhoGEF2 alleles nor to distinguish between P3 and P4, 
hence the total number for the two genotypes (e.g. 4.1/CyO ; P1/P4 and 
Px6/CyO ; P1/P4) or four genotypes (e.g. 4.1/CyO ; P3/+ and Px6/CyO ; P3/+ 
and 4.1/CyO ; P4/+ and Px6/CyO ; P4/+) was divided by two or four 
respectively to give the number of adult flies and resulting percentage in each 
class. P3 is a line with the same genetic background as P4 and is used here as 
a control.
Experiments were performed with phosphatase inhibitors in the lysis and 
immunoprecipitation buffers in order to test the possibility that DRhoGEF2 
may exist in an inactive form to which DMCC cannot bind. Many 
signalling proteins are phosphorylated by kinases resulting in their 
activation, and dephosphorylated by phosphatases resulting in their 
inactivation. Human MCC becomes phosphorylated upon serum 
stimulation (Matsumine, Senda et al. 1996), and it is possible that the 
same is true for Drosophila MCC. The addition of phosphatase inhibitors, 
therefore, was an attempt to push the system towards a permanently 
active, signalling state. Similarly, the addition of GTPyS, which locks G 
proteins into an active signalling conformation, was another attempt to 
push the equilibrium towards a state of active signalling (with Concertina, 
the Ga protein that is likely to activate DRhoGEF2, particularly in mind). 
However, neither of these approaches led to a successful co- 
immunoprecipitation.
The co-immunopreciptation experiments using full-length proteins were 
performed using Drosophila S2 cells which are macrophage-like (Ramet, 
Manfruelli et al. 2002). DRhoGEF2 has many potential signalling 
domains, and a signalling complex is likely to be built up around it. Some
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of the factors contributing to this complex may be required in order for the 
PDZ domain to be active in binding targets, and these may not be 
expressed in S2 cells. Since these cells are derived from haemocytes 
which probably do not express DMCC (they were not seen to be stained 
in the in situ, chapter 3) and do not participate in epithelial folding events 
(which DRhoGEF2 is required for, see Introduction), they could contain 
factors inhibitory to interaction between DMCC and DRhoGEF2, or 
between DRhoGEF2 and other factors required for a “binding competent” 
PDZ domain. If this was the case, these factors would have to be 
inhibiting the interaction between DRhoGEF2 and DMCC via a site on 
DRhoGEF2 other than the PDZ domain, since the PDZ domain on its own 
can immunoprecipitate DMCC from an S2 cell lysate.
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Figure 5.6. Model for DRhoGEF2 interaction with DMCC. A: DRhoGEF2 
inactive conformation where the PDZ domain is inaccessible to target proteins. 
B: DRhoGEF2 changes to an active conformation as a result of an activating 
signal, and targets such as DMCC can bind. N: N-terminus, C: C-terminus.
Another factor that could influence the interaction is the choice of lysis 
buffer and wash buffer used for the immunoprecipitation. Lysis buffer 
contains detergent, and this can disrupt protein:protein interactions. For 
this reason a mild lysis buffer (20mM Tris-CL pH 7.5,m 1% NP40, 150mM 
NaCI) was used and this was also used as a wash buffer for the co-
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immunopreciptation experiments. It should be noted that the successful 
co-immunoprecipitation using the recombinant PDZ domain used these 
same buffers, therefore if these were influencing the protein:protein 
interaction it would have to be via a part of DRhoGEF2 other than the 
PDZ domain.
Perhaps the most likely explanation for the lack of interaction between 
DMCC and DRhoGEF2 when co-expressed in cells is that the expression 
levels are not sufficiently high to enable co-immunopreciptation. Getting 
all three constructs (GAL4-Act5C, UAS-DRhoGEF2 and pFASTBACI- 
DMCC) to express at levels high enough to visualise on a Western blot 
was difficult and unreliable. In many cases, a band was visualised on the 
whole cell lysate blot, but it was very weak indicating low expression 
levels. Even if all three were visualised on a blot, it was not necessarily 
the case that all three had co-transfected into any given single cell 
(although the fact that DRhoGEF2 was expressed indicates that it must 
be co-transfected with the Act-GAL4 construct). When attempting to co­
transfect two constructs into the same S2 cell the success rate is >90% 
(personal communication, B. Baum), but for three constructs it is 
unknown. The rate of co-transfection of three constructs into a single cell 
is probably a significant limiting factor for these experiments. In order to 
overcome this, making use of the pFASTBAC1-Act5C vector to express 
DRhoGEF2, thereby negating the need for the GAL4-UAS system, could 
be employed. Alternatively, the DMCC construct could be expressed in 
one dish of cells and the Act5C and UAS-DRhoGEF2 constructs 
expressed in another, and the lysates of these could be mixed for the 
immunoprecipitation experiment.
In summary, although a successful co-immunoprecipitation of full-length 
DRhoGEF2 and DMCC was not achieved here, it does not necessarily 
mean that the two proteins do not interact within cells within a fruit fly due 
to the large number of factors potentially affecting the interaction in these 
experiments.
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5.8.2. PDZ-target interaction specificity
The cell is a protein-rich environment, and at the region of the cell 
membrane there are likely to be a large number of PDZ proteins since 
many participate in signal transduction pathways at this cellular location. 
The Drosophila proteome contains 128 proteins (or predicted proteins) 
that contain PDZ domains (SMART search result). Many of these 
proteins contain more than one PDZ domain, and each PDZ domain may 
have a different set of targets to which it binds. Although not every PDZ- 
domain-containing protein will be expressed in every cell, specificity of 
binding is likely to be important, especially in the region of the cell 
membrane, to avoid potentially damaging cross-talk between signalling 
pathways.
DMCC carries a classic PDZ binding motif at its C-terminus: Threonine -  
x -  Leucine -  COOH. The number of potential target proteins with classic 
C-terminal PDZ-binding motifs (T/S/Y -  X -  V/L/l - COOH) in Drosophila 
is vast. Although the amino acids at the 0 and -2 positions of PDZ targets 
form specific interactions with residues of the PDZ binding pocket (Doyle, 
Lee et al. 1996), they are not the only amino acids important in the 
interaction. Structural studies have shown that the C-terminal five amino 
acids of the target all contribute to binding the PDZ domain (Skelton, 
Koehler et al. 2003). In vitro studies with peptide libraries indicate that 
perhaps as far back as the -8 position is important for binding (Songyang, 
Fanning et al. 1997). It is likely that PDZ-target interactions in vivo are 
determined by subtle differences in binding affinities of potential targets 
with PDZ domains based on the exact C-terminal sequence of the target. 
Thus, a given PDZ domain is likely to be able to bind to a subset of the 
large pool of potential targets based on this sequence specificity.
The fact that all three proteins identified in the yeast-2-hybrid with the 
DRhoGEF2 PDZ domain have a proline residue at the -4 position, as well 
as the common threonine at -2 and leucine at 0 positions, could be 
merely coincidence. However, all the yeast 2-hybrid positive interactors
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that were later confirmed by co-immunoprecipitation have this sequence, 
whereas those that were not confirmed do not have PXTXL (they have 
DELEQ, IVTNL and VRTQN - K.Barrett, unpublished). Therefore, it is 
likely that this sequence is important for binding to DRhoGEF2. It should 
be noted that, recently, a fourth potential interactor for DRhoGEF2 has 
been identified by yeast 2-hybrid. This interactor carries an IXTXL motif 
at its C-terminus (M.Leptin, unpublished).
The results of the mutation analysis (fig. 5.2) illustrate that the proline is 
likely to be necessary for binding to DRhoGEF2 since mutation of this 
residue to an alanine inhibits binding. Similarly, mutation of the leucine 
residue at the 0 position to an alanine prevents the PDZ domain from 
binding to DMCC. It should be noted that the total amount of 
immunoprecipitated protein in the DMCCL~*A lane did not appear to be as 
high as for the other mutants, since the background bands in the Western 
blot are fainter than in the other lanes (fig. 5.2 blot A). The expression 
levels for this mutant appeared to be the same as the other mutants in 
the whole cell lysate analysis (fig. 5.2 blot C), and therefore it appears 
there was an inefficiency in immunoprecipitation in this particular case.
Mutation of the threonine residue to an alanine compromises binding of 
DMCC to DRhoGEF2, but does not prevent it altogether. Although it is 
tempting to speculate that this implies the threonine is not as important 
for binding DRhoGEF2 as the proline or leucine, it would be important to 
quantify the interaction, for example using a fluorescein-tagged PXTXL 
peptide in a colorimetric assay (Lim, Hall et al. 2002). Although the co- 
immunoprecipitation experiment is not highly quantitative, it does illustrate 
that the proline, threonine, and leucine residues are likely to be important 
for the interaction between DMCC and DRhoGEF2. It should be kept in 
mind that these experiments were not performed with full-length 
DRhoGEF2, and, as described in section 5.9.1, there are other factors 
that must be taken into account when considering whether these 
interactions actually take place in vivo. It should also be noted that these
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results contradict previous results using the same MCC mutants in a 
yeast 2-hybrid approach. In this case, both the DMCCT^ Aand DMCCL""A 
mutants showed a complete loss of interaction, whereas the DMCCP_+A 
mutation had no effect on the interaction (K.Barrett, unpublished).
The DMCCd isoform also co-immunoprecipitated with DRhoGEF2 PDZ 
domain. This isoform is truncated and lacks the C-terminal PXTXL motif. 
This result implies that this motif is not required for binding to DRhoGEF2 
PDZ domain, and presumably therefore, that the binding site is elsewhere 
within DMCC. However, this protein was vastly over-expressed 
compared to the wild-type and mutants (fig. 5.2 blot C) for reasons that 
are unclear. It is possible that an MCC isoform lacking the C-terminus is 
more stable than full-length MCC. The extremely high concentration of 
this particular isoform could lead to it artificially binding to the PDZ 
domain. It is unlikely that this isoform does bind the PDZ domain perse  
since the full-length proteins with a single amino acid change at the C- 
terminus do not bind whereas the wild-type does, indicating that the 
binding site is highly likely to be at the C-terminus.
It is possible that amino acids other than proline, threonine or leucine at 
the -4, -2 and 0 positions respectively could also allow binding of DMCC 
to DRhoGEF2, and that these amino acids are not strictly necessary for 
binding since others could perhaps substitute. In order to test this, the 
complete complement of amino acids would have to be tested at the 0, -2 
and -4 positions in an interaction assay. It is likely that most amino acids 
would not successfully substitute due to the nature of the specific 
interactions formed between a PDZ domain and its target.
In order to test whether the proline, threonine and leucine residues are 
sufficient for binding to the DRhoGEF2 PDZ domain, the PXTXL motif 
could be introduced to the C-terminus of a protein that does not carry 
such a motif (and does not bind DRhoGEF2) and this protein tested for 
binding to the PDZ domain of DRhoGEF2. As before, each amino acid
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could be mutated to an alanine in turn to determine which combination is 
sufficient for binding. Ideally, these experiments would be performed with 
full-length DRhoGEF2 co-transfected with the mutants into cells in order 
to make the experiment as physiologically relevant as possible.
In order to determine whether the proline at the -4 position (in 
combination with the TXL motif) confers specificity of binding to 
DRhoGEF2 there are two questions that could be asked: are proteins 
with C-terminal motifs other than PXTXL able to bind DRhoGEF2, and 
are proteins with PXTXL motifs at their C-terminus able to bind to other 
PDZ domains?
To answer the first of these questions, DMCC (or another of the PXTXL 
proteins) could be co-transfected into cells with a protein containing a 
PDZ domain that does not preferentially select for PXTXL, but does 
select for XXTXL (such as Shank -  see below), and co- 
immunoprecipitation tests performed. Ideally, a number of different 
XXTXL-selecting PDZ domains would be tested. If DMCC did bind to 
these other PDZ domains it would indicate that the proline does not allow 
exclusive binding to DRhoGEF2 for PXTXL proteins. To test the second 
question, a protein containing a ZXTXL C-terminal motif, where Z is an 
amino acid known to be selected for by a different PDZ domain, could be 
tested in a similar co-immunoprecipitation experiment using the 
DRhoGEF2 PDZ domain. If PDZ target proteins carrying non-PXTXL 
motifs were able to bind to DRhoGEF2 this would indicate that the proline 
was not necessary for binding DRhoGEF2. The results of both 
experiments would carry more weight if carried out in conjunction with a 
quantitative in vitro approach such as a colorimetric assay.
Specificity for a proline at the -4 position in vivo has not been 
documented for a PDZ domain to date. The third PDZ domain of human 
Ptp-bas3 strongly selects for a proline at this position in an in vitro 
experiment using a peptide library (Songyang, Fanning et al. 1997).
However, in vivo the third PDZ domain of Ptp-bas3 interacts with the Fas 
antigen which has the C-terminal sequence IQSLV-COOH.
5.8.3. Modelling PDZ domain interactions
In order to reliably model the interaction of a PDZ domain with a potential 
target peptide, the crystal structure of the protein is required. For this 
reason, it is not possible to model the PDZ domain of DRhoGEF2 with 
any reliability. The PDZ domain of the human protein Shank shows 
selectivity for targets with TXL at their C-terminus. A known target of the 
Shankl PDZ domain is Guanylate kinase associated protein (GKAP1), 
which has an EAQTRL motif at its C-terminus.
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sequence
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constant
KD/pM
EAQTRL-COOH 3.96
EPQTRL-COOH 2.9
EPQARL-COOH 15.8
EPQTRA-COOH 615
Figure 5.7. Model of the Shank PDZ domain interacting with a peptide 
target. A: Ribbon model of the Shank PDZ domain (blue) interacting with the 
peptide EAQTRL-COOH (red) B: predicted dissociation constants for the 
Shank:peptide interaction. For details of the methods see (Reina, Lacroix et al.
2002). Model generated by G. Fernandez. EMBL.
The crystal structure of this interaction has been solved (Im, Lee et al.
2003). This crystal structure was used as the basis for a computational 
model of the Shank PDZ domain binding to a short peptide (fig. 5.7,
G.Fernandez). This computational model makes use of novel computer- 
aided design techniques (Reina, Lacroix et al. 2002).
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Using the model, predictions were run to test the same C-terminal 
sequences used in the co-immunoprecipitation experiments. The results 
predict that mutation of the leucine has a strong effect on binding to the 
PDZ domain, mutation of the threonine has some effect, and mutation of 
the proline has very little effect. The results of this computational 
prediction may indicate that the Shank PDZ domain is not selective for 
the amino acid at the -4 position since the dissociation constant is 
predicted to be similar for an alanine residue at the -4 position (the “wild- 
type”) and a proline residue. It would be very interesting to perform such 
a prediction using the PDZ domain of DRhoGEF2, but unfortunately this 
is not presently possible due to the lack of crystal structure.
In order to predict the amino acids of the DRhoGEF2 PDZ domain that 
may be interacting with the 0, -2 and -4 positions of its targets, the best 
that can currently be done is to line up the primary sequence of the 
DRhoGEF2 PDZ domain with PDZ domains whose crystal structures 
have been solved. The third PDZ domain of psd-95 was the first crystal 
structure of a PDZ domain to be solved (Doyle, Lee et al. 1996). The C- 
terminal residue of the psd-95 PDZ3 target interacts with the 
characteristic Glycine-Leucine-Glycine-Phenylalanine (GLGF) motif seen 
in many PDZ domains (fig. 5.8). The -2 position residue of the target 
interacts with the residue immediately following the GLGF motif, and the 
histidine at the base of the aB alpha helix. The -4 position does not 
appear to be significantly involved in binding, and lies outside the PDZ 
pocket.
Lining up the primary sequence of the DRhoGEF2 PDZ domain with the 
psd-95 PDZ domain illustrates that the GLGF motif of psd-95 is a GYGM  
motif in DRhoGEF2, and that the histidine at the base of the aB helix of 
psd-95 is conserved in DRhoGEF2 (fig. 5.9). The GYGM motif is likely to 
interact with the C-terminal leucine of the DRhoGEF2 predicted PXTXL 
targets, and the conserved histidine of DRhoGEF2 with the threonine 
residue at the -2 position.
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Figure 5.8. PDZ-target interactions. Crystal structure of the binding pocket of 
psd-95 PDZ3 interacting with a peptide target. A: PDZ domain ribbon structure, 
B and C: PDZ binding pocket (blue), target peptide (red/green). Taken from 
(Nourry, Grant et al. 2003)
Comparing DRhoGEF2 PDZ domain with the Shank PDZ domain, which 
binds a target with an AQTRL motif at its C-terminus, and the FAP-1 PDZ 
domain, which selects for a proline at the -4 position in an in vitro assay 
(Songyang, Fanning et al. 1997), one can see that there is no more 
similarity between these proteins and DRhoGEF2 than there is between 
DRhoGEF2 and psd-95 PDZ3 within the regions that interact with the C- 
terminus of the target for psd-95. This indicates that for each PDZ 
domain there are likely to be additional or different amino acids of the 
PDZ domain forming specific interactions with the target than those 
indicated in yellow in figure 5.9. The crystal structure is therefore an 
invaluable tool in predicting PDZ binding specificity.
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The amino acid proline has a small, non-polar side chain and is mildly 
hydrophobic (as glycine and alanine). It is not an amino acid commonly 
associated with protein-protein interaction sites, and is more likely to be 
found at the loops or bends of proteins. It could, therefore, be the case 
that the proline residue at the -4 position of DRhoGEF2 predicted targets, 
is not involved perse in binding to DRhoGEF2, but instead is required to 
provide a loop in the C-terminus of the target that enables the formation 
of specific interactions between amino acids of the target and the PDZ 
binding pocket or residues around it.
DRG2 : 260
PA 3B 
= >  = >
TLTVRK-DSNGYGMKVSGD--------------
P C  a A  PD
--NPVFVES-VKPGGAAEIAG-LVAGDMI 301
Psd-95: 313 RIVIHKGPK-GLGFNIVGGED------------ --GEGIFISFILAGGPADLSGELRKGDQI 359
Shank: 665 TVLLQKKDSEGFGFVLRGAKAQTPIEEFTPTPAFPALQYLES-VDEGGVAWRAG-LRMGDFL 722
FAP-1: 1175 EVELAK-NDNSLGISVTGGVNTSVRH- - --GGIYVKA-VIPQGAAESDGRIHKGDRV 1234
DRG2 : 302
pE aB pF
d  c5 .------- —  f= i>
LRVNGHEVRLEKHPTWGLIKAST-TVELAVK 333
Psd-95: 360 LSVNGVDLRNASHEQAAIALKN--- AGQTVT 387
Shank: 723 IEVNGQNWKVGHRQWNMIRQGGNT LMVKW 754
FAP-1: 1235 LAVNGVSLEGATHKQAVETLRNTGQWHLLLE 1261
Figure 5.9. PDZ domain primary sequence line-ups. DRG2: DRhoGEF2 
PDZ domain, psd-95: psd-95 PDZ3 domain, Shank; Shank PDZ domain, FAP- 
1: FAP-1 PDZ domain. Yellow highlights residues that are important in forming 
interactions with the target peptide for psd-95 PDZ3. Blue arrows indicates 
beta sheets, green arrows indicate alpha helices. Numbers refer to published 
amino acid sequences of the full-length proteins.
5.8.4. Additional targets
If the DRhoGEF2 PDZ domain does indeed select for a PXTXL motif in 
vivo, there are three further potential targets in the Drosophila proteome 
(table 5.2) in addition to the three identified with the yeast 2-hybrid 
experiment. The approach of determining the consensus binding 
sequence for a particular PDZ domain and subjecting this sequence to a 
genomic search to identify potential targets has been carried out 
previously. The consensus binding sequences (the last five amino acids) 
for the second and third PDZ domains of psd-95 were determined, and 
these used to BLAST search the C-terminal human proteome revealing
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fifty potential targets (Lim, Hall et al. 2002). Three of these (with available 
antibodies) were tested by co-immunoprecipitation and two were found to 
bind. This novel method of identifying targets for PDZ domains is one 
that may become popular in this age of availability of genomic sequence, 
although it is likely to reveal false positives due to the consensus 
sequence being of inadequate stringency, and identify many interactions 
that could never physically happen in vivo due to non-overlapping 
expression patterns.
The following section describes analysis of the available data for the 
three DRhoGEF2 PDZ targets identified in the yeast 2-hybrid and the 
three potential targets identified bioinformatically based on their C- 
terminal sequence. There is currently no evidence that the latter three 
genes have any link to DRhoGEF2, and therefore the proposed 
experiments would be highly speculative. For the three targets identified 
in the yeast 2-hybrid and confirmed by immmunoprecipitation there is 
biochemical evidence of an interaction, but this has not been functionally 
confirmed for any of the three to date.
The three potential DRhoGEF2 targets identified by proteome-wide 
BLAST analysis could be tested in a co-immunoprecipitation experiment 
with DRhoGEF2. It is interesting to note that all three of these proteins 
contain predicted signal sequences at their N-termini implying that they 
are processed along the secretory pathway. The yeast 2-hybrid screen 
using the DRhoGEF2 PDZ domain was performed using an S2 cell library 
with the GAL4 activation domain and nuclear localisation signal placed at 
the N-terminus of the protein (Du, Vidal et al. 1996). It is unlikely, 
therefore, that an N-terminal signal sequence would have been 
successful in sending the protein up the secretory pathway and not to the 
nucleus where the assay is performed, but this could perhaps provide an 
explanation for why these targets were not picked up in the screen if they 
are indeed real targets.
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Of the three, one has been characterised in Drosophila, this being 
capricious (caps). Caps protein is expressed in subsets of neurons and 
muscles during late stages of embryogenesis, and facilitates the correct 
partnering of a motor neuron with its target muscle (Shishido, Takeichi et 
al. 1998). Caps is also required for proper dorsal/ventral boundary 
formation during Drosophila imaginal disc development (Milan, Weihe et 
al. 2001). In this case, caps protein is observed in filopodia-like 
structures that extend from ventral cells over the surface of dorsal cells at
the dorsal/ventral 
boundary (Milan, Weihe 
et al. 2001). Caps is a 
transmembrane protein 
with fourteen leucine rich 
repeats (LRR) in its 
extracellular domain (fig. 
5.10). LRR domains 
may mediate 
protein:protein 
interactions (Kobe and 
Deisenhofer 1994), and 
although it is tempting to 
speculate that caps 
functions by homophillic 
cellicell interactions, this 
does not appear to be 
the case since S2 cells 
do not aggregate if caps 
is expressed on their surface (Shishido, Takeichi et al. 1998; Milan,
Weihe et al. 2001). Thus, it is likely that there is an, as yet undiscovered, 
cell surface binding partner of caps.
In order for any of the six PXTXL targets to interact with DRhoGEF2, they 
would have to be expressed in the same tissue, be localised to the same
N
C cytoplasm
Figure 5.10. Caps protein structure. Dark blue 
indicates leucine-rich repeats, yellow indicates 
transmembrane domain, green indicates PXTXL at 
C-terminus. N: N-terminus, C: C-terminus. Not to 
scale.
194
sub-cellular region, and be expressed at the same stage of development. 
DRhoGEF2 mRNA is maternally loaded and expressed at a low level 
almost ubiquitously throughout embryogenesis (Barrett, Leptin et al. 
1997). DRhoGEF2 protein is expressed predominantly in epithelia 
throughout embryogenesis (Padash Barmchi, Rogers et al. 2005). 
DRhoGEF2 protein is specifically enriched in the furrow canals during 
cellularisation (stage 5) (Grosshans, Wenzl et al. 2005), in the ventral 
furrow during gastrulation (stage 6/7), in the lateral epidermis during 
dorsal closure (stage 13), in ventral epidermal cells of thoracic and 
abdominal segments in a repeated pattern (stage 14), and in the 
longitudinal and commissural axons of the central nervous system (stage 
17) (Padash Barmchi, Rogers et al. 2005).
Although there is no data on the protein localisation of the PXTXL genes 
(with the exception of capricious), there is information on the mRNA 
localisation for some. DMCC mRNA is expressed in the central nervous 
system (fig 5.12 of Chapter 3), group 3 mRNA is maternally loaded and 
expressed in the germ band, central nervous system and gut (G. Escott, 
unpublished), Capricious protein is expressed in a subset of 
motorneurons and muscles of late stage embryos (Shishido, Takeichi et 
al. 1998), and CG3777 mRNA is expressed in the posterior spiracles, the 
tracheal system, the salivary glands and the dorsal and ventral epidermis 
from around stage 11 of embryogenesis (data from the BDGP in situ 
database website - http://www.fruitflv.org/cqi-bin/ex/insitu.pi.). If the 
mRNA localisations reflect protein localisation, DMCC, Group 3, Caps 
and CG3777 proteins could all, potentially, interact with DRhoGEF2 since 
their expression patterns overlap.
Although there is no in situ data available for the other PXTXL proteins, 
there is microarray data which catalogues their expression during 
embryogenesis (fig. 5.11). The microarray data is of limited use since it 
gives no information about the tissues in which the gene is expressed. 
However, it does allow comparison of expression levels at one stage of
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embryogenesis with another. Figure 5.11 illustrates that all the PXTXL 
genes are expressed during embryogenesis.
The microarray data suggests that DRhoGEF2 mRNA has a particular 
expression level pattern during embryogenesis. DRhoGEF2 mRNA 
levels are particularly high at around stages 2-4 before they drop off and 
then rise to a second high at around stage 11-12 where they persist until 
the end of embryogenesis (fig. 5.11). None of the PXTXL genes have 
this exact pattern of expression levels, but one has highest expression 
levels early in embryogenesis from around stages 1-5 (Group 3) and four 
have highest expression levels around stage 13 (Mec-2, MCC, caps and 
CG3777). The microarray data, therefore, illustrates that DRhoGEF2 is 
expressed at high levels at the same time that many of the PXTXL genes 
are also experiencing high expression levels.
At the subcellular level, DRhoGEF2 is localised apically in cells of the 
invaginating ventral furrow and later (stage 11) is apically localised in all 
epidermal cells (Padash Barmchi, Rogers et al. 2005). In S2 cell culture 
DRhoGEF2 co-localises with the plus ends of microtubules (Rogers, 
Wiedemann et al. 2004). Given that DRhoGEF2 interacts with Rho, 
which, by virtue of its geranylgeranylation, is localised to the plasma 
membrane upon activation, and that DRhoGEF2 probably interacts with 
Cta, which is likely to be plasma membrane localised upon activation of 
its G-protein coupled receptor presumptive binding partner, it is likely that 
DRhoGEF2 is also recruited to the plasma membrane upon activation of 
signalling through the putative pathway from Cta to Rho via DRhoGEF2. 
DRhoGEF2 would be an unusual PDZ-containing protein if it were not 
localised in the region of the plasma membrane when it interacted with its 
PDZ targets.
There is no sub-cellular localisation information available for any of the 
PXTXL genes except Caps which is localised to the synaptic sites of both 
motor neurons and muscles (Shishido, Takeichi et al. 1998).
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Figure 5.11. Embryonic gene expression profiles of DRhoGEF2 and the 
six PXTXL genes (previous page). Microarray expression data taken from 
the BDGP expression database website - http://www.fruitfly.org/cai- 
bin/ex/insitu.pl. For details of methods see fig. 3.11, chapter 3) A:
DRhoGEF2, B: Mec-2, C: DMCC, D: Group 3, E: Caps, F: CG3777, G:
CG5539. Green indicates the mRNA is present, blue indicates marginal, red 
indicates absent. The y axis cannot be compared between different graphs as 
it represents an arbitrary unit.
Of the six potential in vivo binding partners for the DRhoGEF2 PDZ 
domain, caps has a single predicted transmembrane domain, and 
CG5539 predicted protein has two predicted transmembrane domains. A 
signal sequence plus a single transmembrane domain leads to the 
topology illustrated in figure 5.10, where the N-terminus is extracellular 
(or luminal if the protein is not at the cell surface), and the C-terminus is 
cytoplasmic. The existence of a second transmembrane domain 
indicates that the C-terminus is likely to be extracellular/luminal. In this 
respect, it is possible that Caps C-terminus could interact with 
DRhoGEF2 PDZ domain, but unlikely that CG5539 predicted protein C- 
terminus could. CG3777 protein has a signal sequence but no predicted 
transmembrane domain, and may, therefore, be secreted or directed to 
the lysosome. It is unlikely, therefore, that it would interact with 
DRhoGEF2 within a cell since DRhoGEF2 is likely to be cytoplasmically 
localised. Therefore, of the three potential PXTXL targets identified by 
proteome search, only Caps protein is likely to be able to interact with 
DRhoGEF2 via its C-terminus. None of the three targets identified in the 
yeast 2-hybrid have a signal sequence or predicted transmembrane 
domains, and therefore their localisation would be presumed to be 
cytoplasmic, and they would therefore be able to interact with 
DRhoGEF2.
Of particular interest would be how the targets compete for interaction 
with the DRhoGEF2 PDZ domain if they are expressed in the same cell. 
Presumably only one target molecule could interact with one PDZ domain
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at any one time, and it may be the case that the target with the highest 
affinity target sequence would “win” for interaction (in this case the X 
residues of PXTXL may determine subtle differences in the binding 
affinity between targets). Alternatively, there may be subcellular 
localisation mechanisms for the targets that allow them to interact with 
different pools of DRhoGEF2 in different regions of the cell and therefore 
competition between targets would not be relevant.
5.8.5. Genetic interactions
In order to better understand the interaction between DRhoGEF2 and 
DMCC, genetic interaction experiments were performed to look for 
suppression or enhancement of a DRhoGEF2 phenotype by MCC mutant 
alleles.
The results of the genetic interaction experiments indicate that there is 
not a strong genetic interaction between DRhoGEF2 and DMCC alleles. 
There does appear to be a weak genetic interaction observed in the 
experiments, but this is likely to be a result of mutations on the 
chromosome other than DMCC. The implication of these results is that 
DMCC does not have a significant effect on DRhoGEF2 function during 
development since mutations in DMCC do not enhance or suppress the 
DRhoGEF2 phenotype. It is, therefore, likely that DMCC is not 
participating in the signalling pathway governing cell shape changes in 
which DRhoGEF2 functions. Since there were no additional phenotypes 
observed which could not be attributed to DRhoGEF2 function, it is not 
possible to say anything further about DMCC function.
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6. Summary, conclusions and future work
The hypothesis behind the work in this thesis was:
The Drosophila melanogaster orthologue of human MCC interacts 
with DRhoGEF2 during development, and this interaction affects 
DRhoGEF2 signalling and Drosophila development.
This thesis set out with two main goals: to characterise the function of 
Drosophila MCC, and investigate the significance of its interaction with 
DRhoGEF2.
6.1. Summary of results
In chapter 3 the Drosophila orthologue of the human MCC gene was 
investigated and confirmation presented that only one orthologue exists in 
Drosophila. Although the Drosophila predicted protein bears limited 
primary sequence similarity to the human protein (up to 51% in regions of 
high similarity), the likely functional motifs are conserved i.e. five coiled 
coils, a potentially significant arginine residue, and a C-terminal PDZ 
binding motif. BLAST analysis revealed the presence of MCC 
orthologues in various species, many carrying a C-terminal PDZ-binding 
motif. mRNA expression analysis revealed that there are likely to be at 
least four different mRNAs produced from the MCC locus, two of which 
include an exon from a neighbouring predicted gene. mRNA expression 
analysis during development revealed that MCC is expressed 
predominantly in the central nervous system.
In chapter 4 a preliminary analysis of loss-of-function and gain-of-function 
MCC scenarios, concluded that neither has an obviously visible effect on 
development. A further analysis of function of MCC was pursued by 
making an MCC mutant. Two P-element insertion lines were generated, 
the first an insertion and deletion that disrupts other genes in addition to 
MCC, the second a clean insertion into MCC. The MCC mutant shows
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no obviously visible phenotype, and is viable when combined with a 
deficiency removing the gene.
Results from chapter 5 demonstrate that DMCC can interact with the 
isolated PDZ domain of DRhoGEF2, but it was not shown to interact with 
the full-length protein. Genetic interaction analysis revealed that DMCC 
mutation does not have a significant impact on the DRhoGEF2 mutant 
phenotype, indicating that DMCC is not likely to participate in a genetic 
pathway with DRhoGEF2.
6.2. MCC function
Overall, the results disprove the hypothesis that DMCC affects 
DRhoGEF2 signalling and Drosophila development since DMCC does not 
genetically interact with DRhoGEF2, and does not itself have a 
phenotype when mutated or over-expressed. The lack of phenotype 
upon MCC mutation was unexpected, and raises the question as to the 
function of DMCC in Drosophila. There are two possibilities, the first of 
which breaks down into two categories:
■ MCC has a function in Drosophila:
o that is redundant with the function of another gene 
o that is more subtle than the analysis presented here can 
detect
■ MCC has no function in Drosophila
The possibility that MCC has functional redundancy with another gene is 
quite likely. Although there is no MCC primary sequence homologue in 
flies, there may be a functional homologue i.e. there could be another 
protein expressed that is able to compensate for loss of MCC function in 
an MCC mutant. Therefore, a phenotype would only be observed when 
both genes were mutated. Since MCC protein is likely to be
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predominantly localised in the central nervous system and possibly the 
gut, this protein would presumably function in these tissues.
If MCC acts as a tumour suppressor in flies, as it is proposed to do in 
humans, it is possible that an effect of MCC mutation could be seen in a 
background of perturbation of other genes promoting overgrowth. Human 
cancer patients with mutated MCC have mutations in many other genes 
that contribute to the stepwise generation of colon cancer (Fearon and 
Vogelstein 1990). It is possible that MCC mutation in the fruit fly would 
contribute to tumour formation if additional mutations accumulated, but 
that the lifetime of a fly is too short for this to occur. Since MCC is 
predominantly expressed at high levels in the central nervous system of 
the fly, and not in various other epithelia as it is in the mouse, any 
phenotype associated with loss of tumour suppressor function may not be 
seen in the fly (since the majority of cells of the nervous system are not 
continuously growing and dividing like epithelial cells do).
It is possible that MCC mutation gives rise to a subtle phenotype that is 
not observed here but is present. Since MCC protein is likely to be 
functioning in the central nervous system this phenotype would 
presumably be manifested there. This phenotype would probably mildly 
affect the development and/or function of the cells in which MCC is 
functioning, whether they are neurons or other cells of the central nervous 
system. However, it would presumably not grossly affect the function of 
the CNS since this would have been observed as a phenotype. Although 
MCC mutant flies appear to feed and behave normally, they may exhibit a 
subtle phenotype if subjected to behavioural tests for example.
The final possibility is that MCC has no function in the fly. It is hard to 
imagine that the expression of a protein for which there is no function 
would persist during evolution. However, there are proteins that are 
expressed for which no function is known, the mammalian prion protein 
being an example. Prion knockouts have no phenotype and there has
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been no cellular function assigned to the prion protein, yet prion is 
expressed in various mammalian tissues (Prusiner 1998).
Since the MCC mutant in Drosophila has no obvious phenotype, but MCC 
appears to provide a tumour suppressor role in mammals, it would be 
interesting to characterise the function of mammalian MCC further. 
Experiments have confirmed the role proposed by Matsumine et al of 
MCC as providing a block on the cell cycle at the G1 to S phase transition 
(S.Loh, unpublished). Preliminary evidence suggests that MCC may play 
a role in the regulation of the actin cytoskeleton, since MCC over­
expression leads to a mild increase in stress fibre formation in NIH3T3 
cells (S.Loh, unpublished). PDZRhoGEF over-expression leads to a 
redistribution of actin to the cell cortex and cell rounding (Togashi, Nagata 
et al. 2000; Banerjee and Wedegaertner 2004). Over expression of 
PDZRhoGEF leads to Rho activation using an SRE reporter assay, and 
this is further stimulated by concurrent over-expression of MCC (L. 
Gardano, unpublished). A link between MCC, Rho and the actin 
cytoskeleton could indicate that MCC modulates RhoGEF’s activation of 
Rho.
It would be interesting to test whether mutation of the arginine residue 
that appears to be important in cell cycle control has any effect on MCC’s 
regulation of Rho or the actin cytoskeleton. Since mammalian RhoA is 
involved in the regulation of entry into G1 and progression into S-phase 
(Olson, Ashworth et al. 1995), it is possible that MCC exerts its influence 
on cell cycle progression via Rho.
6.3. DRhoGEF2 PDZ domain function
The lack of genetic interaction between DRhoGEF2 and DMCC also 
raises the question as to the function of the PDZ domain of DRhoGEF2. 
The PDZ domain of DRhoGEF2 is conserved in the human orthologues, 
PDZRhoGEF and LARG, and in these orthologues it is used as a protein 
binding module, for example for binding to plexin B (Swiercz, Kuner et al. 
2002). Unless the PDZ domain of DRhoGEF2 is very unusual, it is
205
probable that its function is to mediate interaction with other proteins.
The interaction of a protein with the PDZ domain of DRhoGEF2 could 
have two outcomes, which are not mutually exclusive:
■ Affect the function of DRhoGEF2 e.g. affect activation of Rho1
■ Affect the function of the PDZ-binding protein
Put another way, proteins interacting with the PDZ domain could be either 
upstream or downstream of DRhoGEF2 in a signalling pathway.
If the DRhoGEF2 PDZ domain does not interact with DMCC in vivo, it 
may interact with the other potential targets picked up in the yeast 2- 
hybrid screen, mec-2 and group 3. A rapid approach to test whether 
these genes are likely to function genetically with DRhoGEF2 would be to 
over-express DRhoGEF2 in S2 culture cells and look for rescue of the 
resulting contraction phenotype by addition of dsRNA to mec-2 or group 
3. This would indicate whether the protein products of either of these 
genes are likely to influence DRhoGEF2 signalling. There may also be 
an RNAi phenotype associated with mec-2 or group 3 on their own, and if 
this were the case, addition of DRhoGEF2 dsRNA could be tested for 
enhancement/suppression of these phenotypes. Another indication that 
these genes are interacting with DRhoGEF2 in vivo would be if their 
protein products biochemically interacted with full-length DRhoGEF2, and 
this could be tested via co-immunoprecipitation experiments. Both the 
biochemical and RNAi tests could also be applied to the other PXTXL 
genes, or other potential DRhoGEF2 interactors. If positive results were 
achieved with these tests, the longer term projects of generating a UAS- 
RNAi transgenic fly, a mutant, or a UAS overexpression fly could be 
employed to test for genetic interaction in vivo.
It is also possible that there are further targets for the PDZ domain of 
DRhoGEF2 that were not identified in the screen. The microtubule- 
binding protein, EB1, has been identified as an interactor of DRhoGEF2,
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and its site of interaction is unknown (although it does not have a classic 
PDZ-binding motif at its C-terminus). Other potential interactors could be 
identified from RNAi screens for enhancement or suppression of the 
DRhoGEF2 RNAi phenotype, or genetic modifier screens using whole 
flies. These sort of screens would not be specific for proteins interacting 
with the PDZ domain, but if any potential interactors from these screens 
carried PDZ-binding motifs at their C-terminus it could indicate that they 
interact with DRhoGEF2 via this domain.
It is possible that the PDZ domain of DRhoGEF2 does not have functional 
significance for DRhoGEF2. A mutant form of DRhoGEF2 that lacked the 
PDZ domain of DRhoGEF2 could be generated and used to attempt 
rescue of the DRhoGEF2 null phenotype. If this mutant were to give 
none or only a partial rescue, this would imply that the PDZ domain does 
have a functional role, and the resulting phenotype may give some clue 
as to this role. There is the possibility that deletion of the PDZ domain 
from the protein would lead to an unstable protein being produced, and 
therefore wild-type DRhoGEF2 protein levels would need to be confirmed 
in this mutant.
Another way to test the function of the PDZ domain would be to generate 
a protein that carried a PDZ-binding motif and over-express this in either 
Drosophila cells in culture or in whole flies by making a transgenic fly, and 
observe any resulting phenotype. For example, a short polypeptide with 
TXL at its C-terminus might be expected to interact with the DRhoGEF2 
PDZ domain and prevent targets from binding. If DRhoGEF2 requires a 
protein to bind to its PDZ domain in order for it to be activated, a short 
polypeptide such as this would be expected to act as a dominant 
negative. Similarly, if the PDZ targets required binding to DRhoGEF2 in 
order to become activated themselves, this would also act as a dominant 
negative for them. However, a TXL motif would be likely to affect other 
PDZ domains in addition to DRhoGEF2, so a longer sequence such as
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PXTXL (if this were determined to be specific for DRhoGEF2) could be 
employed.
Similarly, the PDZ domain of DRhoGEF2 on its own could be over- 
expressed in a different dominant negative approach (it may have to be 
expressed as a fusion since it may not be stable when isolated). In this 
case targets would be saturated by the isolated PDZ domain and 
therefore not able to bind DRhoGEF2 and activate it. However, the 
targets themselves may be hyper-activated since there would be an 
excess of PDZ domain for them to bind to. It is possible that binding of a 
target to the PDZ domain of DRhoGEF2 may inhibit, rather than activate, 
signalling from either the target or DRhoGEF2, and therefore lead to 
different outcomes for each of these dominant negative approaches. The 
results of these experiments may be difficult to interpret, as is the case for 
many dominant negative approaches, but they could certainly give an 
idea as to whether the PDZ domain does indeed have a function, and 
some clues as to what that function is.
In conclusion, both MCC and RhoGEF require further study to determine 
whether the interaction between them is real in vivo, and if so, to 
understand the significance of the interaction. Since studies using 
Drosophila have not proved fruitful in determining function, studies on cell 
cycle progression and regulation of the actin cytoskeleton in mammalian 
cells will be required to determine the precise function of these proteins. 
Of particular interest is how these proteins influence cellular growth, since 
both MCC and the Rho GTPases are implicated in the progression to 
cancer.
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Appendix 1: DNA and protein sequences 
CG6156 (3002bp)
1 CTTCCGCGCA GCTTGAGCTG CCTGTGCTGC AGCGATACGC CATCGGTGCC CAACGACAAG
61 AGACGCAGTT GGGAGTATAC GCTGATGGCT CATCCTCTGG CCAGACGGCC CATAAACGTG
121 ATGACCCCAA GAATAACCAC TTAGAAAGCT CTAATCCGCC TCTTTTCTTT TGATTCACCT
181 CCAGGTTGAG CAACTGTCGG TACAACAGCT AGAAAACCGG GTGCGGGATC TAACGCAGCG
241 TCTGCAGCAG GCGGAAAGAC AGCTCACTGA GAGCAACACA GAGCGGGAAA TATGCCACAA
301 GCGCTTGGAG GTTGTCAGCC AGGCCCACGA GTGTCGCATC ACAGAGATGC ACTGTGTCAT
361 CGCCGAGTTA AGCAAGAAAT TGCGCAGTAA GCAGGACCAC GTTATCATGG AGGAGCAGGA
421 GCCCGACGGC AGCGGTGCGT AGCAGTTTCA AATGAGGGAA ACAAACCCCT AACCGACAGT
481 CTTGTTTTCA GAACTCAGCT TTCAGGAGGG TTCAGTGTAC AATTCCGAGC TTAACCTCAC
541 CAATCCTGAT GCCGAATGTC AAACAGAACC ACTGGAAGAC TTCGAGGGCG CCTGCAGTAC
601 CACCAGCGTG GGTAACGTTG CCCACAAACC GCCGGAACTG AGCCATAAGG GACAAGTGGA
661 GGCACTGCAG GAGGAAGTTC TGCACTTGAG AGCTCGAATC GCCCTCCTCC AGTCCGAGAT
721 TTCCACCAAG GATGCTGCTG TGGTCGAGGA ACAGACCAAA GTCGCCTTCG ACTGCGAATC
7 81 GGAAGTCAAC GAGTGCGGAC AGCGACTGAA TGATTTGAAT GGTAATATAA ATAATCCTGA
841 TGATAAAAGA ATGGTTACAC ATTTAGATGC TTTCAGTTTG CACTTCCTTG ACAAGTCCGC
901 AAAAACGCAT TCCAGCGGTA CCGAAAATGG CTGAACGGGT TAAGTTGCGG TGCGCCAGCA
961 AACATGAATC CGGAGAAGAT CCATCCCAAG ATACTTCATT GAGCAACGAG GTGTGTTGAC
1021 CAAAACTTTA TTCAGAGAAT ACATTTCAAC CCATACAACC CATAATTTTA AGCAAATTAA
1081 TCTGGTCGAA CATTTGGTGT CGGAGCTAAA GGAGCAAAAT CTATATATGG AGAACTTTAT
1141 GGAGCCCCTA CATTTGAGCA AAGACTTGGA GCGACTGCAA CGACGTGTTG AACAATTGGA
1201 GATGCGAAAC ACCATGCTGG CACTGACGCT AGACGAATGC AAGGAGCACA CTGAGCATCT
1261 GTATCTGCTA TGCGGAAAGT ACGAGTCCAA TGCGGTTGCT CTTCAGTTGG CGCTTAATTG
1321 CAGTGATCGC GCCATCGAGG CCTACGACGT AATGTTGGCT CTGCTCGAAA GCAAGTAAGT
1381 ACAATCACCA TAAGACGCGG GTTGTTGTCC CTATTTCACA ATTCATCACT TCCAGGTTGG
1441 CACTGCTGGG GGAGAAATCA GTGGCAGCGG AAGAGAGTCG ACGATCGGTG GAGGCGGTGG
1501 CCAGGCACCT GCTAGCCCGT TTGGATAGCG AGAAAAACGT TTGTGAGAAC AGCCTGGGAC
1561 CGTGGCAACA CAACATCAAC CTGGGCCCAG AGGATGCCCC AAAAACTGGC CGCCCGTGGT
1621 GTGCCGACGA CGACAACCGC CTGCGTTACC ACGTCTCCAA GCTGAAGGGA CGTCGTTCCA
1681 ATGTCCAGCA TACCATTGTC AGTTTGGAAT CACCCTTCAG CGACATATAC GAAAGAAAGC
1741 GCCTGGCTTT GGAAAAGGAG CACGAACTTC GGAGCGCGGA CAAGAAGTCA CCCATTGACT
1801 TGGAGACAGC AGTGATTATG CAAGAAATAC TCGAGCTGCG GGATTCGAAT TTGCAGCTGA
1861 AGACAAAAAT GGAAGAGGCC GAGCAGGAAC GGCAGAACGC CAACGAACGA GTGGGCATAC
1921 TCCACGAAGC CCTAAAGCAG CTACAGGCAA ACAACCGGGT CTCGTATTCG GAGGCGGAGC
1981 ATGCGGCTCT CACAGAGCAG CAGTTGGTGG AGGCCTTAAC TCGAGAAACG GAGCTCAAGG
2041 GTCGCATACA GACGCTATTG GCAAATGTAA CAGCTTCGCA GAAGGCCTTC GACGAAAAAT
2101 ACGAGCAACT GCATCAGAAC GTGCGTGAAC TGCAGAAATC CAACCAGTAA GATTCGTTTT
2161 ATTTTGACTG TTTCATACAT AATTTCTTCA TATTTCCCTT TTAGCAATCT GGGCCAAATG
2221 TTAGATCACA CCAAGCGCAA GTACCAGCTG CGGGTGAGGA AGCTAGAGCA GAAGATTGTT
2281 GACCTGCGGC TGGACTACGA GCAAGGCCAT AACCATGTTC CTGAGACTAC TCTGTAGGAA
2341 ACGCATGACG ACCTTCCAGG AGGACTGAGC AACTGGGCGT GGAGCGGGCG CGCTTGTCAC
2401 ATATCCCGCA AAAGATCTTT CCCTCTCGAT CATATCGCTT ATTTTACCTT TAATGCAATG
2461 ACCACCCGCC CAGCAGTCGC CGTGGATCCG CCATGACCAA GACAGTATCA CGAATGTGCC
2521 ATGCGACTTA ATTGCAGTCG GCTGGGGCTT GGGCGGTGTC CCTGCCTCGC AGATAAGGCT
2581 GCAGTAACTA CATACTCAAA TACATACATA TTCAGAGGTG CCATGAGCAA GGCTCCACCA
2641 ACCTATCCAT AGATCCGTGG GATTGGAGCA TCCGTCTATG GGCCACAAGC AATTACATAT
27 01 ACACACATAC GAATAGACAA ACTAAGGAGT TATTCAAGAC GCATACACGG GATCCTATAT
2761 TTATACAATG TATTCGCATT TTGCTTGTTA TATGATTCAA TATGTATTTA AAACTGTACA
2821 AAATATAAAA CGTCTACTAA AACTCGATAA AATTCACGAA TTTGAAATTG GCTCCAATAA
2881 TTAATCGATA AGCTAATGAA ACTAACTTAA GCATCCATCA CCATTTCGTG TAGTGTTGCA
2941 AATCACCAGA ATCAAGTATA TGAGTACTTG TGAAATAAAA ATGTTTTGAA AATTTAACTT
3001 AA
210
cDNAa (2486bp)
1 CTTCCGCGCA GCTTGAGCTG CCTGTGCTGC AGCGATACGC CATCGGTGCC
51 CAACGACAAG AGACGCAGTT GGGAGTATAC GCTGATGGCT CATCCTCTGG
101 CCAGACGGCC CATAAACGTT GAGCAACTGT CGGTACAACA GCTAGAAAAC
151 CGGGTGCGGG ATCTAACGCA GCGTCTGCAG CAGGCGGAAA GACAGCTCAC
201 TGAGAGCAAC ACAGAGCGGG AAATATGCCA CAAGCGCTTG GAGGTTGTCA
251 GCCAGGCCCA CGAGTGTCGC ATCACAGAGA TGCACTGTGT CATCGCCGAG
301 TTAAGCAAGA AATTGCGCAG TAAGCAGGAC CACGTTATCA TGGAGGAGCA
351 GGAGCCCGAC GGCAGCGAAC TCAGCTTTCA GGAGGGTTCA GTGTACAATT
401 CCGAGCTTAA CCTCACCAAT CCTGATGCCG AATGTCAAAC AGAACCACTG
451 GAAGACTTCG AGGGCGCCTG CAGTACCACC AGCGTGGGTA ACGTTGCCCA
501 CAAACCGCCG GAACTGAGCC ATAAGGGACA AGTGGAGGCA CTGCAGGAGG
551 AAGTTCTGCA CTTGAGAGCT CGAATCGCCC TCCTCCAGTC CGAGATTTCC
601 ACCAAGGATG CTGCTGTGGT CGAGGAACAG ACCAAAGTCG CCTTCGACTG
651 CGAATCGGAA GTCAACGAGT GCGGACAGCG ACTGAATGAT TTGAATGTTT
701 GCACTTCCTT GACAAGTCCG CAAAAACGCA TTCCAGCGGT ACCGAAAATG
751 GCTGAACGGG TTAAGTTGCG GTGCGCCAGC AAACATGAAT CCGGAGAAGA
801 TCCATCCCAA GATACTTCAT TGAGCAACGA GCAAATTAAT CTGGTCGAAC
851 ATTTGGTGTC GGAGCTAAAG GAGCAAAATC TATATATGGA GAACTTTATG
901 GAGCCCCTAC ATTTGAGCAA AGACTTGGAG CGACTGCAAC GACGTGTTGA
951 ACAATTGGAG ATGCGAAACA CCATGCTGGC ACTGACGCTA GACGAATGCA
1001 AGGAGCACAC TGAGCATCTG TATCTGCTAT GCGGAAAGTA CGAGTCCAAT
1051 GCGGTTGCTC TTCAGTTGGC GCTTAATTGC AGTGATCGCG CCATCGAGGC
1101 CTACGACGTA ATGTTGGCTC TGCTCGAAAG CAAGTTGGCA CTGCTGGGGG
1151 AGAAATCAGT GGCAGCGGAA GAGAGTCGAC GATCGGTGGA GGCGGTGGCC
1201 AGGCACCTGC TAGCCCGTTT GGATAGCGAG AAAAACGTTT GTGAGAACAG
1251 CCTGGGACCG TGGCAACACA ACATCAACCT GGGCCCAGAG GATGCCCCAA
1301 AAACTGGCCG CCCGTGGTGT GCCGACGACG ACAACCGCCT GCGTTACCAC
1351 GTCTCCAAGC TGAAGGGACG TCGTTCCAAT GTCCAGCATA CCATTGTCAG
1401 TTTGGAATCA CCCTTCAGCG ACATATACGA AAGAAAGCGC CTGGCTTTGG
1451 AAAAGGAGCA CGAACTTCGG AGCGCGGACA AGAAGTCACC CATTGACTTG
1501 GAGACAGCAG TGATTATGCA AGAAATACTC GAGCTGCGGG ATTCGAATTT
1551 GCAGCTGAAG ACAAAAATGG AAGAGGCCGA GCAGGAACGG CAGAACGCCA
1601 ACGAACGAGT GGGCATACTC CACGAAGCCC TAAAGCAGCT ACAGGCAAAC
1651 AACCGGGTCT CGTATTCGGA GGCGGAGCAT GCGGCTCTCA CAGAGCAGCA
1701 GTTGGTGGAG GCCTTAACTC GAGAAACGGA GCTCAAGGGT CGCATACAGA
1751 CGCTATTGGC AAATGTAACA GCTTCGCAGA AGGCCTTCGA CGAAAAATAC
1801 GAGCAACTGC ATCAGAACGT GCGTGAACTG CAGAAATCCA ACCACAATCT
1851 GGGCCAAATG TTAGATCACA CCAAGCGCAA GTACCAGCTG CGGGTGAGGA
1901 AGCTAGAGCA GAAGATTGTT GACCTGCGGC TGGACTACGA GCAAGGCCAT
1951 AACCATGTTC CTGAGACTAC TCTGTAGGAA ACGCATGACG ACCTTCCAGG
2001 AGGACTGAGC AACTGGGCGT GGAGCGGGCG CGCTTGTCAC ATATCCCGCA
2051 AAAGATCTTT CCCTCTCGAT CATATCGCTT ATTTTACCTT TAATGCAATG
2101 ACCACCCGCC CAGCAGTCGC CGTGGATCCG CCATGACCAA GACAGTATCA
2151 CGAATGTGCC ATGCGACTTA ATTGCAGTCG GCTGGGGCTT GGGCGGTGTC
2201 CCTGCCTCGC AGATAAGGCT GCAGTAACTA CATACTCAAA TACATACATA
2251 TTCAGAGGTG CCATGAGCAA GGCTCCACCA ACCTATCCAT AGATCCGTGG
2301 GATTGGAGCA TCCGTCTATG GGCCACAAGC AATTACATAT ACACACATAC
2351 GAATAGACAA ACTAAGGAGT TATTCAAGAC GCATACACGG GATCCTATAT
2401 TTATACAATG TATTCGCATT TTGCTTGTTA TATGATTCAA TATGTATTTA
2451 AAACTGTACA AAATATAAAA CGTCTACTAA AACTCG
cDNAb (2702bD)
1 CTTCCGCGCA GCTTGAGCTG CCTGTGCTGC AGCGATACGC CATCGGTGCC
51 CAACGACAAG AGACGCAGTT GGGAGTATAC GCTGATGGCT CATCCTCTGG
101 CCAGACGGCC CATAAACGTG ATGACCCCAA GAATAACCAC TTAGAAAGCT
151 CTAATCCGCC TCTTTTCTTT TGATTCACCT CCAGGTTGAG CAACTGTCGG
201 TACAACAGCT AGAAAACCGG GTGCGGGATC TAACGCAGCG TCTGCAGCAG
251 GCGGAAAGAC AGCTCACTGA GAGCAACACA GAGCGGGAAA TATGCCACAA
301 GCGCTTGGAG GTTGTCAGCC AGGCCCACGA GTGTCGCATC ACAGAGATGC
351 ACTGTGTCAT CGCCGAGTTA AGCAAGAAAT TGCGCAGTAA GCAGGACCAC
401 GTTATCATGG AGGAGCAGGA GCCCGACGGC AGCGAACTCA GCTTTCAGGA
451 GGGTTCAGTG TACAATTCCG AGCTTAACCT CACCAATCCT GATGCCGAAT
501 GTCAAACAGA ACCACTGGAA GACTTCGAGG GCGCCTGCAG TACCACCAGC
551 GTGGGTAACG TTGCCCACAA ACCGCCGGAA CTGAGCCATA AGGGACAAGT
601 GGAGGCACTG CAGGAGGAAG TTCTGCACTT GAGAGCTCGA ATCGCCCTCC
651 TCCAGTCCGA GATTTCCACC AAGGATGCTG CTGTGGTCGA GGAACAGACC
701 AAAGTCGCCT TCGACTGCGA ATCGGAAGTC AACGAGTGCG GACAGCGACT
751 GAATGATTTG AATGTTTGCA CTTCCTTGAC AAGTCCGCAA AAACGCATTC
801 CAGCGGTACC GAAAATGGCT GAACGGGTTA AGTTGCGGTG CGCCAGCAAA
851 CATGAATCCG GAGAAGATCC ATCCCAAGAT ACTTCATTGA GCAACGAGCA
901 AATTAATCTG GTCGAACATT TGGTGTCGGA GCTAAAGGAG CAAAATCTAT
951 ATATGGAGAA CTTTATGGAG CCCCTACATT TGAGCAAAGA CTTGGAGCGA
1001 CTGCAACGAC GTGTTGAACA ATTGGAGATG CGAAACACCA TGCTGGCACT
1051 GACGCTAGAC GAATGCAAGG AGCACACTGA GCATCTGTAT CTGCTATGCG
1101 GAAAGTACGA GTCCAATGCG GTTGCTCTTC AGTTGGCGCT TAATTGCAGT
1151 GATCGCGCCA TCGAGGCCTA CGACGTAATG TTGGCTCTGC TCGAAAGCAA
1201 GTTGGCACTG CTGGGGGAGA AATCAGTGGC AGCGGAAGAG AGTCGACGAT
1251 CGGTGGAGGC GGTGGCCAGG CACCTGCTAG CCCGTTTGGA TAGCGAGAAA
1301 AACGTTTGTG AGAACAGCCT GGGACCGTGG CAACACAACA TCAACCTGGG
1351 CCCAGAGGAT GCCCCAAAAA CTGGCCGCCC GTGGTGTGCC GACGACGACA
1401 ACCGCCTGCG TTACCACGTC TCCAAGCTGA TGGGACGTCG TTCCAATGTC
1451 CAGCATACCA TTGTCAGTTT GGAATCACCC TTCAGCGACA TATACGAAAG
1501 AAAGCGCCTG GCTTTGGAAA AGGAGCACGA ACTTCGGAGC GCGGACAAGA
1551 AGTCACCCAT TGACTTGGAG ACAGCAGTGA TTATGCAAGA AATACTCGAG
1601 CTGCGGGATT CGAATTTGCA GCTGAAGACA AAAATGGAAG AGGCCGAGCA
1651 GGAACGGCAG AACGCCAACG AACGAGTGGG CATACTCCAC GAAGCCCTAA
1701 AGCAGCTACA GGCAAACAAC CGGGTCTCGT ATTCGGAGGC GGAGCATGCG
1751 GCTCTCACAG AGCAGCAGTT GGTGGAGGCC TTAACTCGAG AAACGGAGCT
1801 CAAGGGTCGC ATACAGACGC TATTGGCAAA TGTAACAGCT TCGCAGAAGG
1851 CCTTCGACGA AAAATACGAG CAACTGCATC AGAACGTGCG TGAACTGCAG
1901 AAATCCAACC ACAATCTGGG CCAAATGTTA GATCACACCA AGCGCAAGTA
1951 CCAGCTGCGG GTGAGGAAGC TAGAGCAGAA GATTGTTGAC CTGCGGCTGG
2001 ACTACGAGCA AGGCCATAAC CATGTTCCTG AGACTACTCT GTAGGAAACG
2051 CATGACGACC TTCCAGGAGG ACTGAGCAAC TGGGCGTGGA GCGGGCGCGC
2101 TTGTCACATA TCCCGCAAAA GATCTTTCCC TCTCGATCAT ATCGCTTATT
2151 TTACCTTTAA TGCAATGACC ACCCGCCCAG CAGTCGCCGT GGATCCGCCA
2201 TGACCAAGAC AGTATCACGA ATGTGCCATG CGACTTAATT GCAGTCGGCT
2251 GGGGCTTGGG CGGTGTCCCT GCCTCGCAGA TAAGGCTGCA GTAACTACAT
2301 ACTCAAATAC ATACATATTC AGAGGTGCCA TGAGCAAGGC TCCACCAACC
2351 TATCCATAGA TCCGTGGGAT TGGAGCATCC GTCTATGGGC CACAAGCAAT
2401 TACATATACA CACATACGAA TAGACAAACT AAGGAGTTAT TCAAGACGCA
2451 TACACGGGAT CCTATATTTA TACAATGTAT TCGCATTTTG CTTGTTATAT
2501 GATTCAATAT GTATTTAAAA CTGTACAAAA TATAAAACGT CTACTAAAAC
2551 TCGATAAAAT TCACGAATTT GAAATTGGCT CCAATAATTA ATCGATAAGC
2601 TAATGAAACT AACTTAAGCA TCCATCACCA TTTCGTGTAG TGTTGCAAAT
2651 CACCAGAATC AAGTATATGA GTACTTGTGA AATAAAAATG TTTTGAAAAT
2701 TT
cDNAc (2834bp)
1 GGAGTAATTT CGAGTTTTTG AATTAAAAAT GCCTTAAGAA AAGTTTTTAA
51 TGAGCCATGT AGAGTTAACA CCAGTGCCAC ATATCCAGGG AATGGAGCAC
101 CAATCAAAAG TCATCATCAA GCGGCCCAAA TCAGGCCAAT TCTAGTCGGA
151 AAGTCGTTGC AGCCGCCCAT TGCCACCATG TCGAATGATG TGCAGGTCGC
201 CCGGGTGGCC AAGATAGCTA CCGATGTGCC GCGTCGCAGT GGCAAGCAGC
251 GTGACTCCAG CGGATTCCAG GGCAAGCACT CCGGCAGCGC GGCTGGCGAG
301 GATTTCGAGT ACGTCTTCGG TAGCATTTCG CCGCGCGGTG GAGGACCCGG
351 TGGCAGGCAC TTGGTGGGAT CCTCCGACCT GGACTCTCCG GAGCACACGC
401 AGCGGGACAC CACCGAGAGT GACAACAACA TATCCAGCTG CTCCACGCTA
451 GACATTGTCA ACAAAGTTGA GCAACTGTCG GTACAACAGC TAGAAAACCG
501 GGTGCGGGAT CTAACGCAGC GTCTGCAGCA GGCGGAAAGA CAGCTCACTG
551 AGAGCAACAC AGAGCGGGAA ATATGCCACA AGCGCTTGGA GGTTGTCAGC
601 CAGGCCCACG AGTGTCGCAT CACAGAGATG CACTGTGTCA TCGCCGAGTT
651 AAGCAAGAAA TTGCGCAGTA AGCAGGACCA CGTTATCATG GAGGAGCAGG
701 AGCCCGACGG CAGCGAACTC AGCTTTCAGG AGGGTTCAGT GTACAATTCC
751 GAGCTTAACC TCACCAATCC TGATGCCGAA TGTCAAACAG AACCACTGGA
801 AGACTTCGAG GGCGCCTGCA GTACCACCAG CGTGGGTAAC GTTGCCCACA
851 AACCGCCGGA ACTGAGCCAT AAGGGACAAG TGGAGGCACT GCAGGAGGAA
901 GTTCTGCACT TGAGAGCTCG AATCGCCCTC CTCCAGTCCG AGATTTCCAC
951 CAAGGATGCT GCTGTGGTCG AGGAACAGAC CAAAGTCGCC TTCGACTGCG
1001 AATCGGAAGT CAACGAGTGC GGACAGCGAC TGAATGATTT GAATGTTTGC
1051 ACTTCCTTGA CAAGTCCGCA AAAACGCATT CCAGCGGTAC CGAAAATGGC
1101 TGAACGGGTT AAGTTGCGGT GCGCCAGCAA ACATGAATCC GGAGAAGATC
1151 CATCCCAAGA TACTTCATTG AGCAACGAGC AAATTAATCT GGTCGAACAT
1201 TTGGTGTCGG AGCTAAAGGA GCAAAATCTA TATATGGAGA ACTTTATGGA
1251 GCCCCTACAT TTGAGCAAAG ACTTGGAGCG ACTGCAACGA CGTGTTGAAC
1301 AATTGGAGAT GCGAAACACC ATGCTGGCAC TGACGCTAGA CGAATGCAAG
1351 GAGCACACTG AGCATCTGTA TCTGCTATGC GGAAAGTACG AGTCCAATGC
1401 GGTTGCTCTT CAGTTGGCGC TTAATTGCAG TGATCGCGCC ATCGAGGCCT
1451 ACGACGTAAT GTTGGCTCTG CTCGAAAGCA AGTTGGCACT GCTGGGGGAG
1501 AAATCAGTGG CAGCGGAAGA GAGTCGACGA TCGGTGGAGG CGGTGGCCAG
1551 GCACCTGCTA GCCCGTTTGG ATAGCGAGAA AAACGTTTGT GAGAACAGCC
1601 TGGGACCGTG GCAACACAAC ATCAACCTGG GCCCAGAGGA TGCCCCAAAA
1651 ACTGGCCGCC CGTGGTGTGC CGACGACGAC AACCGCCTGC GTTACCACGT
1701 CTCCAAGCTG AAGGGACGTC GTTCCAATGT CCAGCATACC ATTGTCAGTT
1751 TGGAATCACC CTTCAGCGAC ATATACGAAA GAAAGCGCCT GGCTTTGGAA
1801 AAGGAGCACG AACTTCGGAG CGCGGACAAG AAGTCACCCA TTGACTTGGA
1851 GACAGCAGTG ATTATGCAAG AAATACTCGA GCTGCGGGAT TCGAATTTGC
1901 AGCTGAAGAC AAAAATGGAA GAGGCCGAGC AGGAACGGCA GAACGCCAAC
1951 GAACGAGTGG GCATACTCCA CGAAGCCCTA AAGCAGCTAC AGGCAAACAA
2001 CCGGGTCTCG TATTCGGAGG CGGAGCATGC GGCTCTCACA GAGCAGCAGT
2051 TGGTGGAGGC CTTAACTCGA GAAACGGAGC TCAAGGGTCG CATACAGACG
2101 CTATTGGCAA ATGTAACAGC TTCGCAGAAG GCCTTCGACG AAAAATACGA
2151 GCAACTGCAT CAGAACGTGC GTGAACTGCA GAAATCCAAC CACAATCTGG
2201 GCCAAATGTT AGATCACACC AAGCGCAAGT ACCAGCTGCG GGTGAGGAAG
2251 CTAGAGCAGA AGATTGTTGA CCTGCGGCTG GACTACGAGC AAGGCCATAA
2301 CCATGTTCCT GAGACTACTC TGTAGGAAAC GCATGACGAC CTTCCAGGAG
23 51 GACTGAGCAA CTGGGCGTGG AGCGGGCGCG CTTGTCACAT ATCCCGCAAA
2401 AGATCTTTCC CTCTCGATCA TATCGCTTAT TTTACCTTTA ATGCAATGAC
2451 CACCCGCCCA GCAGTCGCCG TGGATCCGCC ATGACCAAGA CAGTATCACG
2501 AATGTGCCAT GCGACTTAAT TGCAGTCGGC TGGGGCTTGG GCGGTGTCCC
2551 TGCCTCGCAG ATAAGGCTGC AGTAACTACA TACTCAAATA CATACATATT
2601 CAGAGGTGCC ATGAGCAAGG CTCCACCAAC CTATCCATAG ATCCGTGGGA
2651 TTGGAGCATC CGTCTATGGG CCACAAGCAA TTACATATAC ACACATACGA
2701 ATAGACAAAC TAAGGAGTTA TTCAAGACGC ATACACGGGA TCCTATATTT
2751 ATACAATGTA TTCGCATTTT GCTTGTTATA TGATTCAATA TGTATTTAAA
2801 ACTGTACAAA ATATAAAACG TCTACTAAAA CTCG
cDNAd (1249bp)
1 GGAGTAATTT CGAGTTTTTG AATTAAAAAT GCCTTAAGAA AAGTTTTTAA
51 TGAGCCATGT AGAGTTAACA CCAGTGCCAC ATATCCAGGG AATGGAGCAC
101 CAATCAAAAG TCATCATCAA GCGGCCCAAA TCAGGCCAAT TCTAGTCGGA
151 AAGTCGTTGC AGCCGCCCAT TGCCACCATG TCGAATGATG TGCAGGTCGC
201 CCGGGTGGCC AAGATAGCTA CCGATGTGCC GCGTCGCAGT GGCAAGCAGC
251 GTGACTCCAG CGGATTCCAG GGCAAGCACT CCGGCAGCGC GGCTGGCGAG
301 GATTTCGAGT ACGTCTTCGG TAGCATTTCG CCGCGCGGTG GAGGACCCGG
213
351 TGGCAGGCAC TTGGTGGGAT CCTCCGACCT GGACTCTCCG GAGCACACGC
401 AGCGGGACAC CACCGAGAGT GACAACAACA TATCCAGCTG CTCCACGCTA
451 GACATTGTCA ACAAAGTTGA GCAACTGTCG GTACAACAGC TAGAAAACCG
501 GGTGCGGGAT CTAACGCAGC GTCTGCAGCA GGCGGAAAGA CAGCTCACTG
551 AGAGCAACAC AGAGCGGGAA ATATGCCACA AGCGCTTGGA GGTTGTCAGC
601 CAGGCCCACG AGTGTCGCAT CACAGAGATG CACTGTGTCA TCGCCGAGTT
651 AAGCAAGAAA TTGCGCAGTA AGCAGGACCA CGTTATCATG GAGGAGCAGG
701 AGCCCGACGG CAGCGAACTC AGCTTTCAGG AGGGTTCAGT GTACAATTCC
751 GAGCTTAACC TCACCAATCC TGATGCCGAA TGTCAAACAG AACCACTGGA
801 AGACTTCGAG GGCGCCTGCA GTACCACCAG CGTGGGTAAC GTTGCCCACA
851 AACCGCCGGA ACTGAGCCAT AAGGGACAAG TGGAGGCACT GCAGGAGGAA
901 GTTCTGCACT TGAGAGCTCG AATCGCCCTC CTCCAGTCCG AGATTTCCAC
951 CAAGGATGCT GCTGTGGTCG AGGAACAGAC CAAAGTCGCC TTCGACTGCG
1001 AATCGGAAGT CAACGAGTGC GGACAGCGAC TGAATGATTT GAATGTTTGC
1051 ACTTCCTTGA CAAGTCCGCA AAAACGCATT CCAGCGGTAC CGAAAATGGC
1101 TGAACGGGTT AAGTTGCGGT GCGCCAGCAA ACATGAATCC GGAGAAGATC
1151 CATCCCAAGA TACTTCATTG AGCAACGAGG GTGTGTTGAC CAAAACTTTA
1201 TTCAGAGAAT ACATTTCAAC CCATACAACC CAATCGAATT CCCGCGGCC
HsMCC cDNA (4180bp)
1 CCTCCTGCAG CAATGGCTCG TCCGTGAAAC GCGAGCCACG GCTGCTCTTT TTAAGAGTGC
61 CTGCATCCTC CGTTTGCGCT TCGCAACTGT CCTGGGTGAA AATGGCTGTC TAGACTAAAA
121 TGTGGCAGAA GGGACCAAGC AGTGGATATT GAGCCTGTGA AGTCCAACTC TTAAGCTCCG
181 AGACCTGGGG GACTGAGAGC CCAGCTCTGA AAAGTGCATC ATGAATTCCG GAGTTGCCAT
241 GAAATATGGA AACGACTCCT CGGCCGAGCT GAGTGAGCTC CATTCAGCAG CCCTGGCATC
301 ACTAAAGGGA GATATAGTGG AACTTAATAA ACGTCTCCAG CAAACAGAGA GGGAACGGGA
361 CCTTCTGGAA AAGAAATTGG CCAAGGCACA GTGCGAGCAG TCCCACCTCA TGAGAGAGCA
421 TGAGGATGTC CAGGAGCGAA CGACACTTCG CTATGAGGAA CGCATCACAG AGCTCCACAG
481 CGTCATTGCG GAGCTCAACA AGAAGATAGA CCGTCTGCAA GGCACCACCA TCAGGGAGGA
541 AGATGAGTAC TCAGAACTGC GATCAGAACT CAGCCAGAGC CAACACGAGG TCAACGAGGA
601 CTCTCGAAGC ATGGACCAAG ACCAGACCTC TGTCTCTATC CCCGAAAACC AGTCTACCAT
661 GGTTACTGCT GACATGGACA ACTGCAGTGA CCTGAACTCA GAACTGCAGA GGGTGCTGAC
721 AGGGCTGGAG AATGTTGTCT GCGGCAGGAA GAAGAGCAGC TGCAGCCTCT CCGTGGCCGA
781 GGTGGACAAG CACATTGAGC AGCTCACCAC AGCCAGCGAG CACTGTGACC TGGCTATTAA
841 GACAGTCGAG GAGATTGAGG GGGTGCTTGG CCGGGACCTG TATCCCAACC TGGCTGAAGA
901 GAGGTCTCGG TGGGAGAAGG AGCTGGCTGG GCTGAGGGAA GAGAATGAGA GCCTGACTGC
961 CATGCTGTGC AGCAAAGAGG AAGAACTGAA CCGGACTAAG GCCACCATGA ATGCCATCCG
1021 GGAAGAGCGG GACCGGCTCC GGAGGAGGGT CAGAGAGCTT CAAACTCGAC TACAGAGCGT
1081 GCAGGCCACA GGTCCCTCCA GCCCTGGCCG CCTCACTTCC ACCAACCGCC CGATTAACCC
1141 CAGCACTGGG GAGCTGAGCA CAAGCAGCAG CAGCAATGAC ATTCCCATCG CCAAGATTGC
1201 TGAGAGGGTG AAGCTATCAA AGACAAGGTC CGAATCGTCA TCATCTGATC GGCCAGTCCT
1261 GGGCTCAGAA ATCAGTAGCA TAGGGGTATC CAGCAGTGTG GCTGAACACC TGGCCCACTC
1321 ACTTCAGGAC TGCTCCAATA TCCAAGAGAT TTTCCAAACA CTCTACTCAC ACGGATCTGC
1381 CATCTCAGAA AGCAAGATTA GAGAGTTTGA GGTGGAAACA GAACGGCTGA ATAGCCGGAT
1441 TGAGCACCTC AAATCCCAAA ATGACCTCCT GACCATAACC TTGGAGGAAT GTAAAAGCAA
1501 TGCCGAGAGG ATGAGCATGC TGGTGGGAAA ATACGAATCC AATGCCACAG CGCTGAGGCT
1561 GGCCTTGCAG TACAGCGAGC AGTGCATCGA AGCCTACGAA CTCCTCCTGG CGCTGGCAGA
1621 GAGTGAGCAG AGCCTCATCC TGGGGCAGTT CCGAGCGGCG GGCGTGGGGT CCTCCCCTGG
1681 AGACCAGTCG GGGGATGAAA ACATCACTCA GATGCTCAAG CGAGCTCATG ACTGCCGGAA
1741 GACAGCTGAG AACGCTGCCA AGGCCCTGCT CATGAAGCTG GACGGCAGCT GTGGGGGAGC
1801 CTTTGCCGTG GCCGGCTGCA GCGTGCAGCC CTGGGAGAGC CTTTCCTCCA ACAGCCACAC
1861 CAGCACAACC AGCTCCACAG CCAGTAGTTG CGACACCGAG TTCACTAAAG AAGACGAGCA
1921 GAGGCTGAAG GATTATATCC AGCAGCTCAA GAATGACAGG GCTGCGGTCA AGCTGACCAT
1981 GCTGGAGCTG GAAAGCATCC ACATCGATCC TCTCAGCTAT GACGTCAAGC CTCGGGGAGA
2041 CAGCCAGAGG CTGGATCTGG AAAACGCAGT GCTTATGCAG GAGCTCATGG CCATGAAGGA
2101 GGAGATGGCC GAGTTGAAGG CCCAGCTCTA CCTACTGGAG AAAGAGAAGA AGGCCCTGGA
2161 GCTGAAGCTG AGCACGCGGG AGGCCCAGGA GCAGGCCTAC CTGGTGCACA TTGAGCACCT
2221 GAAGTCCGAG GTGGAGGAGC AGAAGGAGCA GCGGATGCGA TCCCTCAGCT CCACCAGCAG
2281 CGGCAGCAAA GACAAACCTG GCAAGGAGTG TGCTGATGCT GCCTCCCCAG CTCTGTCCCT
214
2341 AGCCGAACTC AGGACAACGT GCAGCGAGAA TGAGCTGGCT GCGGAGTTCA CCAACGCCAT
2401 TCGTCGAGAA AAGAAGTTGA AGGCCAGAGT TCAAGAGCTG GTGAGTGCCT TGGAGAGACT
2461 CACCAAGAGC AGTGAAATCC GACATCAGCA ATCTGCAGAG TTCGTGAATG ATCTAAAGCG
2521 GGCCAACAGC AACCTGGTGG CTGCCTATGA GAAAGCAAAG AAAAAGCATC AAAACAAACT
2581 GAAGAAGTTA GAGTCGCAGA TGATGGCCAT GGTGGAGAGA CATGAGACCC AAGTGAGGAT
2641 GCTCAAGCAA AGAATAGCTC TGCTAGAGGA GGAGAACTCC AGGCCACACA CCAATGAAAC
27 01 TTCGCTTTAA TCAGCACTCA CGCACCGGAG TTCTGCCCAT GGGAAGTAAA CTGCAGCAGG
2761 CCACTGGGGA CAGAAGGGCC CATGTACTTG TTGGGAGGAG GAGGAAAGGG AAGGCTGGCA
2821 GGTAGGTCGG CACTTGGACA ATGGAGTGCC CCAACTCAAC CCTTGGGGCG ACTGGCCATG
2881 GTGACATTGT GGACTGTATC CAGAGGTGCC CGCTCTTCCC TCCTGGGCCC ACAACAGCGT
2941 GTAAACACAT GTTCTGTGCC TGCTCAGCAG AGCCTCGTTT CTGCTTTCAG CACTCACTCT
3001 CCCCCTCCTC TTCTGGTCTG GCGGCTGTGC ATCAGTGGGA TCCCAGACAT TTGTTTCTGT
3061 AAGATTTTCC ATTGTATCCT CTTTTTGGTA GATGCTGGGC TCATCTTCTA GAATCTCGTT
3121 TCTCCTCTTT CCTCCTGCTT CATGGGAAAA CAGACCTGTG TGTGCCTCCA GCATTTAAAA
3181 GGACTGCTGA TTTGTTTACT ACAGCAAGGC TTTGGTTTCC AAGTCCCGGG TCTCAACTTT
3241 AAGATAGAGG CGGCCATAAG AGGTGATCTC TGGGAGTTAT AGGTCATGGG AAGAGCGTAG
3301 ACAGGTGTTA CTTACAGTCC CAGATACACT AAAGTTACAA ACAGACCACC ACCAGGACTG
3361 TGCCTGAACA ATTTTGTATT GAGAGAATAA AAACTTCCTT CAATCTTCAT TTTGGAGGCA
3421 GGGCTGGGAA GGGAGCGCTC TCTTGATTCT GGGATTTCTC CCTCTCAGTG GAGCCTTATT
3481 AATATCCAAG ACTTAGAGCT GGGAATCTTT TTGATACCTG TAGTGGAACT AAAATTCTGT
3541 CAGGGGTTTC TTCAAGAGCT GAGAAACATT ATTAGCACTT CCCGCCCCAG GGCACTACAT
3601 AATTGCTGTT CTGCTGAATC AAATCTCTTC CACATGGGTG CATTTGTAGC TCTGGACCTG
3661 TCTCTACCTA AGGACAAGAC ACTGAGGAGA TACTGAACAT TTTGCAAAAC TTATCACGCC
3721 TACTTAAGAG TGCTGTGTAA CCCCCAGTTC AAGACTTAGC TCCTGTTGTC ATGACGGGGA
3781 CAGAGTGAGG GAATGGTAGT TAAGGCTTCT TTTTTGCCCC CAGATACATG GTGATGGTTA
3841 GCATATGGTG CTTAAAAGGT TAAATTTCAA GCAAAATGCT TACAGGGCTA GGCAGTACCA
3901 AAGTAACTGA ATTATTTCAG GAAGGTCTTC AATCTTAAAA CAAATTCATT ATTCTTTTTC
3961 AGTTTTACCT CTTCTCTCTC AGTTCTACAC TGATACACTT GAAGGACCAT TTACTGTTTT
4021 TTTCTGTAGC ACCAGAGAAT CCATCCAAAG TTCCCTATGA AAAATGTGTT CCATTGCCAT
4081 AGCTGACTAC AAATTAAAGT TGAGGAGGTT TCTGCATAGA GTCTTTATGT CCATAAGCTA
4141 CGGGTAGGTC TATTTTCAGA GCATGATACA AATTC CACAG
DRho GEF2 cDNA - RF isoform (8442bp)
1 AAAAGAAAAG AACGTCGTGT GCGTGTTGAT GGCGCGATAA GTGAAAAAAA TAAAAACATT
61 TTTCGTGTCT TTATGGAATA CAATACGAGT GCGTTTTAAG TTTAAGTGAA AAGTAGCAGT
121 GCAAAATATA TATACACATA TCAAAACCCA TTGGAATAGT GCAACCAAAA AATCATAAAA
181 CAGAACTAAA GCAACGAAAA TCGAGGCAAT TAAATCACTT CTGGATTCAT TTCGGCCCGT
241 TTTTACTAGC TAATTTAAAA ATAGCTGCCG AAAGCATTCC GCAACCACTT CTGGTGACTG
301 GCCCCACACC AATGCGAACA ATACTCCACG GGATCCTCCG ACTTCGAGTG GCTTACGCAT
361 GCCTTTGAAT TTGCATCTTC GCACCCGCAC AGCAGCCAGC AAAAGCCATC GCAGGAAACC
421 CTATGGATGA CCCATCAATC AAAAAACGGT TACTAGATTT ATATACTGAC GAACATGAAT
481 ACGATGAGGT TCAAGAGATA CCAGAAGAGT CAAGCATTCA GCCCCCGGAG ACATCAACGA
541 GCCATACCAG CACAAACGGA TCCAGCCACT CAGGCCCTGG AACTGCAACT GGACCAGGAG
601 CGACATCTGC AGGCCCGTCA GCGGGTGCGC CACAGTCACC AGTAATTGTT GTGGACTCGG
661 TTCCCGAGCT GCCAGCGCCC AAGCAGAAAT CTGTTAAGAA CTCGAAGAGC AAACAGAAGC
721 AAAAGCAGTT GGCGAACAAA TCGAAGATTC CACGATCTCC TTCGTTGGCG AGCAGCCTGA
781 GTAGTCTGGC CAGCAGCCTT AGTGGTCATA GGGATCGGGA CAAAGATCGG GACAAGGATC
841 GGGAGAACCA GAACGCCGTG CCGCCGCAGA CGCCGCCGTT GCCACCGAGC TACAAGCAGA
901 ACCAAATGAA TGGTGACTCT ACGGCTGCAG CTGGTGGTGG TGTTTCTGCC CCAGCCACGC
961 CCACCACCGC CAATAATAAC AATGCGAGCC ACAACAACGG CAGCATAATG GGCGGAGGCG
1021 TGCAATTGAA TCAATCGGAC AACTCCAACC CCGTTCTCCA GGCGCCGGGG GAGCGCAGTA
1081 GCCTCAATCT GACTCCCCTC TCCCGGGATC TGAGTGGTGG CCACACCCAG GAGTCCACGA
1141 CGCCAGCGAC CACGCCGAGT ACGCCAAGCC TAGCATTACC AAAAAATTTT CAGTATTTAA
1201 CCCTGACTGT GCGAAAAGAT AGCAACGGAT ACGGGATGAA GGTTTCCGGA GATAATCCTG
1261 TGTTTGTGGA GAGCGTTAAA CCCGGAGGCG CAGCGGAGAT TGCAGGCCTG GTTGCTGGCG
1321 ATATGATACT AAGGGTAAAC GGCCATGAAG TGCGACTAGA GAAGCATCCA ACTGTAGTGG
1381 GTCTTATAAA AGCCTCGACA ACTGTTGAGC TGGCGGTGAA GCGAAGTCAG AAGCTAACGC
1441 GACCCTCTTC GGTATCAGTG GTAACGCCCT CGACACCCAT TCTCTCTGGA CGAGATCGTA
1501 CCGCTTCAAT AACTGGGCCA CAGCCGGTGG ACAGTATTAA ACGAAGGGAG ATGGAGACTT
215
1561 ACAAAATTCA GACGTTGCAG AAAATGCTGG 
1621 AAAGCGATCA AAATAATCCG AGCTACAAGC 
1681 AGCAACTTCA TCAAGTGGGA GCTGAGGATG 
1741 GCAATAAGAA CACAGCATTA CTAACGCCCA 
1801 CTCACAGCAA TCAGCAATTC CATCATCTTC 
1861 ATCCGCCACA GCAACAGCCA GCTAGCACCT 
1921 CCCTTTCGTC CTTGTCGCTG GGCACGCGCA 
1981 CATCTCCCTT TGGCCTAACG ACGGATTTCC 
2041 AGTCGATGTC TCAATCGATG CATCAGCACA 
2101 ATCCGCATCA GCAACAACAT CGCTTTAAGG 
2161 AGTTCCTAAT TTCGAGGAGT TTGATCGAGG 
2221 ATCCGCCCAG GCAGTTAAAT TTGGACCTGA 
2281 ATCTAGTGGC TCCAGTTTCC GATCTGGATC 
2341 AACAACAGCA ACTGCCTAGC AGCACTGACA 
2401 CCAAGATCAA AACGAAGGCC CTATCGGATC 
2461 TGGAATCGGC GAGTGCAGCT GGAGCAGCCG 
2521 CACCGCTACC GCCTCGCTTG CCTGGCATGA 
2581 AGAATCTCGC TCAACCCAAT TCCGTGGGCA 
2641 CAACAGCGGT GCAGAACGAT AACCTGAACA 
2701 TTGTCCAGCA GCTGCAGCAA TATCAACAGC 
2761 CCACAGGCGC TCTGGGACAG ACTCCGAATT 
2821 CTTCACCGGA CAATATGCAT CCACGTCATC 
2881 CGTGGGAGAT TGTTGAAAAG GATGGCGAAT 
2941 ATCTATCCAG CTCCCACATG ACCGTGCTGG 
3001 CAGCAGCCGG ACCTGGAGTC TTTATCGAGT 
3061 CTTCTCCGAT CCCGATATCC TTACATTCCA 
3121 CGCAGAAGGA GATCATCTCG ATGGAGGACG 
3181 ACGAGAACGG ACCCTTTAAC AATCTAACTC 
3241 TAGCCATCTT CCTAAACTAC GTGATCTCAA 
3301 TGATTACTGA GTTGTACAAG GAGGGCACCT 
3361 TCCACTCCAC ATTCCTCGTG CCGCGGGCTC 
3421 TGGCCCGCGA GGTGGATAAT GTCCTGCAGT 
3481 CAGTTTTTCT GCGTAGCCGA AAGCGGGCCA 
3541 TTCAGCAGAA GCGCACCGCC GGCCTGGGAA 
3601 CCGAGGCGAA GACGGATAAG CTAAGGGAGC 
3661 TTCACGCGCT TATTGAGGAT GAGAACGGTT 
3721 TGTGTTCTGC TCTTTCCACC GTCATCTACC 
3781 GCATCGTTGA GCGGGTCCAT CACTTTGTGA 
3841 TGGGCAAAAA TCGCAAGATG AATGTTCGTG 
3901 AAGTGACGCA CTGCAATCAT TGTCAGACGA 
3961 ATTGTACAGA CTGTAAATTG AACATACACC 
4021 GTCCCGGTCC CTTGCCCCAG GCAAAACGTC 
4081 TGGGCAAAAT TCGACCGCGT ACCAGCGACG 
4141 ATGAGGAATT GGATGTTGAG TTGACTCCAG 
4201 CCTCTGATCG GCGACCGGAT GCGAACATAT 
4261 ACACTTCGGG GCTGAACACC ACCGACCTGC 
4321 ACAGTATTAA CCCCGGCGGT GGAGCCGGAT 
4381 CAACGACTCC GTCGACCAGT GGATCCGTGG 
4441 ACGCCCTGGA TACAGTGGAT AAAGAAGCGC 
4501 ACAAAAGTGC ACCAGTCTCT GTGAATCGGT 
4561 AGAGGAACCG CAACAGTCGC CGCAAGACCT 
4621 ATGAACAACT GGACTTGGGT CTATCGAATG 
4681 TCTCTTCAGC TGGCGGCAGC GAGAGTCCCA 
4741 GAGCAGCGGG TGGCGTCCAG GTGCCGCCAA 
4801 TGCTCATCCA GCAGCACGCC CAGCAGTACT 
4861 CAGGGGCCGC TGGGAGCAGT GCAGCTAGCA 
4921 TGCCTGTAGC TCGTTGGACG CTGGAGAGCG 
4981 GGAGTTCCAT GGTGGCCGCA GAGGTGTTGG 
5041 AGGAGATTAT AAATGAAATC TATCAAACTG 
5101 TGGATCGATT ATTCTTCCTG CCACTCTACG 
5161 TGTTGTTGTT CCCGCCCGCC TTGCTGTCGC
AGCAGGAGAA ACTAAATCTG GAGCGATTAA 
TATCTGAGGC GAATATCCGT AAGCTGCGCG 
CACCGACTGT TAAACTTCAG GCGGCCGCTG 
ACCAAATCCA ACACTTGTCC GCGTCCGCCA 
ACCACCACCA CAATCTCCAC AACAACAATT 
CACCCGCATT CCTGTCCCTC CTGCCGCGTT 
AAAACAAGAC CGAAAAGGAC CTAACGACTT 
TGCAGCAGCA ACGGATGAGC CACCAAGCGG 
CCAGCACTCC GACCTCGCAG CAGTTCTTCC 
AAACTGGACC GACGTCGAAA GGCAAGAACA 
AGGATGTGCC GCCACCACTG CCGCAGAGGA 
AGAACGGAAA CGCGTCGCCG GGTGGGTCAC 
GCGCCACAAG TCCCCAATTA AATAGATCCC 
ACAGCCCGAG CAATGCCAAG TCCAAGCGTT 
CTAAGATGTC CACTCAGATG TTCCTGCAAA 
GAGGTTCCAT CGAGGTAGAT GGGGGTCCAC 
TGACGGAGGA TATGAGCCGC GGCAGCTGTC 
CTGCCTTCAA CTATCCTCTG GTGTCCACAA 
TTGCCTTTCC TTTGTCCCAA CGACCCAACA 
AGCAGCAGCA TCAAATGAGC GGTGGCCAGG 
TGGGAAAAAA CAAGCATCGA CGCGTTGGTT 
CAGATCGGAT AACGAAAACG ACTTCGGGCT 
CCTCCCCGCC CGGAACACCG CCGCCTCCAT 
AAGATCCGAA TGAGAACAAT CGTGGAGCAG 
CGCATCAGTT TACGCCGATG GCGGGAGCCT 
GCCACATGCA TGCGGCCCAG TCGAACGATA 
AAAACTCGGA CTTGGATGAG CCCTTCATTG 
GTTTGTTAGA GGCCGAGAAC GTCACTTTCC 
ACTCGGATCC CGCGCCACTT CTGTTTTACC 
CCAAGGACAT GCGGAAATGG GCCTACGAAA 
CATTGTCATG GTATCGCCAA GATGAATCGC 
TGGAGTATGA CAAAGTGGAG ATCCTAAGGA 
AGGACCTAAT CAGTGAGCAG CTGCGTGAGT 
CCATTTACGG ACCCACGGAC GACAAGCTGG 
AAATCATCGA CAAATATTTA ATGCCCAATC 
CACCGCCGGA GGATGTACGC AAGGTGGCGT 
GTATTTTCAA CACTCGTCCG CCTCCAAGCA 
GCAGGGACAA GAGTTTCAAG TCGCGTATTA 
GTCATCCATT GGTATTGCGT CAATACTATG 
TTATCTGGGG CGTGAGCCCG CAAGGTTATC 
GTCAGTGCTC GAAAGTAGTG GACGAGAGTT 
TCGCCCACAA CGACAAGATC AGTAAATTCA 
TCATTGGAAA TGAAAAGCGA AGTCGTCAAG 
ACCGTGGTCA GGCGTCGATT GTGCGTCAAC 
CGATAAGGTC GAATGGAAAT ACCTCCTGCA 
AAAGTTCTTT TCACGGCAGC TGTGCCAACG 
GCAACATGGA TTTATCCACG AGCGTGGCGT 
CAGCCGGTCT GAGTGCTTTT GCCGAACTGA 
GTAGGGAGCG TTACAGTCAG CATCCGAAGC 
CGGAATCCTA CAAGGAGCGC TTGTCCAACA 
CTGATCCAAG CTTGTCGTCG CGTCCCAATG 
CCACTTATGT GGGCAGTTCG AATTCTAGTC 
GCACGTCAAT GGAGCACTTT GCTGCACCCG 
TGGGATTGAA CCAGAACCAG CACCCCCATC 
GCCAGCAGGA TTCCTTTCAG GCGGGTTTGG 
ACTCTAGTTT CTGGAATGCT GGCCACCCAT 
AGGATGAAGA CGACGTGAAC GAGGCGGACT 
CAGCCTTAAC GGACGCTGAG AAGAAGCGTC 
AACGCAACCA TGTGCGCACC CTAAAGCTGC 
AGAGTGGATT GCTGTCCCAG GATCATTTGC 
TCCGTGAGAT TCATGGCGCC TTCGAGCAGA
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5221 GTCTTAAGCA ACGACGCATC GAGCATAACC ACGTGGTGAA CACCATAGGG GATCTGCTCG
5281 CCGACATGTT CGATGGTCAG TCTGGAGTTG TTCTTTGCGA GTTTGCGGCT CAGTTCTGTG
5341 CCCGCCAGCA AATCGCCTTG GAGGCACTCA AGGAGAAGCG CAACAAGGAC GAGATGCTGC
5401 AAAAGCTATT GAAAAAGTCG GAGTCACACA AGGCATGTCG CCGCCTCGAG CTAAAGGACT
5461 TGCTGCCCAC CGTGCTGCAG CGCCTCACCA AGTATCCGCT TTTGTTTGAG AACCTTTACA
5521 AGGTGACCGT GCGCTTGCTG CCAGAAAACA CCACCGAGGC GGAAGCCATT CAACGGGCAG
5581 TGGAATCCTC TAAAAGGATT CTTGTCGAGG TCAACCAGGC AGTAAAGACA GCAGAGGATG
5641 CTCACAAGCT GCAAAACATT CAGCGTAAGT TAGACAGATC CTCCTATGAC AAGGAAGAGT
5701 TTAAGAAATT GGACCTGACC CAACATCACC TCATCCATGA CGGCAATCTG ACGATCAAGA
5761 AGAATCCTAG CGTGCAGCTA CATGGACTTC TGTTTGAAAA CATGATTGTT TTGCTGACCA
5821 AGCAGGATGA TAAATATTAT CTAAAGAACT TGCACACCCC GCTATCGATC ACCAATAAGC
5881 CAGTCAGTCC AATTATGAGC ATTGATGCGG ACACTTTGAT CCGGCAGGAG GCGGCTGATA
5941 AAAATTCCTT TTTCCTCATC AAGATGAAGA CATCACAAAT GTTGGAGCTA CGCGCGCCTA
6001 GTAGCTCGGA GTGCAAGACA TGGTTTAAAC ACTTCTCGGA TGTGGCTGCT CGTCAGTCTA
6061 AGAATCGTTC AAAGAACGCA TCAAGCAACC ATGACACGAG TATTAGTGAT CCAGCTCTCG
6121 CCGCTATTCC GCATTCCAAC ACCAAAGAGT CGTTGGAGTT GAGCACTGAT ACAGTACAGC
6181 CATTGGCTGC GACAGCCACA TTGACTACCA CACCATTGGC CCCAATGCTG CCTATAGCCA
6241 CGGTTACACC GGCTCCAGCG ACCAATAATA GTAACGTTAG CTCTCTTACT GGAGTTCAGT
6301 TGCGAAACCC TCAACGGGAT GCGACAGCAA GTGAATCTGA TGCGGATTAT GTAAACACAC
6361 CAAAGCCGCG TTCGAGCCAA AATGAAGTTA ATCGCACTAT GTCCATAAGA AGCACTGGCG
6421 AACCCATTCA GAAGTATTCG GCGAATGGGA CGGAAGCAAA CGACGTTACT TTACGACACT
6481 CTCAGTCGAC TAGGGAATCG GTTAGACCAG GATCTACTGG GGAGGAGCGA AACTCCACGT
6541 ATGGTATGGT TGGAGGTAAC TCCAAACGCG ACAGCGCCAG CATTGTCTGC TCGAACAACT
6601 CGAACAACAC GCGCACCCTT CTGATGCAGA GTCCCTTGGT GGACCCTACG GCCATTCAGG
6661 TCAGCATTAG TCCCGCTCAC ACAGCGGAAC CTGTGTTGAC ACCAGGAGAG AAGTTACGCC
6721 GCTTGGACGC CTCCATTAGG AATGATTTGC TGGAGAAGCA GAAAATCATT TGTGATATCT
6781 TCCGTTTGCC AGTGGAACAC TACGACCAGA TTGTGGACAT TGCCATGATG CCAGAGGCGC
6841 CGAAAGACAG TGCAGATATT GCTTTAGCTG CTTACGATCA GATTCAAACC CTGACCAAGA
6901 TGCTGAACGA GTACATGCAC GTCACGCCTG AGCAAGAGGT CTCAGCGGTG TCCACGGCGG
6961 TTTGTGGCCA CTGTCACGAG AAGGAAAAGC TTCGTAAGAA GGTGGCACCA TCCTCATCGT
7021 TTTCTTCATC ACCACCACCG CTGCCGCCTC CCAATAGGCA GCATGCCCAG GCTCAGGCCC
7081 AGATACCGCC ATCGCGGCTG ATGCCCAAAC TACAAACTCT TGATCTTGAC GAAGTTGCCA
7141 TACACGAAGA CGATGACGGA TACTGTGAGA TCGACGAACT GCGCTTACCG GCTATTCCGT
7201 CCAAACCACA TGAGCGGCCC ACAACGCCAC TGGCTCCTTT CAATACTGAG CCGAAAACTT
7261 CACAATCTGT TATAGATGCC TCGAAACGTC AATCCACTGA TGCCGTTCCG GAGGGATTAC
7321 TGGAACAAGA ACCACTCGAA GGCGATAAGA CGGAGACCAA GGGTGAAGAT AATGAAGTGA
7381 AAACTGTGCC GTCAGATAAG CTAAGTGAAT CATGCAATGA AGAGAGGCAA TGTGTGGAGG
7441 CGGATATCAC AAAGGAAGTG GCAGATCCAA CGACCTCTAA GAATGAAGCT GCAGCATCGG
7501 TGGATGAATT ACCAAGCCAG AGCCGGGAGA TAAAAACGGC TGAAAACGCA AGCAAATCTG
7561 TAGCTGACAA AAAGGAAGAC AACGAGGAAA CCATCGAAGA AGGTGTGGCA TCCACGGTCG
7621 ATAGCTCCAC TCAAACATCA CCAACTGAAT CGCCGAAAGA GACGGATAAG TTAACTGGAG
7681 GATCGAGCAG CACCTGTGGG CCGAATCGCA TTCAGCACGC TAGTGTGCTG GAGCCGAGTG
7741 TGCCCTGCCA TGCACTCAGC AGCATTGTAA CAATACTGAA TGAGCAGATT TCCATGCTTT
7801 TGCCAAAAAT TAACGAACGC GATATGGAAA GGGAGCGATT GCGTAAAGAG AATCAACACC
7861 TTCGCGAGCT CTTGAGTGCG CTGCATGATC GACAGCGAGT TGATGAAGTA AAGGAAACTC
7921 CGTTTGATCT AAAGAAGCTG ATGCATGCTG AGGATGTAGA GTTTGACGAT GATATTGACG
7981 CCATTTCCAA CAGTTCGCTG ACGCCAACGC CTACGCCGAT TCCCACAGCA TCACCAAGCG
8041 CCAGCGGCCA GGTAGAGACA GCGGAAGCCA TGAGGATTAC TAGCACTGAG GATGAGGAAT
8101 AGGAAACTTG TTTAATTTTT TTTTGTATAA AATACATATT TGTTCTTGTT TTTCCCGCAC
8161 GCATTTGACC AATTGAATTG GCGGCGTCTA TGTTTTACGA GTAGCCTTTC TTAGAGCATG
8221 CCTTTTACTA CTGTTAATGT AGCTTCATTT GTTTTCTTAA AATATTATGT ATTCCACAAG
8281 AGCCGATAAC ACTTTAAATT AAGTCTAACA TTGTCCCCTC GTAAAACTAA TTAAATACAT
8341 ATATATATGC ATATTATCGA CTTAAAAAAT ATCAGATAAA CACACAATGT TTGATACATT
8401 TATAAAGAAC AATAAACAAC ATAGTTATTG AGAAGAATAG CA
217
Protein sequences
DMCCa (630aa. 72KDa)
1 MAHPLARRPI NVEQLSVQQL ENRVRDLTQR LQQAERQLTE SNTEREICHK
50 R L E W S Q A H E  CRITEMHCVI AELSKKLRSK QDHVIMEEQE PDGSELSFQE
101 GSVYNSELNL TNPDAECQTE PLEDFEGACS TTSVGNVAHK PPELSHKGQV
151 EALQEEVLHL RARIALLQSE I S T K D A A W E  EQTKVAFDCE SEVNECGQRL
201 NDLNVCTSLT SPQKRIPAVP KMAERVKLRC ASKHESGEDP SQDTSLSNEQ
251 INLVEHLVSE LKEQNLYMEN FMEPLHLSKD LERLQRRVEQ LEMRNTMLAL
301 TLDECKEHTE HLYLLCGKYE SNAVALQLAL NCSDRAIEAY DVMLALLESK
351 LALLGEKSVA AEESRRSVEA VARHLLARLD SEKNVCENSL GPWQHNINLG
401 PEDAPKTGRP WCADDDNRLR YHVSKLKGRR SNVQHTIVSL ESPFSDIYER
451 KRLALEKEHE LRSADKKSPI DLETAVIMQE ILELRDSNLQ LKTKMEEAEQ
501 ERQNANERVG ILHEALKQLQ ANNRVSYSEA EHAALTEQQL VEALTRETEL
551 KGRIQTLLAN VTASQKAFDE KYEQLHQNVR ELQKSNHNLG QMLDHTKRKY
601 QLRVRKLEQK IVDLRLDYEQ GHNHVPETTL
DMCCb (565aa. 64KDa)
1 MHCVIAELSK KLRSKQDHVI MEEQEPDGSE LSFQEGSVYN SELNLTNPDA
51 ECQTEPLEDF EGACSTTSVG NVAHKPPELS HKGQVEALQE EVLHLRARIA
101 LLQSEISTKD A A W E E Q T K V  AFDCESEVNE CGQRLNDLNV CTSLTSPQKR
151 IPAVPKMAER VKLRCASKHE SGEDPSQDTS LSNEQINLVE HLVSELKEQN
201 LYMENFMEPL HLSKDLERLQ RRVEQLEMRN TMLALTLDEC KEHTEHLYLL
251 CGKYESNAVA LQLALNCSDR AIEAYDVMLA LLESKLALLG EKSVAAEESR
301 RSVEAVARHL LARLDSEKNV CENSLGPWQH NINLGPEDAP KTGRPWCADD
351 DNRLRYHVSK LKGRRSNVQH TIVSLESPFS DIYERKRLAL EKEHELRSAD
401 KKSPIDLETA VIMQEILELR DSNLQLKTKM EEAEQERQNA NERVGILHEA
451 LKQLQANNRV SYSEAEHAAL TEQQLVEALT RETELKGRIQ TLLANVTASQ
501 KAFDEKYEQL HQNVRELQKS NHNLGQMLDH TKRKYQLRVR KLEQKIVDLR
551 LDYEQGHNHV PETTL
DMCCc (718aa. 82KDa)
1 MSNDVQVQAR VAKIATDVPR RSQKQRDSSQ FQQKHSQSAA GEDFEYVFQS
51 ISPRGGGPGP GGRHLVGSSD LDSPEHTQRD TTESDNNISS CSTLDIVNKV
101 EQLSVQQLEN RVRDLTQRLQ QAERQLTESN TEREICHKRL E W S Q A H E C R
151 ITEMHCVIAE LSKKLRSKQD HVIMEEQEPD GSELSFQEGS VYNSELNLTN
201 PDAECQTEPL EDFEGACSTT SVGNVAHKPP ELSHKGQVEA LQEEVLHLRA
251 RIALLQSEIS T K D A A W E E Q  TKVAFDCESE VNECGQRLND LNVCTSLTSP
301 QKRIPAVPKM AERVKLRCAS KHESGEDPSQ DTSLSNEQIN LVEHLVSELK
351 EQNLYMENFM EPLHLSKDLE RLQRRVEQLE MRNTMLALTL DECKEHTEHL
401 YLLCGKYESN AVALQLALNC SDRAIEAYDV MLALLESKLA LLGEKSVAAE
451 ESRRSVEAVA RHLLARLDSE KNVCENSLGP WQHNINLGPE DAPKTGRPWC
501 ADDDNRLRYH VSKLKGRRSN VQHTIVSLES PFSDIYERKR LALEKEHELR
551 SADKKSPIDL ETAVIMQEIL ELRDSNLQLK TKMEEAEQER QNANERVGIL
601 HEALKQLQAN NRVSYSEAEH AALTEQQLVE ALTRETELKG RIQTLLANVT
651 ASQKAFDEKY EQLHQNVREL QKSNHNLGQM LDHTKRKYQL RVRKLEQKIV
701 DLRLDYEQGH NHVPETTL
DMCCd (337aa. 37KDa)
1 MSNDVQVQAR VAKIATDVPR RSQKQRDSSQ FQQKHSQSAA GEDFEYVFQS
51 ISPRGGGPGP GGRHLVGSSD LDSPEHTQRD TTESDNNISS CSTLDIVNKV
101 EQLSVQQLEN RVRDLTQRLQ QAERQLTESN TEREICHKRL E W S Q A H E C R
151 ITEMHCVIAE LSKKLRSKQD HVIMEEQEPD GSELSFQEGS VYNSELNLTN
201 PDAECQTEPL EDFEGACSTT SVGNVAHKPP ELSHKGQVEA LQEEVLHLRA
218
251 RIALLQSEIS T K D A A W E E Q  TKVAFDCESE VNECGQRLND LNVCTSLTSP 
301 QKRIPAVPKM AERVKLRCAS KHESGEDPSQ DTSLSNE
HsMCCI (829aa. 93 KDal
1 MNSGVAMKYG NDSSAELSEL HSAALASLKG DIVELNKRLQ QTERERDLLE KKLAKAQCEQ 
61 SHLMREHEDV QERTTLRYEE RITELHSVIA ELNKKIDRLQ GTTIREEDEY SELRSELSQS 
121 QHEVNEDSRS MDQDQTSVSI PENQSTMVTA DMDNCSDLNS ELQRVLTGLE N W C G R K K S S  
181 CSLSVAEVDR HIEQLTTASE HCDLAIKTVE EIEGVLGRDL YPNLAEERSR WEKELAGLRE 
241 ENESLTAMLC SKEEELNRTK ATMNAIREER DRLRRRVREL QTRLQSVQAT GPSSPGRLTS 
301 TNRPINPSTG ELSTSSSSND IPIAKIAERV KLSKTRSESS SSDRPVLGSE ISSIGVSSSV 
361 AEHLAHSLQD CSNIQEIFQT LYSHGSAISE SKIREFEVET ERLNSRIEHL KSQNDLLTIT 
421 LEECKSNAER MSMLVGKYES NATALRLALQ YSEQCIEAYE LLLALAESEQ SLILGQFRAA 
481 GVGSSPGDQS GDENITQMLK RAHDCRKTAE NAAKALLMKL DGSCGGAFAV AGCSVQPWES 
541 LSSNSHTSTT SSTASSCDTE FTKEDEQRLK DYIQQLKNDR AAVKLTMLEL ESIHIDPLSY 
601 DVKPRGDSQR LDLENAVLMQ ELMAMKEEMA ELKAQLYLLE KEKKALELKL STREAQEQAY 
661 LVHIEHLKSE VEEQKEQRMR SLSSTSSGSK DKPGKECADA ASPALSLAEL RTTCSENELA 
721 AEFTNAIRRE KKLKARVQEL VSALERLTKS SEIRHQQSAE FVNDLKRANS NLVAAYEKAK 
781 KKHQNKLKKL ESQMMAMVER HETQVRMLKQ RIALLEEENS RPHTNETSL
HsMCC2. AIE-75 binding protein (723aa. 76Kda)
1 MSARATRPRS RRGRHAPPGE LDPVAESSEE VEAASGSSKP SFAPPPVSSG LEQLGPMEEV 
61 SGQGLGSRTD KKMDGGSGRE LASAPEVPHK PAVEAHQAPE AALQYKETVP PGNGAPDVFQ 
121 TLQHTLSSLE AAAAAWRHQP PSHSGPMEFE GTSEGGAGSL GKQEGAGSCQ REAARLAERN 
181 AWLRLALSSR EDELVRTQAS LEAIRAEKET LQKEVQELQD SLLRLEPCPH LSHNQAGGSG 
241 SGSSSSEADR EPWETQDSFS LAHPLLRRLR SHSSTQILGS LPNQPLSPEM HIMEAQMEQL 
301 RGSIEKLKCF NRLLSAVLQG YKGRCEGLSM QLGQREAEAT ALHLALQYSE HCEEAYRVLL 
361 ALREADSGAG DEAPMSDLQA AEKEAWRLLA QEEAAMDAGA QQNPQPSPEG SSVDKPTPQE 
421 VAFQLRSYVQ RLQERRSLMK ILSEPGPTLA PMPTVPRAEA MVQAILGTQA GPALPRLEKT 
481 QIQQDLVAAR EALADLMLRL QLVRREKRGL ELREAALRAL GPAHVLLLEQ LRWERAELQA 
541 GGANSSGGHS SGGGSSGDEE EWYQGLPAVP GGTSGIDGGQ VGRAWDPEKL AQELAASLTR 
601 TLDLQEQLQS LRRELEQVAQ KGRARRSQSA ELNRDLCKAH SALVLAFRGA HRKQEEQRRK 
661 LEQQMALMEA QQAEEVAVLE ATARALGKPR PPLPPPQLGD 
721 TFL
DRho GEF2 (2559aa. 281 KDa)
1 MDDPSIKKRL LDLYTDEHEY DEVQEIPEES SIQPPETSTS HTSTNGSSHS GPGTATGPGA
60 TSAGPSAGAP Q S P V I W D S V  PELPAPKQKS VKNSKSKQKQ KQLANKSKIP RSPSLASSLS
120 SLASSLSGHR DRDKDRDKDR ENQNAVPPQT PPLPPSYKQN QMNGDSTAAA GGGVSAPATP
180 TTANNNNASH NNGSIMGGGV QLNQSDNSNP VLQAPGERSS LNLTPLSRDL SGGHTQESTT
240 PATTPSTPSL ALPKNFQYLT LTVRKDSNGY GMKVSGDNPV FVESVKPGGA AEIAGLVAGD
300 MILRVNGHEV R L E K H P T W G  LIKASTTVEL AVKRSQKLTR P S S V S W T P S  TPILSGRDRT
360 ASITGPQPVD SIKRREMETY KIQTLQKMLE QEKLNLERLK SDQNNPSYKL SEANIRKLRE
420 QLHQVGAEDA PTVKLQAAAG NKNTALLTPN QIQHLSASAT HSNQQFHHLH HHHNLHNNNY
480 PPQQQPASTS PAFLSLLPRS LSSLSLGTRK NKTEKDLTTS SPFGLTTDFL QQQRMSHQAE
540 SMSQSMHQHT STPTSQQFFH PHQQQHRFKE TGPTSKGKNK FLISRSLIEE DVPPPLPQRN
600 PPRQLNLDLK NGNASPGGSH LVAPVSDLDR ATSPQLNRSQ QQQLPRSTDN SPSNAKSKRS
660 KIKTKALSDP KMSTQMFLQM ESASAAGAAG GSIEVDGGPP PLPPRLPGMM TEDMSRGSCQ
720 NLAQPNSVGT AFNYPLVSTT TAVQNDNLNI AFPLSQRPNI VQQLQQYQQQ QQHQMSGGQA
780 TGALGQTPNL GKNKHRRVGS SPDNMHPRHP DRITKTTSGS WEIVEKDGES SPPGTPPPPY
840 LSSSHMTVLE DPNENNRGAA AAGPGVFIES HQFTPMAGAS SPIPISLHSN HMHAAQSNDT
900 QKEIISMEDE NSDLDEPFID ENGPFNNLTR LLEAENVTFL AIFLNYVISN SDPAPLLFYL
960 ITELYKEGTS KDMRKWAYEI HSTFLVPRAP LSWYRQDESL AREVDNVLQL EYDKVEILRT
1020 VFLRSRKRAK DLISEQLREF QQKRTAGLGT IYGPTDDKLA EAKTDKLREQ IIDKYLMPNL
1080 HALIEDENGS PPEDVRKVAL CSALSTVIYR IFNTRPPPSS IVERVHHFVS RDKSFKSRIM
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1140 GKNRKMNVRG HPLVLRQYYE VTHCNHCQTI IWGVSPQGYH CTDCKLNIHR Q C S K W D E S C
1200 PGPLPQAKRL AHNDKISKFM GKIRPRTSDV IGNEKRSRQD EELNVELTPD RGQASIVRQP
1260 SDRRPDANIS IRSNGNTSCN TSGLNTTDLQ SSFHGSCAND SINPGGGAGC NMDLSTSVAS
1320 TTPSTSGSVA AGLSAFAELN ALDTVDKEAR RERYSQHPKH KSAPVSVNWS ESYKERLSNK
1380 RNRNSRRKTS DPSLSSRPND EQLDLGLSNA TYVGSSNSSL SSAGGTESPS TSMEHFAAPG
1440 AAGGVQVPPM GLNQNQHPHL LIQQHAQQYC QQDSFQAGLA GAAGSSAASN SSFWNAGHPL
1500 PVARWTLESE DEDDVNEADW SSMVAAEVSA ALTDAEKKRQ EIINEIYQTE RNHVRTLKLL
1560 DRLFFLPLYE SGLLSQDHLL LLFPPALLSL REIHGAFEQS LKQRRIEHNH W N T I G D L L A
1620 D M F D G Q S G W  LCEFAAQFCA RQQIALEALK EKRNKDEMLQ KLLKKSESHK ACRRLELKDL
1680 LPTVLQRLTK YPLLFENLYK VTVRLLPENT TEAEAIQRAV ESSKRILVEV NQAVRTAEDA
1740 HKLQNIQRKL DRSSYDKEEF KKLDLTQHHL IHDGNLTIKK NPSVQLHGLL FENMIVLLTK
1800 QDDKYYLKNL HTPLSITNKP VSPIMSIDAD TLIRQEAADK NSFFLIKMKT SQMLELRAPS
1860 SSECKTWFKH FSDVAARQSK NRSKNASSNH DTSISDPALA AIPHSNTKES LELSTDTVQP
1920 LAATATLTTT PLAPMLPIAT VTPAPATNNS NVSSLTGVQL RNPQRDATAS ESDADYVNTP
1980 KPRSSQNEVN RTMSIRSTGE PIQKYSANGT EANDVTLRHS QSTRESVRPG STGEERNSTY
2040 GMVGGNSKRD SASIVCSNNS NNTRTLLMQS PLVDPTAIQV SISPAHTAEP VLTPGEKLRR
2100 LDASIRNDLL EKQKIICDIF RLPVEHYDQI VDIAMMPEAP KDSADIALAA YDQIQTLTKM
2160 LNEYMHVTPE QEVSAVSTAV CGHCHEKEKL RKKVAPSSSF SSSPPPLPPP NRQHAQAQAQ
2220 IPPSRLMPKL QTLDLDEVAI HEDDDGYCEI DELRLPAIPS KPHERPTTPL APFNTEPKTS
2280 QSVIDASKRQ STDAVPEGLL EQEPLEGDKT ETKGEDNEVK TVPSDKLSES CNEERQCVEA
2340 DITKEVADPT TSKNEAAASV DELPSQSREI KTAENASKSV ADKKEDNEET IEEGVASTVD
2400 SSTQTSPTES PKETDKLTGG SSSTCGPNRI QHASVLEPSV PCHALSSIVT ILNEQISMLL
2460 PKINERDMER ERLRKENQHL RELLSALHDR QRVDEVKETP FDLKKLMHAE DVEFDDDIDA
2520 ISNSSLTPTP TPIPTASPSA SGQVETAEAM RITSTEDEE
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Appendix 2: Primer sequences
In situ_1 
In situ__2 
MCC RT P C R jl 
MCC RT PCR_2 
MCC RT PCR_3 
MCC RT PCR_4 
MCC RT PCR_5 
MCC RT PCR_6 
MCC RT PCR_7 
cDNA_for 
cDNA_rev 
cDNA_int_for 
cDNA_int_rev 
Gen_for 
Gen_rev 
PlacW5’ 
PlacW3’
G8
G9
G10
G11
Pp3
Taq1
Taq2
Taq3
Taq4
3’gen
5’gen
LacW5’probe1
LacW’5’probe2
LacW3’probe1
LacW3’probe2
Pel2.8out
Pel3.8out
Pel4.8out
Pel5.8out
Pel6.8out
Pel7.8out
Pel8.8out
Pel9.5out
Pel10.2out
Pel1.8in
Pel3.8in
Pel7.8in
Gen4Kb
Gen8Kb
Gen12Kb
Gen16Kb
T CT AGAT GAGAGCAACACAGAGCG 
CT CGAGGCAATT AAGT CGCATGGC 
GCCAATT CTAGT CGGAAAGT CGTTGCA 
GATACGCCATCGGTGCCCAACGACAA 
GGGTT GTATGGGTT GAAAT GT ATT CT CT GA 
GTATGTAGTTACTGCAGCCTTATCTGCG  
ACTT GAT CAT GTTT AGTACCAAT GT AT CATTGC 
CGAGGGGCTT CTACTAATGGAACT CCA 
GGTGTCGGAGCTAAAGGAGCAAAATCT 
GCT CTAGAAAT CGGAAGT CAACGAGT 
CAG AATT CACTT GCTTT CGAGCAGAGC 
GCACTGCAGCTAGACGAATGCAAG 
TAGCTGCAGTGCCAGCATGGTGTT 
T GCGGCCGCAAT CGGAAGT CAACGAGT 
CCCGAATT CTGCCAACCTGGAAGT GAT G 
TCCTCTCAACAAGCAAACGTGCACTG 
CGCT GT CT CACT CAGACT CAAT ACG A 
TACAGCCGATAGTGGCGCTAAACGAA 
TT CGTTT AGCGCCACT AT CGGCT GTA 
CCC AAAT CAGGCC AATT CT AGT CGG A 
T CCGACT AGAATTGGCCT GATTT GGG 
AT CCGGCCGCT GT CATTTCCTT GTTT 
TAG ATTTT GCT CCTTTAGCT CCGACAC 
GTGTCGGAGCTAAAGGAGCAAAATCTA 
CCACGCCCATAAAGAAACTACTCGATG 
TAAGCCCGT CT AGGTT GT GATAAT GTT GT 
AT CATGCATT GCCTT AGGGCTGGAATTT A 
TAATAGCGAACTT CTGGCT GT CGGT 
TT CATCCACCACAT ACAGGCCGT AG 
CAGT GCACGTTT GCTT GTT GAGAGGA 
T CGTATT GAGT CT GAGT GAGACAGCG 
AAG ATGCT G AAGAT CAGTT GGGT GCAC 
CGGTTAAATTGCCAACGCTTATTACCC 
T GCT GATATGGTT GAT GT CAT GTAGCC 
CT CCGCG AATT AAT AGCT CCT GAT C 
AAAGAGGT CAT CCT GCTGGACATAG 
GGCAACCAT CT GCAAATTAAAATGTTACTCG 
GTTCGAAGGGGAAATACTTGTATTCTATAGG 
GTGCACCCAACT GAT CTT CAGCAT CTT 
CT GACAGTTACCAAT GCTT AAT CAT GT AG 
TTGCGTTGCTGGCGTTTTTCCATAGGC 
CTACGGCCTGTATGTGGTGGATGAA 
GGCTACAT G ACAT C AACC AT AT C AGCA 
CCTATAGAATACAAGTATTTCCCCTTCGAAC 
CACATAGCT CGAACAT CGT GTGGGAA 
CCGAGGTGTAGTTGGAGCCATTCATTA 
TATTT GCCGCCCAT CCAATT CACACA 
TATGGCACAATACTGACTGAGGTCCT
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Gen20Kb ATGTCTCTCATTTGGGGTGGGCTC
Gen24Kb TATTGCGTTGTAACCACTGACACTGAC
Gen28Kb TTTCAACTTCCAGTCGTATCCCCGC
Gen4Kb2 TT CCCACACG AT GTT CG AGCTAT GT G
Gen8Kb2 TAAT GAATGGCT CCAACTACACCT CGG
Gen12Kb2 TGTGTGAATTGGATGGGCGGCAAATA
Gen16Kb2 AGGACCT CAGT CAGTATT GTGCCAT A
Gen20Kb2 GAGCCCACCCCAAAT GAGAG ACAT
MyctagA5’ GAT CCAACATGGAGCAGAAGCT GAT CAGCGAAG
(cont’d) AGGATCTG
MyctagA3’ AATT CAGAT CCT CTT CGCT GAT CAGCTT CTGCT
(cont’d) CCATGTTG
MyctagB5’ GAT CCAACATGGAGCAGAAGCT GAT CAGCGAAG
(cont’d) AGGATCTGG
MyctagB3’ AATT CCAGAT CCT CTT CGCT GAT CAGCTT CTGC
(cont’d) TCCATGTTG
MyctagC5’ GAT CCAACATGGAGCAGAAGCT GAT CAGCGAAG
(cont’d) AGGATCTGAG
MyctagC3’ AATT CT CAGAT CCT CTTCGCT GAT CAGCTT CT G
(cont’d) CTCCATGTTG
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Appendix 3: TXL-COOH genes of Drosophila (PATSCAN result)
Gene C-terminus Gene C-terminus Gene C-termii
CG10002 TSL CG2189 TAL CG7248 TEL
CG10194 TKL CG2595 THL CG7285 TDL
CG10210 TEL CG2849 TLL CG7635 TNL
CG10405 TKL CG30033 TAL CG7919 TRL
CG10413 TTL CG30361 TNL CG7997 TAL
CG10420 TEL CG30479 TIL CG8085 TRL
CG10493 TEL CG31009 TEL CG8261 TVL
CG10874 TGL CG31043 TAL CG8484 TYL
CG10933 TSL CG31066 TRL CG8507 TEL
CG11136 TEL CG31100 THL CG8759 TML
CG11282 TEL CG31321 TSL CG8856 TDL
CG11560 TNL CG3204 TLL CG8983 TEL
CG11598 TFL CG32045 TNL CG9169 TFL
CG 11898 TTL CG32089 TKL CG9240 TGL
CG12724 TNL CG32096 TDL CG9302 TEL
CG12928 TTL CG32220 TEL CG9512 TEL
CG12931 TIL CG32387 TYL CG9610 TGL
CG12991 TKL CG32578 TTL CG9764 TQL
CG13068 TVL CG32594 TDL CG9864 TKL
CG13566- TDL CG32711 TFL CG9993 THL
CG13702 TDL CG3318 TEL CG9997 TIL
CG13711 TEL CG3389 TEL CG1907 TGL
CG13949 TDL CG3638 TEL CG7218 TQL
CG14112 TTL CG3777 TIL
CG14117 TKL CG3897 TEL
CG14427 TDL CG4099 TDL
CG14669 TIL CG4301 TYL
CG1467 TKL CG4376 TDL
CG14723 TFL CG4462 TRL
CG 14973 TNL CG4626 TLL
CG15097 TNL CG4889 TCL
CG15134 THL CG4928 TRL
CG15153 TDL CG4969 TCL
CG15214 TLL CG5235 TLL
CG 15377 TFL CG5270 TPL
CG1636 TAL CG5507 TEL
CG 16752 TVL CG5539 TGL
CG1693- TEL CG5671 TYL
CG17084 TSL CG5874 TIL
CG17131 TGL CG6156 TTL
CG1722 THL CG6477 TAL
CG17389 TIL CG6600 TKL
CG18404 TNL CG6619 TRL
CG18572 TAL CG6805 TQL
CG 18745 TWL CG6988 TPL
CG18746 TWL CG7128 TNL
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